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Abstract 
Metabolite concentrations are fundamental biomarkers of disease. With increasing interest 
in personalised medicine, this work assessed the accuracy of non-invasive metabolite 
quantification with magnetic resonance spectroscopy (MRS) using a combination of 
simulations, phantom and in vivo data. No optimal echo time (TE) was found for measuring a 
range of key metabolites with quantification accuracy generally influenced more by data 
quality than TE choice. The T2 relaxation times of water and metabolites with MRS 
dominated by a singlet could be estimated using 2 TEs and were found to be significantly 
different in paediatric brain tumours compared with normal brain, varying between tumour 
types. The T2 relaxation times of paediatric brain tumours were significantly shorter at 3T 
compared with 1.5T. Metabolite concentrations for individual patients were most affected 
by changes in the T2 relaxation time of water which is quick to measure. A clinical JPRESS 
protocol was developed which aids assignment of overlapping metabolites using changes of 
MRS with TE. Overall, measurement of MRS with a short TE reduces inaccuracies associated 
with variability in metabolite T2 and does not tend to lead to worse quantification of 
overlapping resonances. Further improvements in concentration accuracy can be obtained 
by measuring case-specific water T2. 
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1. INTRODUCTION 
 
Magnetic resonance imaging (MRI) is a method used regularly for structural imaging of the 
brain producing detailed images which enables identification of abnormalities and diagnos es 
for a range of conditions. While MRI is typically interpreted following qualitative expert 
review by radiologists, there is a move towards the use of quantification to yield imaging 
biomarkers.   
Imaging biomarkers provide an objective measurement of indicators of pathogenic 
processes (Biomarkers Definitions Working Group., 2001). MRI biomarkers have become 
widely-used in healthcare and are used to determine response to treatment, through 
tumour size, in oncology (Eisenhauer et al., 2009) and to assess atrophic brain changes in 
neurodegenerative disease (Risacher and Saykin, 2013). However, conventional MRI is 
limited in its ability to provide information on tissue properties. For example, conventional 
MRI provides little information about metabolism, perfusion and cellularity which can be 
used to improve patient management. Structural imaging is therefore increasingly 
complemented with advanced imaging techniques which provide this information (Koh and 
Thoeny, 2010; Peet et al., 2012). However, the difficulties associated with the provision of 
protocols which determine imaging biomarkers in an accurate, reproducible manner in a 
clinically acceptable timescale mean biomarkers have not been widely adopted in clinical 
practice. 
Advanced imaging techniques, such as 1H magnetic resonance spectroscopy (MRS), have 
identified a range of potential imaging biomarkers  (Oz et al., 2014). However, before an 
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imaging biomarker can be used for widespread clinical decision making it requires technical 
validation and an assessment of the precision of measurement. This thesis investigates how 
the quantification accuracy of MRS is affected by a number of experimental factors.  
1.1 Introduction to MRS 
MRS has been used in the assessment of a number of disorders in the brain including brain 
tumours (Howe et al., 2003; Panigrahy et al., 2006; Peet et al., 2012),  HIV/AIDS (Descamps 
et al., 2008), traumatic brain injury (Brooks et al., 2001) and neurodegenerative disease 
(Gujar et al., 2005; Oz et al., 2014a). MRS can be incorporated into MRI investigations using 
the same equipment used for structural imaging and is a non-invasive method for 
measurement of the chemical composition of tissue. Information is extracted from a region 
of interest (ROI) called a voxel. MRS can either be collected from one voxel location, termed 
single voxel spectroscopy (SVS), or can be collected from multiple voxel locations, known as 
Magnetic Resonance Spectroscopic Imaging (MRSI) or Chemical Shift Imaging (CSI).  
 
Figure 1-1: Example MRS of normal brain at TE 35 ms and the peak positions of N-acetylaspartate 
(NAA), creatine (Cr), choline (tCho), glutamate (Glu) and glutamine (Gln). 
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MRS data is displayed as a spectrum of peaks representing the various chemicals present in 
the voxel (Figure 1-1). These chemicals can be grouped into small molecules involved in 
metabolism, known as metabolites, and larger molecules such as lipids and macromolecules. 
Each metabolite has a characteristic spectral appearance and metabolites can be identified 
by their pattern of peaks at specific positions on the horizontal axis which has units of parts 
per million (ppm) (Govindaraju et al., 2000).  The intensity of a peak indicates how much of 
the metabolite is present in the voxel, with larger peaks indicative of higher concentrations. 
The MRS spectrum is a combination of the signals produced by resonating hydrogen atoms 
or protons. The appearance of an MRS spectrum is determined not just by the 
concentrations of the metabolites present but their chemical structure. A single peak 
resonance, called a singlet, is produced when the hydrogen atoms producing the signal are 
said to be uncoupled. However, when the hydrogen atoms of a metabolite interact with 
each other through a process called J-coupling, a complex arrangement of MRS peaks, called 
a multiplet, is produced.  
The MRS spectral appearance will also depend on a number of acquisition parameters. One 
of the most important of these is the echo time (TE). While the appearance of singlets will 
remain the same, regardless of the TE used, the appearance of multiplets will change with TE 
because of J-evolution Figure 1-2. 
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Figure 1-2: Example MRS spectra of paediatric brain tumour at a) TE 35 ms and b) TE 135 ms. The 
lactate (Lac) doublet appears inverted at 135 ms due to J-evolution. 
An MR spectrum can be assessed in either a qualitative (McRobbie et al., 2007) or 
quantitative manner (Graaf, 2007; Mukherji, 1998). The following metabolites are amongst 
the most studied in clinical MRS. The main identifying feature of N-acetylaspartate is a large 
single peak at 2.01 ppm. The peak at 3.20 ppm is a combination of glycerophosphocholine 
(GPC), phosphocholine (PCh) and free choline, these are typically grouped together and 
reported as total choline (tCho) in clinical MRS. Total creatine (Cr) presents as two single 
peaks  at 3.02 and 3.90 ppm on MRS, and is a combination of creatine and phosphocreatine, 
while glycine (Gly) has a single peak at 3.54 ppm on MRS. Gly can be difficult to distinguish 
from myo-Inositol (mI) using MRS. mI is a complex metabolite with its main resonances 
between 3.50 and 3.60 ppm. Lactate (Lac) can be identified by its doublet at 1.31 ppm, this 
doublet is inverted at a long TE of 135 ms (Figure 1-2). Glutamate (Glu) and glutamine (Gln) 
are two chemically similar metabolites, each producing a broad group of resonances 
between 2.00 and 2.50 ppm. The sum of glutamate and glutamine concentrations is often 
reported as a single measurement (Glx).  
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Metabolites are involved in physiological processes and each have a specific biological 
significance. NAA is the most prominent peak in MRS of normal brain and is a marker of 
neuronal integrity; it is often reduced in a range of brain diseases (Gujar et al., 2005). tCho is 
a marker of cell proliferation and membrane disruption. tCr is a marker of energy 
metabolism, while Lac, the end point of anaerobic glycolysis, is an indicator of abnormal 
energy metabolism (Veech, 1991). mI is a pentose sugar which plays an important role in 
osmoregulation of the central nervous system (Fisher et al., 2002). Gly is an antioxidant and 
inhibitory neurotransmitter and Glu is an excitatory neurotransmitter, while Gln is an amino 
acid precursor is a storage form of Glu (Panigrahy et al., 2010a).  
The concentration of these metabolites is known to vary in a number of disease states, 
including paediatric brain tumours and neurodegenerative diseas e (Mukherji, 1998). 
Metabolite concentrations measured with MRS are therefore potentially important imaging 
biomarkers which could inform future clinical decision making. 
While knowledge of altered metabolism and the chemical composition of disease states is 
potentially important for clinical decision making and drug development, MRS has not been 
widely adopted in the clinic. MRS remains predominantly a research tool in the technical 
validation domain of the Imaging Biomarkers Roadmap (O’Connor et al., 2016) for a number 
of reasons. Firstly, when compared to structural imaging, which radiologists have years of 
training and experience of, the complicated spectrum of peaks that MRS produces is less 
readily interpreted than anatomical images.  
Secondly, the most common MRS technique, SVS, collects data from a  relatively large single 
volume of size 6 mL and greater with an acquisition time of 3-5 minutes (Oz et al., 2014). 
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While MRI and MRS are complementary techniques, the voxel size, spatial resolution and 
acquisition time compare poorly to MRI which can acquire whole coverage of the brain in 5-
10 minutes (Ellingson et al., 2015). The multi-voxel technique, MRSI, provides larger 
anatomical coverage and information on tissue heterogeneity from smaller volumes of 1 mL 
and below; however, MRSI is less quantifiable, provides information on fewer metabolites 
than SVS due to its reduced signal, and is acquired at the expense of longer acquisition times 
(Posse et al., 2013). SVS is therefore the more commonly used MRS method in the clinical 
environment. With technological advancements in the form of the improved signal-to-noise 
from higher field strengths clinically and reduced acquisition times due to compressed 
sensing (Geethanath et al., 2012) and parallel imaging (Birch et al., 2015), MRSI is now 
becoming more applicable in the clinical environment.  
A further advance in the field of MR imaging comes in the form of chemical exchange 
saturation transfer imaging (CEST). CEST utilises the change in signal that occurs due to the 
exchange of protons with hydrolysable functional groups with bulk water, to produce 
contrast based on metabolite concentrations while retaining the spatial resolution of MRI. 
As a developing technique, metabolites identified using MRS could be used to determine 
future imaging targets for CEST and to validate its results  in a number of disease states (Cai 
et al., 2013; Haris et al., 2011; Ray et al., 2016). 
1.2 Introduction to Paediatric Brain Tumours  
Brain tumours account for approximately a quarter of all cancers in children (Cancer 
Research UK, 2015) and are the most common solid tumour in children (Bleyer, 1999; Office 
for National Statistics, 2016).  Paediatric brain tumours are the leading cause of death in 
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children’s cancer with a 10-year survival rate of approximately 68% (Cancer Research UK, 
2015).  
The gold standard for diagnosis is from histopathological examination of tissue. Tissue 
samples are stained with haematoxylin and eosin to assess morphology and with 
immunohistochemical stains for cell and tissue specific markers. These stains are used to 
identify tumour type and associated grade according to the World Health Organisation 
(WHO) system (Louis et al., 2016). The WHO classification in paediatric brain tumours is 
graded on a scale of I-IV, with higher grades associated with increased aggressiveness and a 
poorer prognosis. 
Approximately two-thirds of paediatric brain tumours are diagnosed from histology with the 
remaining third of paediatric brain tumours are diagnosed on clinical and imaging grounds. 
The development and validation of non-invasive imaging methods for diagnosis and 
identification of prognostic biomarkers for these tumours would therefore represent a 
substantial advance for clinical management of these patients.  
1.2.1 Tumours Diagnosed By Histopathology 
Astrocytomas 
Pilocytic astrocytomas (PA) are the most common paediatric brain tumour. They are grade I 
glial tumours which most often present in the cerebellum (Gan and Haas-Kogan, 2010). PA 
have a good prognosis with a 5-year overall survival over 90% (Dodgshun et al., 2016). 
Primary treatment of PA consists of maximal resection, with chemotherapy and 
radiotherapy administered when the majority of the tumour has not been resected.  
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Grade II to IV astrocytomas fall on a spectrum of disease. In contrast to the stable PA which 
do not progress, grade II and III astrocytomas can progress to higher grades and progression 
of these tumours has been linked to levels of citrate (Blüml et al., 2011). While glioblastoma 
is the most common grade IV astrocytoma in adults they are rare in children. Despite 
treatment with surgery, radiotherapy and chemotherapy, these tumours tend to have a very 
poor prognosis (Fangusaro, 2012). 
Medulloblastomas 
Medulloblastomas are grade IV tumours that present in the cerebellum. The overall five-year 
survival rate is over 70% (Packer et al., 2013); however, varying prognosis is associated with 
a number of distinct histological and genetic subgroups (Louis et al., 2016). Medulloblastoma 
treatment is stratified by risk and treatment primarily consists of maximal safe resection 
followed by craniospinal radiotherapy and chemotherapy. The combination of tumour and 
treatment can lead to later life cognitive deficits and identification of lower risk tumours 
could therefore improve future quality of life.   
Ependymomas 
Ependymomas are the third most common paediatric brain tumour and make up 6-10% of 
all childhood brain tumours (Smyth and Rubin, 2010). Two thirds of ependymomas present 
in the posterior fossa. Treatment currently involves maximum surgical resection followed by 
either chemotherapy or radiotherapy. The only current prognostic marker used clinically is 
the extent of resection (Vaidya et al., 2012). However, distinct molecular subgroups with 
prognostic significance have emerged recently (Pajtler et al., 2015).    
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1.2.2 Other Tumours 
In cases where tissue samples are not available, they are often described in terms which 
describe their location and their likely underlying biology. Tumours diagnosed on imaging 
grounds can include the following. 
Optic Pathway Glioma 
Optic pathway gliomas (OPG) are often associated with mutations in the neurofibromatosis-
1 gene (Listernick et al., 2007). The vast majority, but not all, of OPG diagnosed with 
histopathology are PA. OPG have a survival rate of over 90%. Despite their good overall 
prognosis, some OPG have multiple episodes of progression (Kelly and Weiss, 2013). These 
are treated with chemotherapy, radiotherapy and surgery (Goodden et al., 2014).  
Diffuse Intrinsic Pontine Glioma  
Diffuse intrinsic pontine gliomas (DIPG) are a rarer form of glial tumours which present in the 
brain stem. DIPG are grade IV tumours and have a poor prognosis with a mean survival of 
less than 12 months (Hargrave et al., 2008).  Resection of DIPG is not typically possible due 
to their location. DIPG are now increasingly biopsied, they are often lower grade tumours 
but rapidly progress to high grade, with molecular subgroups having been identified (Grill et 
al., 2012; Puget et al., 2012).   
As not all patients will have tissue biopsy and the processing time of histopathology results, 
non-invasive imaging methods could facilitate improved clinical outcomes through early 
diagnosis and earlier administration of treatment.  
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1.2.3 Imaging of Brain Tumours  
T1-weighted and T2-weighted imaging are the two most common structural imaging 
modalities used in MR to differentiate between anatomical structures. T1 and T2-weighted 
imaging exploit differences in tissue density and relaxation rates of tissue types to create 
contrast between tissue types. A full description of T1 and T2 relaxation is provided in 
Chapter 2. Structural imaging is performed at multiple time points to confirm the presence 
of a mass, to aid diagnosis and to assess the extent of resection following surgery. Structural 
imaging is subsequently performed at regular intervals to monitor treatment response and 
for tumour surveillance. 
Determination of tumour size, location and blood-brain barrier status from structural 
imaging is often enough to make diagnosis and immediate clinical decisions (Panigrahy and 
Blüml, 2009) However, paediatric brain tumours represent a heterogeneous group and 
diagnosis and determination of optimal biopsy sites is not always possible from imaging 
alone. The ability to increase confidence in these areas would therefore be welcomed. 
Furthermore, structural imaging is limited in its ability to predict survival (Hargrave et al., 
2008) and some tumours of the same grade and tumour type are known to have differing 
survival (Krishnatry et al., 2016). Identification of quantitative biomarkers of diagnosis and 
prognosis is becoming increasingly important and would allow treatment stratification 
according to risk (Dufour et al., 2011; Zacharoulis and Moreno, 2009). 
A number of quantitative MR methods have become available which could provide 
quantitative biomarkers. Texture analysis provides an avenue for quantitative analysis of 
conventional structural MRI, representing the image as mathematical features which can 
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successfully discriminate between paediatric brain tumour types (Fetit et al., 2015; 
Orphanidou-Vlachou et al., 2014; Rodriguez Gutierrez et al., 2014). 
A range of quantitative advanced imaging techniques are also available and these enable 
investigations of tumour metabolism, cellularity and perfusion. Diffusion weighted imaging 
provides information about water diffusion in tissue, giving an indication of the cellularity of 
the tumour. Apparent diffusion coefficients (ADC) are significantly different between tumour 
types, with PA having higher ADC values than the more cellular medulloblastomas and 
ependymomas and the ADC of ependymomas was higher than that of medulloblastomas 
(Rumboldt et al., 2006). In the posterior fossa, ADC histograms correctly classified 80% of 
ependymomas, 100% of astrocytomas and 94% of medulloblastomas (Bull et al., 2012). 
Perfusion imaging enables identification of neo-angiogenesis in tumours. Increased 
perfusion was predictive of shorter survival in DIPG (Hipp et al., 2011), whilst reduction of 
cerebral blood volume during radiotherapy treatment was predictive of increased survival in 
gliomas (Cao et al., 2006).  
1.2.4 MRS of Adult and Paediatric Brain Tumours 
While perfusion and diffusion imaging provide valuable prognostic and diagnostic markers, 
they provide no information about tumour metabolism. MRS is one method capable of 
investigating tumour metabolism. Preoperative short-TE MRS of untreated paediatric brain 
tumours revealed differences in metabolite concentrations between tumour types 
(Panigrahy et al., 2006), with differences in the metabolite concentrations also seen 
between astrocytoma, ependymoma and medulloblastoma and between tumours and 
normal brain (Davies et al., 2008a). Multivariate analysis also identified key differences in the 
metabolite profiles for the three tumour types, with the three classifiers presented 
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accurately classifying 93-95% of cases (Davies et al., 2008a).  In a large multi-centre study, 
the use of two echo times was found to have a balanced accuracy rate of 98% for 
classification of the same tumour types (Vicente et al., 2013). Interestingly, the use of two 
echo times for classification was also found to significantly improve classification 
performance. 
Automatic pattern recognition has been used to cluster spectra according to their pathology 
in adult brain tumours (Tate et al., 2006). This decision support system successfully classified 
81 out of 91 brain tumours, helping to resolve diagnosis in borderline cases, and was a 
significant improvement over the use of MRI alone. Decision support systems based on 
preoperative MRS outperformed MRI evaluation alone in the diagnosis of grade III adult 
astrocytomas and had no negative effect on radiologists’ predictions (Julià-Sapé et al., 2012).  
A number of metabolites measured with MRS have been identified as prognostic 
biomarkers. The tCho/NAA ratio was found to predictive of survival in DIPG (Steffen-Smith et 
al., 2011a). In addition to the tCho/NAA ratio, tCho and Lac were all found to be significantly 
different between survivors and non-survivors in paediatric brain tumours (Marcus et al., 
2007). The same study concluded that tCho + 0.1Lac was an independent predictor of 
survival and that MRS biomarkers predict survival better than standard histopathology. 
Levels of NAA and Gln have been observed to predict improved survival, with lipids and 
scyllo-Inositol associated with poor survival in paediatric brain tumours (Wilson et al., 2013). 
A risk model combining lipids, Scy and Gln predicted survival with a similar accuracy to 
histological grading (Wilson et al., 2013). High levels of lipids are also associated with poor 
survival (Crawford et al., 2009) and grade (Murphy et al., 2003) in adult brain tumours.  
13 
 
Gly has also been identified as a feature of high grade in paediatric brain tumours (Davies et 
al., 2010a). However, whilst grade is associated with prognosis, tumours of the same type 
and grade can belong to molecular subgroups which have very different outcomes (Taylor et 
al., 2012). MRS provides an avenue to investigate molecular subgroups and retrospective 
analysis of medulloblastomas determined that metabolite profiles could distinguish between 
the sonic hedgehog and group 3/4 subgroups (Blüml et al., 2015). Furthermore, Citrate (Cit), 
a metabolite that has been suggested as increased in DIPG (Seymour et al., 2008), was also 
identified in a subgroup of grade II paediatric astrocytomas with aggressive behaviour (Blüml 
et al., 2011). In a small study of pilocytic astrocytomas, lower levels of mI were observed in 
pre-treatment MRS of tumours which progressed compared to those where disease was 
stable (Harris et al., 2008a). MRS has also been used in adult brain tumours to detect 2-
hydroxyglutarate (Choi et al., 2012), a biomarker associated with isocitrate dehydrogenase 
mutations (Dang et al., 2009) and improved survival in adult gliomas (Cohen et al., 2013). 
MRS can also be used as a tool for monitoring response to treatment. Optic pathway 
gliomas, where tumours are often incompletely resected (Nicolin et al., 2009), were found to 
have significantly lower mI levels at follow up in tumours that had progressed compared 
with initial MRS (Harris et al., 2008a). A reduction in Cit has been observed in DIPG following 
radiation therapy (Seymour et al., 2008). DIPG patients with an increase in tCho/NAA 
between imaging time points were at significantly greater risk at death than those with 
stable or reduced levels (Steffen-Smith et al., 2011a). In adult brain tumours, changes in 
normalised tCho between week 4 of radiotherapy and post-radiotherapy were predictive of 
survival (Quon et al., 2011). While a reduction in tCho was closely matched to reductions in 
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tumour volume (Murphy et al., 2004). Finally, changes over 14 months of the MRS profiles of 
grade II gliomas treated with temozolomide are related to outcome (Guillevin et al., 2011).  
1.3 Introduction to Neurodegenerative Disease 
Treatment of brain tumours with radiotherapy can affect brain structure and function 
(Padovani et al., 2012; Parihar and Limoli, 2013).  This loss of function or structure of cells 
with the central nervous system is called neurodegeneration. In addition to 
neurodegeneration following treatment, it can also arise in children as a result of inherited 
metabolic disorders. Neurodegeneration is associated with a number of other disease states, 
including amyotrophic lateral sclerosis (ALS); dementias, such as Alzheimer’s disease; 
Huntington’s disease and multiple sclerosis 
1.3.1 Imaging of Neurodegenerative Disease 
Structural MRI is typically used to assess local and global volume changes (Risacher and 
Saykin, 2013), however diagnosis of neurodegenerative diseases can be difficult due to 
similar clinical presentations and diagnosis is often only confirmed post-mortem (Mok et al., 
2004). Therapies for neurodegenerative disease tend to treat only the symptoms without 
affecting the cause of the disorder; however neuroscience advances could facilitate the 
development of therapies to treat the underlying condition (Stoessl, 2012). Brain volume 
losses, particularly of grey matter, correlate with cognitive impairment in multiple sclerosis 
(De Stefano et al., 2014) and CSF volume in Huntington’s disease is associated with disease 
progression and severity (Squitieri et al., 2009). In Alzheimer’s disease (AD), hippocampal 
volume loss in AD has been identified as an early potential indicator of AD pathology. 
However, regional brain volume changes occur even in elderly people who are unlikely to be 
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presymptomatic of neurodegenerative disease (Fjell et al., 2013). Identification of 
biomarkers of disease and prognosis which can be monitored is therefore required.  
Diffusion tensor imaging (DTI) probes tissue microstructure, providing a measure of tissue 
integrity. In AD, reduced fractional anisotropy (FA) and increased diffusion relative to normal 
brain has been observed in white matter (Stebbins and Murphy, 2009). Reduced white 
matter integrity is also associated with Parkinson’s disease (Auning et al., 2014) and 
Huntington’s disease (Poudel et al., 2014).  
Neuroimaging advances could lead to the early detection of preclinical neurodegenerative 
diseases, enabling improved clinical outcomes following treatment at an early stage.  
1.3.2 MRS of Neurodegenerative Disease 
Alzheimer’s disease (AD), a form of dementia, is one of the most studied neurodegenerative 
diseases with MRS. While much of the following discussion will focus on AD, a number of 
these findings are typical of neurodegenerative diseases and cognitive decline, particularly 
for dementias (Kantarci, 2013). NAA has been identified as a significant biomarker of 
neurodegenerative disease due to its role in neuronal integrity. In longitudinal studies of 
Alzheimer’s patients, a decrease in NAA levels was associated with severity (Adalsteinsson et 
al., 2000; Kantarci et al., 2008), however reductions in NAA levels were not accompanied by 
changes in grey matter volume (Kantarci et al., 2008). In addition to reduced NAA, an 
increase in mI (Kantarci et al., 2000; Miller et al., 1993; Oz et al., 2011) and decreased Glu 
(Oz et al., 2011; Rupsingh et al., 2011; Unschuld et al., 2012) have been observed in a 
number of AD studies. A reduction in NAA accompanied by an increase in mI has also been 
observed in Huntington’s disease (Sturrock et al., 2015) 
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Metabolite biomarkers could provide early indicators of disease in AD. The increase of mI 
levels in AD has been seen to appear early in presymptomatic individuals with familial AD, 
prior to structural changes (Kantarci et al., 2010)).   
MRS has been used as a tool for monitoring treatment and disease progression. A temporary 
increase in NAA for patients treated with donepezil, relative to patients treated with 
placebo, suggested that donepezil could potentially have protective effects in AD (Krishnan 
et al., 2003). Further evaluation with MRS of donepezil treatment observed lower levels of 
NAA, tCho and mI/Cr after four months of treatment, with decreased levels of tCho and 
mI/Cr possibly suggesting a positive treatment effect (Bartha et al., 2008). Changes in 
metabolite levels have also correlated with cognition scores following treatment, with 
increases in Glu following galantine treatment associated with improved cognitive 
performance (Penner et al., 2010). In multiple sclerosis, an increase in the mI/NAA ratio was 
significantly associated with decreasing brain volume and disability evolution (Llufriu et al., 
2014). 
1.4 Introduction to MRS Quantification 
While MRS can be interpreted in a qualitative manner, the association of metabolite 
concentrations with prognosis and their role in non-invasive diagnosis and treatment 
monitoring show that quantified MRS metabolite biomarkers and can potentially become a 
powerful tool for clinical decision making. Quantification of MRS can be performed by either 
calculating the area under the curve of the MRS peak or by fitting the whole spectrum using 
prior knowledge using software such as LCModel (Provencher, 2001a) and TARQUIN (Wilson 
et al., 2011a). The two main ways of expressing quantified MRS data are as metabolite ratios 
and as absolute concentrations. While metabolite ratios will reduce errors associated with 
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partial volume contamination with CSF, they can be confounded by unexpected changes in 
metabolite levels, giving no indication of why the ratio has changed. Furthermore, 
metabolite ratios are less reproducible than absolute concentrations (Minati et al., 2010), 
break down when the denominator is small and can be less sensitive to abnormalities than 
absolute concentrations (Simister et al., 2002). Quantification of MRS, using water as an 
internal reference with known concentration values, enables absolute concentrations to be 
reported (R. Kreis et al., 1993). The use of absolute concentrations in combination with 
pattern recognition techniques has also been shown to improve classification accuracy when 
compared with pattern recognition based on whole spectrum appearance (Opstad et al., 
2007). 
While up to 35 brain metabolites can be quantified in vitro (Govindaraju et al., 2000), far 
fewer can be detected in vivo. Ex vivo and in vitro investigations, such as high-resolution 
magic angle spinning (HR-MAS), can be performed at high field strengths that are not 
available for clinical studies. HR-MAS uses the high field strengths available to improve line 
shape and linewidth, improving peak assignment in brain tumour tissue samples (Barton et 
al., 1999).  
A number of factors can affect the accuracy of metabolite quantification in vivo. The signal -
to-noise ratio (SNR) and spectral resolution of clinical MRS is poor when compared with high 
field HR-MAS. Unambiguous peak assignment of metabolites is therefore restricted to a few 
metabolites in vivo. This is typically due to the spectral overlap of peak resonances, with 
coupled metabolites often overlapping considerably, while metabolites present in very small 
concentrations can be difficult to distinguish from the background noise due to SNR.  
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Though low metabolite concentrations and spectral overlap can affect visual assignment of 
MRS peaks in vivo, quantification of MRS is reproducible and reliable (Mullins et al., 2008). 
However, coupled metabolites typically have higher coefficients of variation. Nonetheless, 
metabolite concentrations measured with LCModel and TARQUIN correlate well with tissue 
concentrations estimated from HR-MAS (Opstad et al., 2010; Wilson et al., 2009b). 
When measured as absolute concentrations with reference to water, quantitative estimates 
of metabolite concentrations will also depend on a phenomenon called T2 relaxation  T2 
relaxation describes the MRS signal decay with echo time and a full description of T2 
relaxation, and the MR theory relevant to the work in the thesis, is provided in Chapter 2.  
The difference in the T2 relaxation decays of water and metabolite is known to affect 
metabolite quantification, with the effect becoming more pronounced at longer echo times 
(Yamamoto et al., 2015a). The discrepancy between the T2 relaxation times of water and 
metabolite is illustrated schematically for typical examples in Figure 1-3. 
 
Figure 1-3: T2 relaxation decays of water and metabolite normalised to 1. 
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To acquire data without T2 relaxation decay is not currently possible in a clinical setting due 
to the technical limitations of clinical MR scanners. TARQUIN and LCModel account for T2 
relaxation by assuming T2 values typical of normal adult brain at 1.5 T. However, T2 
relaxation times are known to change with age (Kirov et al., 2008a), vary in regions of the 
brain (Ganji et al., 2012a) and are reduced at higher field strengths (Träber et al., 2004a).  
The accuracy of metabolite quantification will therefore depend on how well T2 relaxation, 
in addition to spectral overlap and data quality, is dealt with in the MRS analysis. 
1.5 Challenges of MRS Quantification 
Following the advent of field strengths of 3 T and higher, the acquisition of structural and 
advanced imaging in the same session is becoming possible in clinically feasible timeframes. 
With an increasing desire for personalised medicine, metabolite concentrations should be 
evaluated in prospective multi-centre clinical trials which link metabolite biomarkers to 
clinical outcomes. However, a number of factors are known to affect metabolite 
quantification and an investigation into how these factors affect metabolite quantification 
accuracy on a case-by-case basis is therefore required. 
The SNR and spectral resolution of in vivo MRS is poor at clinical field strengths when 
compared with ex vivo HR-MAS. Data quality is known to affect quantification accuracy at 
1.5 and 4 T with accuracy improving with SNR (Bartha et al., 2000); however an assessment 
of quantification accuracy at 3 T has not been performed. With an increasing body of 
evidence that coupled metabolites are potential prognostic biomarkers (Cohen et al., 2013; 
Harris et al., 2008a; Wilson et al., 2014, 2013), accurate quantification of them becomes 
more important. 
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Coupled metabolites can be difficult to detect using conventional short-TE MRS due to their 
lower signal intensity and significant spectral overlap with other metabolites. Various 
methods have been proposed to improve their detection and measurement. One common 
method is to use an optimised echo time. Optimised TEs exploit the J-evolution of coupled 
metabolites to enhance the signal intensity of a particular metabolite relative to 
neighbouring resonances. While optimised TEs may improve the visual identification of 
coupled metabolites, there is limited evidence that they improve measurement accuracy. An 
assessment of how the J-modulation and spectral overlap of coupled metabolites affects 
metabolite quantification would therefore be welcomed. 
Metabolite quantification at optimised TEs could also be confounded by T2 relaxation times 
with differences in the T2 values of water and metabolites having a greater effect at long TEs 
(Yamamoto et al., 2015a). Furthermore, relaxation times are also known to vary significantly 
between normal brain and pathology (Isobe et al., 2002; Li et al., 2008; Madan et al., 2015a; 
Sijens and Oudkerk, 2002). Whilst T2 relaxation times are known to affect quantification, 
there has been little formal assessment of how T2 variation affects metabolite quantification 
on a case-by-case basis at short-TE. Research has instead focused on how T2 differences will 
affect metabolite ratios (Li et al., 2008) and quantification at long echo times (Yamamoto et 
al., 2015a). 
J-resolved spectroscopy (JPRESS) has also been proposed to reduce the spectral overlap of 
metabolites at clinical field strengths. While optimised TEs exploit the J-evolution of coupled 
metabolites to improve metabolite detection at a s ingle TE, JPRESS exploits J-evolution 
differences over many TEs to spread the spectrum into a second dimension. Though JPRESS 
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can reduce the spectral overlap of coupled metabolites, it is characterised by long 
acquisition times and its analysis is not a straightforward task. The development of a clinical 
JPRESS protocol and postprocessing pipeline could therefore increase its utility in the clinical 
setting. 
Given the range of acquisition protocols and analysis methods available, a  systematic 
assessment of the various factors that affect metabolite quantification would help inform 
future protocol design and aid the validation of metabolite biomarkers in clinical trials and 
clinical practice.  Providing this information would be a major advance towards the 
widespread use of MRS biomarkers for clinical decision making.  
1.6 Aim 
To assess the importance of echo time and T2 relaxation in accurate metabolite biomarker 
quantification  
1.7 Objectives: 
 To investigate the effect of J-evolution and T2 relaxation on metabolite 
quantification using simulations, phantoms and volunteers (Chapter 4). 
 To assess how the T2 relaxation times of metabolites and water vary between 
normal brain and pathology at 1.5T and 3T (Chapters 5 and 6). 
 To investigate how the accuracy of metabolite quantification at 1.5 and 3T is 
affected by changes in T2 relaxation times (Chapters 5 and 6). 
 To assess how many echo times need to be collected to estimate the T2 
relaxation time of water at 3T(Chapter 6) 
 To develop a clinical protocol and processing pipeline for JPRESS at 3T and to 
implement it clinically in childhood brain tumours (Chapter 7). 
22 
 
1.8 Thesis Organisation  
Chapter 2 introduces the essential theory of MRS and its acquisition. The process of MRS 
quantification and analysis is also described in Chapter 2 along with further discussion of the 
factors that will affect MRS quantification. The general methods described in this work are 
then described in Chapter 3.  
The importance of echo time choice on accurate metabolite quantification is inves tigated in 
Chapter 4 using a combination of simulations, phantoms and volunteers. Three echo times 
are assessed using three spectral models and volunteer data. Simulated data is used to 
determine whether there is a single optimal echo time for accurate metabolite 
quantification. Whilst simulations allow an investigation into how spectral quality affects 
metabolite quantification, considerations such as T2 relaxation were not modelled. The 
influence of T2 relaxation time and echo time choice is therefore investigated using 
phantoms and volunteers.  
Chapter 5 presents a retrospective study of MRS data collected at 1.5 T using two echo 
times. T2 relaxation times are estimated in paediatric brain tumours and in normal age-
matched controls. The variation of T2 relaxation times between tumour types and between 
tumour and normal brain is assessed.  Metabolite quantification accuracy is assessed by 
correcting metabolite concentrations using case-specific T2 relaxation times and comparing 
to concentrations which have been corrected using various combinations of water and 
metabolite T2 relaxation times. 
Chapter 6 focuses on metabolite quantification and the need for case-specific T2 relaxation 
times at 3 T. A multi-TE MRS sequence is presented for quick estimation of the water T2 
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relaxation time. T2 relaxation times of common paediatric brain tumours are compared from 
1.5 and 3 T cohorts. The use of case-specific and literature T2 relaxation times for relaxation 
correction in paediatric brain tumours is compared. Water and metabolite T2 relaxation 
times are estimated from two echo times in the brain of adults with congenital adrenal 
hyperplasia and age-matched healthy controls. The importance of case-specific metabolite 
and water T2 relaxation times is assessed at 3 T. 
As a logical extension to the use of two echo times, a clinical protocol for the 2D J-resolved 
spectroscopy technique JPRESS is developed and optimised in Chapter 7. Clinical use of 
JPRESS has historically been limited by the long acquisition times associated with it. A 
protocol and processing pipeline which reduces the acquisition time from 40 minutes to 6 
minutes is presented. This protocol and processing pipeline is assessed in four children with 
brain tumours.  
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2. INTRODUCTION TO NUCLEAR MAGNETIC RESONANCE 
Nuclear magnetic resonance (NMR) has important applications in research and clinical use: 
magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). This 
chapter introduces the essential theory behind the NMR phenomenon and its application to 
MRS. A more detailed account of the theory is described in the following references (Graaf, 
2007; Hore, 1989; Keeler, 2010). This chapter also details the acquisition and quantification 
of MRS in a clinical and research setting. 
2.1 NMR Theory 
2.1.1 Nuclear Spin 
All nuclei have the intrinsic properties of mass, charge, magnetism and spin. It is nuclear spin 
upon which nuclear magnetic resonance (NMR) is founded.  
Isotope Nuclear Spin Gyromagnetic Ratio 
(MHz / Tesla) 
Natural Abundance 
(%) 
1H 1/2 42.58 99.985 
3He 1/2 -32.43 1.4 x 10-4 
13C 1/2 10.71 1.108 
19F 1/2 40.05 100 
23Na 3/2 11.26 100 
31P 1/2 17.24 100 
Table 2-1: Nuclear spin, gyromagnetic ratio and natural abundance of selected nuclei. 
 
Table 2-1 presents some of the NMR properties of selected nuclei which are present in vivo. 
Hydrogen is the most abundant nucleus with a non-zero nuclear spin in the human body. 
The high natural abundance of 1H, its high gyromagnetic ratio, γ, and high sensitivity make it 
a convenient target for MRI and MRS.  
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2.1.2 Nuclear Spins in Magnetic Field 
1H nuclei possess a magnetic moment related to its spin. In the absence of an external 
magnetic field, the magnetic moments are randomly distributed (Figure 2-1a).  
 
Figure 2-1: Dipole moment orientation in a) the absence of a magnetic field and b) in the presence of 
a magnetic field. c) The nuclear spin energy between the parallel and antiparallel states for a spin ½ 
nucleus as a function of magnetic field strength. 
 
In the presence of a magnetic field, B0, the spins will rotate around B0 with the speed of 
precession, ω0 (rad s
-1), given by the Larmor equation: 
 𝜔0 = 𝛾𝐵0 (Equation 2-1) 
  
with the spins of the nuclei aligning in either parallel (↑) or antiparallel (↓) to B 0 (Figure 
2-1b). The parallel and antiparallel spins are separated by an energy gap given by: 
 ∆𝐸 = 𝑕 𝜔0 (Equation 2-2) 
and the population of each state is given by:  
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𝑁↑ = 𝑁↓𝑒
∆𝐸 𝑘𝑏𝑇  (Equation 2-3) 
  
Where N↑ is the number of spins parallel to the field, N↓ is the number of spins antiparallel, 
kb is the Boltzmann constant and T is the temperature.  
Nuclei aligned parallel to the magnetic field are at a lower energy level, resulting in more 
spins in this state (Figure 2-1). This is called the equilibrium or ground state. By virtue of 
having more nuclear spins aligned parallel to the external field, a net magnetisation occurs in 
the same direction as B0. This is described as longitudinal magnetisation, Mz, along the z-axis 
by convention and this is the basis of MR signals. As the dipole moments are distributed 
randomly on the x-y plane, there is no transverse magnetisation and the dipole moments are 
not in phase with each other (Figure 2-2a). 
 
Figure 2-2: Phase orientation of spins at a) thermal equilibrium, where phases are randomly 
distributed, and the net magnetisation is longitudinal only and b) following application of RF pulse 
such that all spins are coherent (i.e. have the same phase) and magnetisation is in the transverse 
plane.  
When a radiofrequency (RF) pulse is applied of Larmor frequency, ω0, protons are excited 
from the low energy ground state to a high energy state. The net magnetisation is tipped 
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towards the transverse x-y plane and the nuclear spins become coherent (Figure 2-2b). 
When the RF pulse is removed, the now transverse magnetisation rotates around B0 and 
induces an electromotive force (emf) on the surrounding receiver coils.  
As the transverse magnetisation rotates around B0, the nuclear spins dephase, losing phase 
coherence, and the emf signal induced on the receiver coils decays exponentially with time. 
The signal induced on the receiver coils is called the free induction decay (FID) and is 
displayed in Figure 2-3.  
 
Figure 2-3: The free induction decay induced by transverse magnetisation. 
2.1.3 Relaxation 
The loss of transverse magnetisation is called T2 relaxation and it is caused by the exchange 
of energy between spins. In practice, due to inhomogeneities in B0 the decay of transverse 
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magnetisation is quicker than would be expected from T2 decay alone. The contribution of 
T2 can be separated from the effect of B0 inhomogeneity through the generation of spin-
echoes. The T2 relaxation time constant is determined by the amount of time it takes for the 
magnetisation to decay to 37% of its original value (Figure 2-4). 
 
 
𝑀𝑥𝑦 = 𝑀0𝑒
−𝑡 𝑇2  (Equation 2-4) 
  
In addition to the decay of the transverse magnetisation, in the absence of the RF pulse the 
magnetisation will also return to its equilibrium state with magnetisation only present in the 
longitudinal plane. This process is called T1 relaxation. The T1 relaxation time is the time it 
takes for the longitudinal magnetisation to recover 63% of its initial magnetisation after 
being tipped into the x-y plane (Figure 2-4). 
 
 
𝑀𝑧 = 𝑀0(1 − 𝑒
−𝑡 𝑇1 ) (Equation 2-5) 
  
Differences in the T1 and T2 relaxation times of different tissue types are exploited in MRI to 
produce anatomical images. The influence of T1 and T2 relaxation on MRS is further 
discussed later in this chapter. 
29 
 
 
Figure 2-4: The decay of a) longitudinal (T1) and b) transverse (T2) relaxation. 
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2.2 MRS Theory 
 
Figure 2-5: a) The free induction decay induced by in vivo MRS in the time domain and b) the 
frequency domain spectrum following a Fourier Transform. 
The FID acquired by in vivo MRS is a combination of signals induced by small molecules 
involved in metabolism, called metabolites, and by larger molecules such as lipids and 
macromolecules.  A Fourier Transform converts the FID from the time domain to the 
frequency domain, producing a spectrum of peaks (Figure 2-5). Metabolites have different 
chemical structures and experience slightly different magnetic fields which cause small 
alterations in resonant frequencies (Equation 2-1). This allows identification of metabolites 
by their characteristic spectroscopy. The spectral appearance of metabolites is governed by 
two chemical properties: chemical shift and J-coupling. 
2.2.1 Chemical Shift  
In the presence of an applied magnetic field B0, the electrons orbiting the nucleus induce a 
small magnetic field, Binduced, which opposes B0 and the nucleus is said to be ‘shielded’. The 
amount of shielding experienced by a nucleus changes the local magnetic field that the 
nucleus experiences. While the size of the induced field is small – typically around 10-6 times 
smaller than B0– the difference in shielding experienced by the nuclei of a molecule is large 
31 
 
enough to cause observable shifts in the resonance frequencies as determined by the 
Larmor equation (Equation 2-1). 
To allow comparison between different field strengths, the chemical shift, σ, is typically 
reported in parts per million (ppm). The ppm unit is independent of field strength and is 
given by:   
 σ = 
ν − νref
νref
× 106 (Equation 2-6) 
 
Magnetically equivalent nuclei – those that experience the same shielding and same local 
magnetic field –   can be grouped together and resonate at the same energy. As is seen in 
Figure 2-6, glycine has two magnetically equivalent protons which produce a single MRS 
peak at 3.54 ppm. Creatine has a group of three protons which resonates at 3.02 ppm and a 
group of two protons which produces a peak at 3.91 ppm. The intensity of a resonance peak 
is proportional to the number of protons in that group. Therefore the creatine peak at 3.02 
ppm is 1.5x more intense than the peak at 3.91 ppm.  
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Figure 2-6: The chemical structure and spectrum of a) glycine and b) creatine at 3 Tesla. Each 
spectrum has been simulated using VESPA at an echo time of 0 ms. 
2.2.2 J-coupling 
Until this point, magnetic resonance has been treated in a semi-classical manner, stating 
that the spins will align either parallel or anti-parallel to the magnetic field. Strictly, spin is 
the intrinsic angular momentum, I, of a nuclei and it is a quantum mechanical property. As 
before, the angular momentum of a 1H nuclei can only exist in two discrete states: +1/2 and -
1/2 which are known as the α and β states respectively. The α and β states correspond to 
two energy eigenstates; however, the system is not restricted to these eigenstates but is a 
superposition of the two energy eigenstates.   
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The spin Hamiltonian H0 for a 
1H nuclei describes its energy and is proportional to Iz: 
 𝐻0 = 𝜔0𝐼𝑧 (Equation 2-7) 
With eigenstates corresponding to the energy of the system given by:  
 
𝐻0 α 
 >= +
1
2
𝜔0 α 
 > 
(Equation 2-8) 
 
𝐻0 β 
 >= +
1
2
𝜔0 β 
 > 
(Equation 2-9) 
Unlike chemical shift, which depends on magnetic field strength, J-coupling is independent 
of the applied magnetic field B0. J-coupling arises because the electrons of nuclei with non-
zero spin can influence each other through chemical bonds.  
The energy, E, of J-coupling is expressed as: 
 𝐸 = 𝐽𝐴𝑋 𝑰𝑨𝑰𝑋  
 
(Equation 2-10) 
Where JAX is called the coupling constant between the two nuclei, A and X, and IA and IX 
represent the angular momentum of the spins. 
The magnitudes of the chemical shift difference between nuclei (Δν) and the coupling 
constant, J, determines the appearance of the spectrum. When Δν >> J, the spins are said to 
be weakly coupled. 
Lactate is a weakly coupled metabolite and its spectrum can be understood by considering 
the energy states that each group can take Figure 2-7.  The three H atoms of the methyl 
group each have the same chemical shift and are each coupled to the methine proton with a 
coupling constant of 6.93 Hz. The methine proton can be in either the α state or the β state. 
The energy difference between the α and β states leads to a splitting of the resonance into 
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two peaks of equal heights called a doublet (Equation 2-8, Equation 2-9). Similarly, the 
methine proton has a chemical shift of 4.10 ppm and is coupled to the three methyl Hs. 
Extending this argument, the methine resonance is split into four peaks (called a quartet) 
with an intensity ratio of 1:3:3:1.  
 
Figure 2-7: a) The energy level diagram and splitting experienced due to J-coupling and b) the 
chemical structure and spectroscopy of lactate at 3 Tesla. 
Whilst the spectra of weakly coupled molecules can be easily understood in this manner, the 
same is not true for strongly coupled molecules. Strong coupling is said to occur when Δν is 
of the same order as J. 
Under strongly coupled conditions, the energy levels for a pair of spin 1/2 nuclei, A and B, do 
not belong to well defined states of spin. The J-coupling interaction mixes the states αAβB 
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and βAαB and modifies their energies, leading to a more complex pattern with deviations in 
the weakly coupled pattern of peak intensities and position. The effects of strong coupling 
are shown for a two spin system in Figure 2-8. As the two resonances move closer together, 
the intensity of the inner peaks increases and the outer peaks reduce in size. This intensity 
distortion of the resonances is sometimes called the roofing effect and can aid the detection 
of strongly coupled metabolites. For systems with more than two spins, such as glutamate, 
more peaks than would be expected under the weak coupling limit can appear. For this 
reason, it is necessary to use computer simulations which describe the system using the 
Hamiltonian, the chemical shifts and coupling constants to predict the spectral appearance. 
 
Figure 2-8: Simulated spectra for two coupled spin 1/2 nuclei for a range of Δν/J 
2.3 MRS Acquisition 
2.3.1 Volume Selection 
MRS acquisition schemes can be described as either single voxel or multi -voxel. These 
phrases describe how many regions of interest MRS is acquired from. Single voxel 
spectroscopy (SVS) is collected from one region of interest and is the focus of this thesis.  
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MRS is acquired following the acquisition of anatomical MRI. The three planes of the 
anatomical image are used to define the voxel. The voxel should be placed carefully to avoid 
bone, scalp and air which can reduce spectral quality or introduce unwanted lipid signals. In 
the case of brain tumours, care should also be taken to avoid placing the voxel over adjacent 
normal brain as prominent signals from normal brain, for example NAA, can confound 
results. 
2.3.2 Shimming 
Imperfections in the magnetic field B0 lead to equivalent nuclei experiencing slightly 
different magnetic fields. A consequence of this is that equivalent nuclei resonate at 
different frequencies and this leads to a broadening of the metabolite peaks. The 
broadening of metabolite peaks has the effect of reducing spectral resolution which can 
make distinguishing different metabolite peaks difficult. Shimming is performed to reduce 
the B0 inhomogeneity over the voxel. This is done by orientating shim coils to produce a 
magnetic field that compensates for B0 inhomogeneity.  
2.3.3 Water Suppression 
Approximately two-thirds of the human body is composed of water. Consequently the 
concentration of water is substantially larger than that of metabolites in the voxel. This leads 
to an MRS water signal which is approximately 10,000 times greater than that of 
metabolites. The water signal is suppressed in order to obtain useful metabolite 
spectroscopy (Castillo et al., 1996). In this thesis the water is suppressed using the chemical 
shift selective (CHESS) method (Haase et al., 1985). CHESS selectively excites the water 
molecules present and a spoiler gradient is applied to dephase the excited spins. 
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2.3.4 Acquisition Methods 
Volumes are excited using pulse sequences with slice selective pulses which are designed to 
acquire data only from that volume. This is accomplished by eliminating signals from outside 
the signal through phase cycling of the RF pulses and by using sufficiently large crusher 
gradients. Various pulse sequences exist and the choice of pulse sequence and acquisition 
parameters will often depend on the goals of the experiment.  This section describes some 
of the acquisition parameters and conventional single voxel pulse sequences used in MRS.  
Key acquisition parameters include the number of signal averages (NSA), the repetition time 
(TR) and the echo time (TE) (Figure 2-9). To maximise the acquired MRS signal, a pulse 
sequence is often applied multiple times with the resulting signals averaged. The number of 
times a pulse sequence is repeated is given by the NSA. The TR describes the time between 
the start of one pulse sequence and the beginning of the next. The choice of TR wi ll 
influence the amount of signal acquired and should be informed by the T1 relaxation times 
of water and metabolites. 
The TE is defined as the time between the first 90° pulse and the signal acquisition. The 
spectrum acquired will depend on the choice of TE. The use of a short TE, used in this thesis 
to describe echo times of approximately 30-40 ms, helps to maximise the number of MRS 
signals observed by minimising the effect of T2 relaxation. Broad resonances from 
macromolecules and lipids are present in short-TE MRS, the combination of these broad 
resonances is often called the macromolecular baseline. Because of their short T2 relaxation 
times relative to metabolites, lipids and macromolecules are not present in MRS at long -TE 
(135 ms in this thesis), producing a flat baseline.  
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Figure 2-9: Simplified PRESS pulse sequence.  
STEAM uses three 90° pulses to stimulate an echo and is able to achieve very short-TEs 
(Frahm et al., 1989). Like STEAM, the PRESS pulse sequence (Figure 2-9) consists of three RF 
pulses. It is a double spin echo technique that consists of a 90° pulse followed by two 
refocusing 180° pulses to create a spin echo (Bottomley, 1987). The TE of the PRESS 
sequence is described by TE1 and TE2 , with TE1 defined as double the time the 90° pulse and 
first 180° pulse and TE2 describing the remaining period of the echo time.  Optimised (TE1, 
TE2) echo time spacing can be used to improve detection of coupled metabolites (Choi et al., 
2012, 2011a; Snyder and Wilman, 2010a).  
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Chemical shift displacement errors arise because molecules resonate at different 
frequencies. The volume of interest excited by pulse sequences such as PRESS will therefore 
differ for each resonance. Chemical shift displacement errors can also lead to signal 
cancellation for coupled resonances due to anomalous J-modulation and errors increase 
with field strength (Lange et al., 2006). LASER is a technique which uses the large bandwidth 
of adiabatic RF pulses to produce a uniform excitation profile, therefore reducing chemical 
shift displacement errors (Garwood and DelaBarre, 2001). While LASER reduces the 
influence of chemical shift displacement and other technical challenges that occur at field 
strengths of 3 T and above (Zhu and Barker, 2011), it is not available on all MR scanners. Of 
the two widely available sequences across vendors and field strengths described here, PRESS 
and STEAM, PRESS is the most widely used MRS sequence in the clinical environment and is 
used in this thesis as a compromise between SNR, multiplet dephasing and reduced baseline 
interference. 
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Figure 2-10: J-modulation of lactate and glutamate with increasing echo time. 
 
JPRESS is also used in this thesis. JPRESS is a two-dimensional spectroscopy technique (Ryner 
et al., 1995; Thomas et al., 1996) based on the PRESS pulse sequence. JPRESS is collected at 
multiple echo times, keeping TE1 constant (Figure 2-9), and exploits the change in coupled 
spin systems with echo time (Figure 2-10) to spread the spectrum into two dimensions. This 
reduces the spectral overlap of metabolite compared to conventional short-TE PRESS.  
2.4 MRS Quantification 
2.4.1 Introduction to Metabolite Quantification 
The simplest method of quantifying metabolites is through integration of the peaks. This 
approach is limited to simple spectra without overlapping resonances. Single value 
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decomposition (SVD) can also be used to decompose the spectrum into a series of 
resonances. The constructed series of resonances is described as a fit to the data. The quality 
of a fit to the data can be assessed by inspection of the residual signal (Figure 2-11). 
However, whilst SVD produces a fit which may look adequate on visual inspection, it does 
not have a biochemical basis. This can lead to resonances from the same metabolite 
appearing out of phase with each other or having the wrong relative peak intensities. These 
approaches may be adequate for single peaks at long-TE where the baseline is flat following 
T2 relaxation. However, with an increasing trend towards using short-TE and the added 
spectral complexity of short-TE, more sophisticated methods are required. This is particularly 
important as short-TE spectroscopy contains coupled metabolites, lipids and 
macromolecules which can be of importance in pathology.  Quantification which has a 
biochemical basis and utilises prior knowledge is therefore key.  
Quantification of the whole spectrum using prior knowledge can be performed using 
software packages such as LCModel (Provencher, 1993) and TARQUIN(Wilson et al., 2011b). 
These use a linear combination of metabolite, macromolecule and lipid signals, called a basis 
set, to model the signal. Basis sets can be made using experimentally acquired data or 
through simulations. Experimental basis sets are acquired from phantom data using the 
pulse sequence and protocol that will be used for MRS investigations. Phantoms are typically 
prepared with high metabolite concentrations, in the region of 100 mM, to ensure high SNR 
spectra are collected. While experimentally acquired basis sets can account for experimental 
factors, such as eddy currents and spatial profiles, they can be time consuming to obtain as 
phantom data is needed for every metabolite and protocol under investigation. 
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Furthermore, phantoms can be expensive to build and should be acquired at a physiological 
temperature which is a non-trivial task. 
 
Figure 2-11: Experimentally acquired data from a phantom containing choline (Cho), glutamate (Glu) 
and lactate (Lac) fitted with TARQUIN using a simulated basis set. 
Simulation of the basis sets using density matrix formalism is therefore an attractive 
proposition. The advantage of simulated basis sets is that they are noiseless and free of 
artifacts. Furthermore, variations in echo time are easily dealt with by simulations as they do 
not require the acquisition of additional experimental basis sets. TARQUIN, the analysis 
package used in this thesis, employs simulated basis sets. 
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2.4.2 Basis Set Simulation 
A priori knowledge of the chemical shift and coupling constants of a molecule is used to 
simulate their spectral appearance. Simulation of metabolites is performed following a 
quantum mechanical assessment of density matrices and is described in full by Levitt (Levitt, 
2008). A density matrix describes the energy levels and populations of a spin system. 
The system is assumed to begin in thermal equilibrium, given by an initial density matrix 
ρ(0). Pulse sequences are modelled as RF pulses followed by time delays. The Hamiltonian 
dictates the free evolution dynamics of a spin system and is determined by considering the 
molecule’s chemical shifts and the J-couplings between spins.  
The evolution of the density matrix, ρ(t), under different Hamiltonians, H, is such that: 
 𝝆 𝑡 = 𝑒−𝑖𝑯𝑡  𝝆(0)𝑒+𝑖𝑯𝑡 
 
(Equation 2-11) 
This enables calculation of the spin-system response to any pulse sequence and can include 
the effects of magnetic field gradients, delays and the RF pulse shapes used if they are 
known. Providing accurate prior knowledge is used, simulations of metabolite spectra agree 
extremely well with experimentally acquired data for both coupled and uncoupled spin-
systems. Furthermore, the density matrix formalism approach is equally suitable for both 
strongly and weakly coupled systems. This is shown in Figure 2-11 where the weakly coupled 
lactate and the strongly coupled glutamate have been fitted using a simulated basis set.  
2.4.3 Metabolite Quantification with TARQUIN 
2.4.3.1 Preprocessing 
TARQUIN  is a fully automatic package for quantification of MRS data (Wilson et al., 2011b). 
The algorithm preprocesses the data, simulates the basis set and then fits the data in the 
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time domain. The initial time domain points are truncated to remove the fast decaying 
components of the FID therefore reducing the influence of baseline components on the fit. 
The residual water signal is removed by Hankel singular value decomposition. A reference 
spectrum of synthesised peaks – for example, NAA, tCho and Cr in normal brain – is used to 
correct for frequency drifts and the data is automatically phased to prevent out of phase 
peaks.  
2.4.3.2 Processing 
The remaining signal is modelled in the time domain by a basis set containing metabolites, 
lipids and macromolecules. Metabolite sets are modelled using published values 
(Govindaraju et al., 2000) whilst lipids and macromolecules are modelled using estimated 
parameters (Provencher, 2001b). TARQUIN then modifies the basis signals to account for 
small differences in the lineshape and frequency due to slight experimental differences in 
the resonant molecules. A non-negative least squares projection is then used to estimate the 
signals of the experimental data, fitting in the time domain. Soft constraints on the ratios of 
NAA/NAAG and of various lipid/lipid and macromolecule/molecule are applied to the signal 
amplitudes to improve fitting stability and reduce overfitting.  
Concentrations are reported with reference to water (Roland Kreis et al., 1993) after 
accounting for the differences in the T2 relaxation times of water and metabolites. While 
concentrations are calculated with reference to an unsuppressed water signal, they can also 
be reported as a ratio to another metabolite present in the spectrum. However ratios can 
provide only limited information about the metabolic changes that occur. Consider a 
decrease in the NAA/Cr ratio. This could signify any of a decrease in NAA, an increase in Cr, 
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alterations to both NAA and Cr or a change in the T2 relaxation times of either or both of the 
metabolites involved. For this reason, concentrations are presented as absolute values. 
2.4.4 Errors in Quantification 
Any quantification method will be subject to error and uncertainty. Errors in metabolite 
concentration estimates are typically reported as Cramér-Rao lower bounds (CRLBs) 
(Cavassila et al., 2001, 2000). CRLBs represent the lower limit of the measurement error and 
are calculated following inversion of the Fisher matrix, F, and are given by the following 
(Graaf, 2007): 
 𝜎 ≥ 𝐶𝑅𝐿𝐵 =  𝑭−1 (Equation 2-12) 
Where F is given by 
 
𝑭 =
1
𝜎2
 𝑷𝑻𝑫𝐻𝑫𝑷  
(Equation 2-13) 
and σ is the standard deviation of the noise, P is the prior knowledge matrix holding 
derivates of one parameter with respect to another, and D holds the partial derivatives of 
the model function with respect to the parameters in question.  
As such, the CRLB will increase with both spectral overlap and noise. Strictly the CRLBs 
reported are only approximate measures as they are not calculated using an exactly known 
model (Graaf, 2007). Using an exact model is not practical for in vivo data as the nature of 
the macromolecular baseline is not precisely known. Differences in how LCModel and 
TARQUIN determine the baseline will therefore mean that CRLB estimates will vary between 
software packages. Furthermore, estimates of the noise are measured in the time domain by 
TARQUIN and in the frequency domain by LCModel and this could also lead to differences in 
CRLB values between the two programs.  
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The use of CRLBs is becoming increasingly controversial for use in MRS studies (Kreis, 2016; 
Near et al., 2013; Tisell et al., 2013). CRLBs are generally reported as a percentage relative to 
the estimated concentration. The relative CRLBs have been used to aid exclus ion of poor 
quality spectra and a maximum CRLB threshold of 50% has been recommended (Oz et al., 
2014). However, as a relative measure, this means that metabolites present at low 
concentrations – as is typically the case with NAA in paediatric brain tumours – will 
inherently have higher CRLBs regardless of fit quality. The use of thresholds can therefore 
lead to the false exclusion of good quality data. For this reason CRLBs should be used with 
caution and be accompanied by visual inspection of the spectrum and fit quality by 
experienced spectroscopists.  
2.4.5 Factors Affecting Metabolite Quantification 
Whilst the estimated concentrations are subject to error due to data quality, spectral 
overlap and imperfect fitting models, they are also subject to error due to assumptions 
made when postprocessing the data. Metabolite concentrations are calculated based on the 
following equation: 
 
Conc =
𝑠𝑖𝑔𝑛𝑎𝑙𝑎𝑚𝑝 ∗ 𝑤𝑎𝑡𝑒𝑟𝑐𝑜𝑛𝑐 ∗ 𝑤𝑎𝑡𝑒𝑟𝑎𝑡𝑡
𝑤𝑎𝑡𝑒𝑟𝑎𝑚𝑝
 
(Equation 
2-14) 
Where wateratt describes the difference in relaxation times between water and metabolites. 
As the concentration of water in vivo is approximately 10,000 ti mes greater than that of 
metabolites, proton density estimates can give an indication of the concentration of water, 
waterconc. Previous imaging data indicates that the proton density of tumour is between 1.25 
and 1.32-times greater than that of normal white matter and is between 1.03 and 1.14-fold 
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greater than that of grey matter. Concentrations determined using the 43,300 mM 
concentration of grey matter are therefore likely to be underestimated by 3-14%. 
By default, TARQUIN assumes the water signal has been collected from a homogenous voxel 
consisting of just white matter. White matter, grey matter and cerebrospinal fluid (CSF) are 
known to have different water concentrations (Roland Kreis et al., 1993), while the water 
content of brain tumours is not well known. Furthermore, the voxel will rarely contain only 
one of these components. Segmentation of the voxel into its different components should 
be performed to obtain the most accurate concentration values  in normal brain (Gasparovic 
et al., 2006a). 
In brain tumours, intravoxel heterogeneity can arise due to the presence of necrosis and 
cysts. Previous studies have shown that metabolite concentrations are inversely 
proportional to the diffusion measure of cellularity (Khayal et al., 2008), ADC, and the 
reduction in cell density that is associated with necrosis will lead to an overall reduction in all 
metabolite concentrations. While care should be taken to avoid placing the MRS voxel over 
necrotic regions, the reduction in metabolite concentrations will cancel through the use of 
ratios, and this is an option for investigating abnormality using the multi -voxel MRSI 
(Raschke et al., 2014). 
However, as described earlier, ratios can be confounded by changes in relaxation times . 
Molecules can relax at different rates depending on their microenvironment and the field 
strength.  Accounting for the relative signal reductions of water and the molecule under 
investigation is therefore important when reporting absolute concentrations.  TARQUIN 
accounts for differences in T2 relaxation time with the parameter Watt : 
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𝑊𝑎𝑡𝑡 =  
𝑒𝑥𝑝(−𝑇𝐸 𝑇2𝑤𝑎𝑡𝑒𝑟 )
𝑒𝑥𝑝(−𝑇𝐸 𝑇2𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 ) 
 
(Equation 2-15) 
By default Watt assumes a short echo time and T2 relaxation times typical of normal brain at 
1.5 T. However, T2 relaxation times are known to change with field strength (Träber et al., 
2004b)  and alter with pathology (Isobe et al., 2002; Li et al., 2008; Madan et al., 2015a; 
Sijens and Oudkerk, 2002). A new Watt value should therefore be calculated when 
quantifying data at long-TE, higher field strength or from pathology.  
The T2 relaxation time of tissue water in adult brain tumours has previously been shown to 
be elevated from 70-100 ms in normal brain to 175 ms at 1.5 T (Isobe et al., 2002) and 150 
ms at 3 T (Madan et al., 2015). The change in tissue water relaxation times in brain tumours 
can lead to metabolite concentration estimates using TARQUIN’s default settings to 
underestimate by approximately 30% and 35% at 1.5 and 3 T respectively at short-TE. 
Furthermore, a previous study has demonstrated that by not adequately accounting for T2 
relaxation, metabolite concentration estimates can be increased 7-fold at a TE of 288 ms 
(Yamamoto et al., 2015). However, paediatric brain tumours are biologically distinct from 
their adult counterparts (Gilheeney and Kieran, 2012) and estimates of T2 relaxation specific 
to paediatric brain tumours would be welcome.  
While the influence of T1 relaxation times on metabolite concentrations is small compared 
to T2 relaxation (Gasparovic et al., 2006), T1 relaxation times will also affect concentration 
estimates. The proportional differences between water and metabolite T1 relaxation times 
are much smaller than those of T2 relaxation (Mlynárik et al., 2001; Stanisz et al., 2005).  
While there is limited information on the T1 of tissue water in paediatric brain tumours, an 
early study indicated that the T1 of tissue water in brain tumours is comparable to that of 
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grey matter (Just and Thelen, 1988) and there are no observed differences in the metabolite 
T1 relaxation times between normal brain and pathology (Li et al., 2008; Sijens and Oudkerk, 
2002) or between field strengths (Träber et al., 2004). Assuming T1s of 1200 and 1400 ms at 
1.5 and 3 T respectively for tissue water and a constant metabolite T1 of 1350 ms, 
concentration estimates are likely to be underestimated by 6% at 1.5 T and overestimated 
by 2% at 3 T when repetition times of 1500 ms and 2000 ms are assumed. 
Overall, T2 relaxation times lead to the most significant source of error in metabolite 
concentration estimation, though T1 relaxation can cancel some of this effect. T2 relaxation 
times can be estimated by acquiring MRS at two echo times and this approach has been 
shown to provide complementary information and improve classification of paediatric brain 
tumours (Vicente et al., 2013). Furthermore, with long-TEs becoming more commonly used 
clinically (Choi et al., 2012), the errors associated with T2 relaxation time are compounded. 
For these reasons, T2 relaxation is investigated as a major source of error in metabolite 
quantification ahead of proton density and T1 relaxation effects in this thesis. 
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3. METHODS 
3.1 Simulations 
 
Simulations are a powerful research tool that can greatly enhance our understanding of MR 
spectroscopy. In this thesis, the spectral appearance of various in vivo metabolites at 3 T 
(127.8 MHz) was simulated for a range of echo times. All simulations were calculated using 
VESPA (Soher et al., 2011). VESPA is based on the GAMMA library (Smith et al., 1994) and 
simulates metabolite appearance using published literature values of chemical shift and J-
coupling values (Govindaraju et al., 2000). 
Spectra were simulated assuming an Ideal PRESS pulse sequence (PRESS Ideal) at various 
echo times (Figure 2-9). PRESS Ideal simulates hard 90 and 180 degree pulses and does not 
account for the specific, vendor-specific pulse shapes used when acquiring real data. The 
first echo time spacing (TE1) of the pulse sequence was kept constant at 10 ms for all 
experiments, such that (TE1 + TE2) = TE was (10 + 25 ms) for TE = 35 ms and (10 + 40 ms) for 
TE = 50 ms. 
Spectra were exported as jMRUI text with a Lorentzian lineshape of FWHM of 1 Hz. The 
sweep width and number of data points were 2000 Hz and 1024 respectively.  
The real and imaginary components of the FID corresponding to each metabolite and echo 
time combination were read into Python from the jMRUI text outputs using code written in 
house. 
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3.1.1 Simulation of PRESS 
The 1H spectral appearance of N-acetylaspartate (NAA), creatine (Cr), 
glycerophosphocholine (GPC), phosphocholine (PCh), glutamate (Glu), glutamine (Gln), 
glycine (Gly), lactate (Lac) and  myo-Inositol (mI) were simulated at echo times of 35, 80 and 
135 ms. These metabolites were combined into various spectral model systems to assess the 
importance of echo time choice for metabolite quantification 
To create the synthesised spectrum for each model, the FIDs corresponding to each 
metabolite were summed to create the overall FID of the spectrum. A residual water peak 
was added to simulate incomplete water suppression and random Gaussian noise was 
applied to the FID and the spectrum was line broadened. The resulting FID data was written 
into a DICOM file for analysis with TARQUIN (Wilson et al., 2011). Spectra were modelled 
under controlled conditions to assess only the influence of the spectral overlap of 
metabolites on metabolite quantification. Overlap of lipid and macromolecular resonances 
and inaccurate baseline modelling is also likely to impair metabolite quantification accuracy 
(Birch et al., 2016). 
3.1.2 Simulation of JPRESS spectra 
The JPRESS appearances of 20 metabolites which can be observed in vivo were simulated to 
aid identification of metabolites. JPRESS was simulated for alanine (Ala), asparate (Asp), 
citrate (Cit), creatine (Cr),  γ-Aminobutyric acid (GABA), glucose (Glc), glutamine (Gln), 
glutamate (Glu), glutathione (Glth), glycine (Gly), glycerophosphocholine (GPC), hypotaurine, 
lactate (Lac), myo-Inositol (mI), N-acetylaspartate (NAA), phosphocholine (PCh), scyllo-
Inositol (Scy) and taurine (Tau). 
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To simulate the dataset, the FIDs of each metabolite were calculated for 18 echo times 
ranging from 42 ms to 297 ms in 15 ms increments. A relaxation penalty given by exp(-
TE/250) was applied to each FID. The FIDs corresponding to each echo time were then 
combined and Fourier Transformed in two dimensions to produce the JPRESS spectrum.  
To assess the utility of JPRESS for discrimination between overlapping metabolites, JPRESS 
was also simulated for the following spectral models: NAA, Glu and Gln; mI and Gly; and 
GPC, PCh, Tau and Scy.  
3.2 MRS Acquisition 
Ethical approval was obtained for all studies and informed consent was granted. Single voxel 
MRS was acquired in a paediatric brain tumour cohort at Birmingham Children’s Hospital at 
1.5 and 3 T and from a congenital adrenal hyperplasia (CAH) population at Birmingham 
University Imaging Centre, with 1.5 T data collected using a Siemens Symphony Magnetom 
NUM4 scanner and 3 T data acquired using a Phillips Achieva scanner. Age matched controls 
were also collected for both cohorts.  
Spectroscopy was collected using either a single echo time (TE) or multiple TEs using a point-
resolved spectroscopy sequence (PRESS) (Bottomley, 1987). Where multiple TEs were 
collected, the spectroscopy sequences were linked as a parameter series to ensure the 
receiver gain stayed constant. MRS followed conventional imaging which consisted of T1 and 
T2-weighted imaging, with T1-weighted images also collected post contrast for the brain 
tumour studies. 
All MRS at 1.5 T was acquired with 35 ms short-TE and 135 ms long-TE and a TR of 1500 ms. 
At 3 T, the core protocol consisted was collected at short 36-41 ms TE and water 
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unsuppressed data collected  at 18 TEs spaced equally between 42 and 297 ms. A TR of 2000 
ms was used for each acquisition. Data was also collected in the CAH cohort at a long -TE of 
135 ms.  
A subset of paediatric brain tumours had JPRESS collected at 3 T from a 30 x 30 x 30 mm 
voxel. The JPRESS protocol consisted of water suppressed data collected at 18 TEs with equal 
spacing of 15 ms between 42 and 297 ms. A TR of 2000 ms was used and the NSA/TE was 8.  
3.3 Processing 
3.3.1 Voxel Segmentation 
A T1-weighted image of the brain was converted from DICOM to NIfTI using MRICron 
(Rorden and Brett, 2000). The T1-weighted image was skull stripped using the FSL (Smith et 
al., 2004) tool BET to remove extra-cerebral tissues such as skin, bone and the eyeballs  
(Smith, 2002). A mask of the spectroscopy voxel was created and segmentation was 
performed using the FSL tool FAST to determine the amount of grey matter (GM), white 
matter (WM) and cerebrospinal fluid (CSF) present in the voxel (Zhang et al., 2001). 
Metabolite Quantification 
Metabolite concentrations were initially quantified with TARQUIN v4.3.8 using the internal 
basis set 1H brain + Cit, Glth, Gly. The following metabolite, lipid and macromolecule signals 
were included in the basis set: Ala, Asp), GABA, GPC, Glc, Gln, Glth, Glu, Gly, mI, Lac, NAA, N-
acetylaspartylglutamate (NAAG),PCh, phosphocreatine (PCr), Scy, Tau, lipids at 0.9, 1.3 (a+b) 
and 2.0 ppm and macromolecules at 0.9, 1.2, 1.4, 1.7 and 2.0 ppm.  
The water attenuation parameter, Watt, was set to 1 and the water concentration was 
assumed to be 43,300 mM, the same as grey matter, unless otherwise stated.  
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3.3. T2 Relaxation Estimation 
The metabolite signal amplitudes estimated by TARQUIN were fitted to a monoexponential 
decay curve to estimate the T2 relaxation times of metabolites. The T2 relaxation time of 
water was estimated from either two TEs collected at 35-41 and 135 ms or from five TEs 
collected between 42 and 112 ms with 15 ms spacing between TEs. 
Concentration Correction for Relaxation Effects 
Metabolite concentrations in brain tumours were corrected for relaxation effects by 
multiplying initial concentration estimates by Watt. Watt is calculated using estimates of the 
relaxation times and is calculated for brain tumours using: 
 
𝑊𝑎𝑡𝑡 =  
𝑒𝑥𝑝(−𝑇𝐸 𝑇2𝑤𝑎𝑡𝑒𝑟 )
𝑒𝑥𝑝(−𝑇𝐸 𝑇2𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 ) 
 
(Equation 3-1) 
For normal brain, the reported metabolite concentrations were corrected for relaxation 
effects in accordance with the method detailed by Gasparovic et al (Gasparovic et al., 
2006b). The volume estimates of grey matter, fGM_v, white matter, fWM_v, and cerebrospinal 
fluid, fCSF_v, from image segmentation were used to estimate the water attenuation factor in 
normal brain, given by: 
  
𝑊𝑎𝑡𝑡 =
𝑓𝐺𝑀𝑅𝐺𝑀 + 𝑓𝑊𝑀𝑅𝑊𝑀 + 𝑓𝐶𝑆𝐹𝑅𝐶𝑆𝐹
(1 − 𝑓𝐶𝑆𝐹)𝑅𝑚𝑒𝑡
 
(Equation 3-2) 
  
Where RGM, RWM, RCSF and Rmet describe the relaxation of GM, WM, CSF and the metabolites 
respectively and fGM, fWM and fCSF describe the MR-visible water densities of these volumes. A 
full description of these parameters is described in the following reference (Gasparovic et al., 
2006b). 
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For MRS data collected at multiple echo times, the spectroscopy was quantified at each TE 
and subsequently corrected for relaxation effects. The mean concentration of the estimates 
at all echo times is reported.  
3.4 Quality Control 
The location of MRS voxels was assessed on conventional MRI to confirm the voxel was 
placed away from bone, scalp and air. For paediatric brain tumour cases, voxel placement 
was also assessed to confirm that the voxel was placed over the solid enhancing component 
and that normal brain was not included.  
MRS was included in the data analysis following visual inspection of the spectrum for 
spectral artifacts. Visual inspection was also used to assess the presence of tNAA, tCho and 
tCr and confirm the TARQUIN fit to these resonances. In addition to visual inspection, 
quantified estimates of spectral quality were used for quality control. Broad peaks can 
hinder accurate metabolite quantification, therefore spectra with a water peak full width 
half maximum line width greater than 10 Hz were excluded from the analysis. Spectra with a 
signal to noise ratio less than 4 were also excluded. 
 
3.5 Statistical Analysis 
All statistical analysis was performed with Python with statistical significance was declared 
for P < 0.05. Paired and unpaired Student’s t-tests and non-parametric Mann-Whitney U-
tests were used to compare metabolite concentrations and T2 relaxation times between 
tissue types. Analysis of variance (ANOVA) tests were used to compare between multiple 
groups.   
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Estimated metabolite concentrations were compared by calculating the percentage 
difference between the two values: 
 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 = 100 × 
(𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛1 −  𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛2)
(𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛1 +  𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛2) 2 
 
(Equation 
3-3) 
 
In cases where the actual concentration was known, the percentage error was used: 
 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝐸𝑟𝑟𝑜𝑟 = 100 × 
(𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑒𝑠𝑡 −  𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑎𝑐𝑡)
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑎𝑐𝑡 )
 
(Equation 3-4) 
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4. INFLUENCE OF ECHO TIME CHOICE ON METABOLITE 
QUANTIFICATION 
4.1 Introduction 
Metabolite concentrations are fundamental biomarkers. The metabolite profile of an MRS 
spectrum can demonstrate differences between both normal brain and brain tumours and 
between tumour types (Davies et al., 2008b; Panigrahy et al., 2010b). Quantified metabolite 
concentrations can also be used for non-invasive diagnosis (García-Gómez et al., 2009; Preul 
et al., 1996), treatment monitoring (Harris et al., 2008b; Steffen-Smith et al., 2011b) and 
treatment planning (Pirzkall et al., 2009).  
MRS has historically focused on metabolites with large singlets without significant spectral 
overlap and lactate. However, there is emerging evidence that two pairs of metabolites are 
important in childhood brain tumours. The first pair, glutamate (Glu) and glutamine (Gln), 
are coupled metabolites, each with multiple resonances spread between 2.0 and 2.5 ppm.  
In high grade cerebellar tumours, Gln was found to be significantly lower and Glu was found 
to be significantly higher, when compared with low grade tumours (Davies et al., 2008b) 
The second pair of metabolites is glycine (Gly) and myo-Inositol (mI). Gly presents as a single 
peak at 3.55 ppm and elevated levels are associated with an increase in grade (Davies et al., 
2010b). The most prominent mI resonance is also at 3.55 ppm. High levels of mI are 
indicative of low tumour grade in brain tumours while low levels of mI have been found in 
tumours which would later progress (Harris et al., 2008b). 
While the introduction of clinical field strengths of 3 T improves the dispersion of 
metabolites, reducing spectral overlap, there is still significant overlap between the 
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metabolites in each pair. This has led to the design of numerous acquisition protocols, each 
aimed at optimising measurement of a specific metabolite. 
 Acquisition methods proposed for measurement of coupled metabolites vary in complexity; 
however one of the simplest is to acquire MRS using an optimised TE. Using the chemical 
shift and J-coupling values of a metabolite, the spectral appearance of metabolites can be 
simulated at a range of echo times. By evaluating the spectral overlap with other 
metabolites and calculating the metabolite yield at each echo time, an echo time optimised 
for metabolite quantification can be proposed where overlapping resonances are minimised. 
Echo times of 40 ms (Mullins et al., 2008) and 80 ms (Schubert et al., 2004a) have been 
proposed for Glu, whilst an echo time of 110 ms has been proposed for measurement of Gln 
(Snyder and Wilman, 2010b). An echo time of 160 ms has been proposed for simultaneous  
measurement of myo-Inositol and glycine (Choi et al., 2011b).  
Though optimal echo times have been proposed to improve metabolite quantification, there 
is limited evidence that they improve the accuracy of metabolite quantification. Accurate 
metabolite quantification requires correction for T2 relaxation effects and correction for T2 
relaxation becomes more important at longer echo times (Yamamoto et al., 2015b). 
However, the effects of T2 relaxation times on accurate quantification have not been 
extensively assessed. 
In this chapter, a combination of simulations, phantoms and volunteer data is used to assess 
three spectral models. The model systems of Glu, Gln and NAA, and Gly, mI and Cho are 
used to investigate quantification of pairs of metabolites with overlapping resonances of 
similar intensities. A model system containing the major metabolites typical of normal brain 
59 
 
is also used. The aims of this chapter are to investigate the influence of J-coupling evolution 
with echo time and the importance of T2 relaxation times on accurate metabolite 
quantification. The chapter is presented in two sections, the first deals with the effect of 
echo time in simulations with T2 relaxation excluded and the second investigates the effects 
of both J-coupling and T2 relaxation using phantoms and volunteers. 
4.2 Quantification of Simulated Metabolite Spectra  
4.2.1 Methods and Materials for Simulation Experiments 
Three model systems containing various combinations of metabolites were assessed. The 
models were as follows: 
1) Glu, Gln, NAA with a ratio of 1:1:1 
2) mI, Gly, phosphocholine (PCh), GPC with a ratio of 2 : 1 : 1 : 1 
3) Brain: NAA, Cho, Cr, Glu, mI, Lac with a ratio of 12.5 : 3 : 10 : 12.5 : 7.5 : 5 
Models 1 and 2 were used to investigate pairs of metabolites important in paediatric brain 
tumours which can lead to contrasting clinical outcomes (Peet et al., 2012). The ratios were 
chosen to produce peaks of equal intensity for Glu and Gln in model 1 and for mI and Gly in 
model 2. Model 3 was chosen to assess concentrations that are typically seen in vivo 
(Govindaraju et al., 2000). 
Simulations  
Simulations of the three model systems were produced at three echo times to assess the 
influence of J-modulation and spectral overlap on metabolite quantification. A complete 
description of the process of simulating metabolite spectra is provided in Chapter 3.  
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Metabolite spectra were simulated at 3T using VESPA (Soher et al., 2011). Spectra were 
simulated at echo times of 35, 80 and 135 ms with a TE1 of 10 ms using an ideal PRESS 
sequence. Individual metabolite spectra were exported as text files with 1024 data points, a 
sweep width of 2000 Hz and a Lorentzian lineshape with a line width of 1 Hz. 
The free induction decays generated for each metabolite were read into Python. The 
metabolites were combined and weighted into various spectra according to the models 
detailed above. These idealised spectra did not include the presence of lipids or 
macromolecules and relaxation effects were not simulated. 
Noise was added to the noiseless spectrum to simulate SNR levels of 25, 15 and 5 and 
spectra were line broadened to a linewidth of FWHM of 3 Hz by applying an exponential 
decay apodisation function in the time domain. A second set of spectra with identical 
metabolite combinations and SNR was also generated and line broadened to a FWHM of 7 
Hz to assess the effect of shim on quantification.  
A new noise seed was created for each spectrum and the resulting spectrum was converted 
in to DICOM format for analysis with TARQUIN. 
The metabolite spectra were referenced to a simulated water spectrum and the metabolite 
concentration simulated was verified by quantifying a noiseless spectrum containing only 
one metabolite. 
The simulated spectra were analysed with TARQUIN with created basis sets which contained 
only the metabolites present in the spectrum. The results for each simulation run were 
recorded. The simulations were run until the mean metabolite concentration for each 
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metabolite in the model had converged on a value. The convergence point was 
mathematically defined as the point at which the mean metabolite concentration over all 
simulation runs did not deviate by more than 0.01 mM from the convergence point for 50 
successive points. 
The mean concentrations measured for each metabolite were compared to the simulated 
concentration to assess the accuracy of metabolite quantification. The percentage error and 
root mean square (rms) percentage errors of estimated concentrations compared with the 
simulated concentrations were calculated for each simulation run to investigate the 
precision and accuracy of metabolite quantification. 
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4.2.2 Results of Simulation Experiments 
4.2.2.1 Data Quality and Metabolite Quantification at 3 T 
 
Figure 4-1: Simulated metabolite spectra and TARQUIN fits of the brain model system including NAA, 
Cho, Cr, Lac, Glu and mI at TEs a) 35 ms, b) 80 ms and c) 135 ms with SNR 25 and FWHM 3 Hz. 
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 Figure 4-2: Simulated metabolite spectra and TARQUIN fits of the brain model system including NAA, 
Cho, Cr, Lac, Glu and mI at TEs a) 35 ms, b) 80 ms and c) 135 ms with SNR 5 and FWHM 7 Hz.  
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  FWHM 3 Hz, SNR 5 
 
FWHM 3 Hz, SNR 15 
 
FWHM 3 Hz, SNR 25 
TE (ms) NAA Cho Cr 
 
NAA Cho Cr 
 
NAA Cho Cr 
35 12.34 ± 1.28 2.94 ± 0.40 9.96 ± 1.09 
 
12.49 ± 0.63 2.96 ± 0.19 9.98 ± 0.53 
 
12.50 ± 0.40 2.97 ± 0.13 9.93 ± 0.33 
80 12.27 ± 1.16 2.97 ± 0.38 10.00 ± 1.08 
 
12.36 ± 0.54 2.98 ± 0.18 10.01 ± 0.49 
 
12.39 ± 0.33 2.99 ± 0.11 10.00 ± 0.32 
135 12.29 ± 1.52 2.94 ± 0.48 10.01 ± 1.35 
 
12.47 ± 0.64 2.97 ± 0.20 9.98 ± 0.55 
 
12.45 ± 0.36 2.97 ± 0.12 9.92 ± 0.32 
 
             FWHM 7 Hz, SNR 5 
 
FWHM 7 Hz, SNR 15 
 
FWHM 7 Hz, SNR 25 
TE (ms) NAA Cho Cr 
 
NAA Cho Cr 
 
NAA Cho Cr 
35 12.43 ± 1.20 2.95 ± 0.37 9.89 ± 1.01 
 
12.30 ± 0.62 2.90 ± 0.18 9.65 ± 0.49 
 
12.28 ± 0.37 2.89 ± 0.11 9.60 ± 0.30 
80 12.19 ± 1.02 2.96 ± 0.35 9.96 ± 0.96 
 
12.10 ± 0.47 2.93 ± 0.16 9.78 ± 0.45 
 
12.06 ± 0.26 2.92 ± 0.08 9.73 ± 0.24 
135 12.30 ± 1.08 2.97 ± 0.36 9.99 ± 0.93 
 
12.07 ± 0.49 2.91 ± 0.16 9.68 ± 0.40 
 
11.90 ± 0.32 2.86 ± 0.10 9.54 ± 0.27 
Table 4-1: Mean ± SD metabolite concentration for NAA (12.5 mM), Cho (3 mM) and Cr (10 mM) in the brain model system. 
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The brain model system, which contains NAA, Cho, Cr, Glu, mI and Lac at physiological 
concentrations, was simulated at TEs of 35, 80 and 135 ms. Representative spectra with SNR 
25 and linewidth 3 Hz and SNR 5 and linewidth 7 Hz are shown in Figures 4-1 and 4-2. The 
system was simulated with different metabolite linewidths and SNRs to evaluate the effect 
that changes in experimental conditions has on metabolite quantification.  Different noise 
seeds were applied to each simulation run and each run was analysed with TARQUIN. The 
spectral appearance of NAA, Cho and Cr is dominated by large single peak resonances. The 
mean and standard deviation of the concentrations estimated by TARQUIN for these 
metabolites is presented in Table 4-1. As the SNR increased, the standard deviation of the 
concentration estimate decreased. The mean concentrations were less accurate with a 
linewidth of 7 Hz compared with the mean at 3 Hz, however the standard deviation was 
smaller.  
The root mean square (RMS) percentage error of the estimated concentration is presented 
for NAA, Cho and Cr in Figure 4-2. The RMS percentage errors reduced with increasing SNR 
and were smaller with a linewidth of 3 Hz. The average RMS percentage error for an SNR of 5 
was 11.5% for NAA, Cho and Cr. The average RMS percentage errors were 5.6% and 4.1% for 
SNRs of 15 and 25 respectively.  
Overall, the mean estimated metabolite concentrations improved with narrow linewidths 
and increasing SNR. Metabolites with prominent singlet peaks without significant spectral 
overlap could be measured with an error of 5% with an SNR ≥ 15. 
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Figure 4-3: Root mean square (RMS) percentage error from the simulated concentration for N-
acetylaspartate (NAA), choline (Cho) and creatine (Cr) in the brain model system with SNRs and 
FWHMs of a) SNR 5; FWHM 3 Hz; b) SNR 15, FWHM 3 Hz;  c) SNR 25, FWHM 3 Hz; d) SNR 5, FWHM 7 
Hz; e) SNR 15, FWHM 7 Hz; f) SNR 25, FWHM 7 Hz 
4.2.2.2 Quantification of Coupled Metabolites and the Effect of Spectral Overlap 
Whilst NAA, Cho and Cr present with large single MRS peaks to facilitate quantification, Glu, 
mI and Lac have complex spectral appearances. The mean and standard deviation of the 
estimated Glu, mI and Lac concentrations in the brain model system are presented in Table 
4-2. As for NAA, Cho and Cr, the lowest standard deviations were found with an SNR of 25. 
Figure 4-3 presents the RMS percentage errors from the simulated concentrations for Glu, 
mI and Lac in the brain model system. The RMS percentage errors were significantly larger 
for Glu, mI and Lac compared to NAA, Cho and Cr at SNR 25 and FWHM 3 Hz (3.5% vs 10.9%, 
Student’s t-test, t = -6.8,  P = 0.0001). 
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  FWHM 3 Hz, SNR 5 
 
FWHM 3 Hz, SNR 15 
 
FWHM 3 Hz, SNR 25 
TE (ms) Glu mI Lac 
 
Glu mI Lac 
 
Glu mI Lac 
35 12.20 ± 4.43 7.06 ± 1.84 4.94 ± 1.96 
 
12.14 ± 2.54 7.17 ± 1.07 4.84 ± 1.12 
 
12.26 ± 1.57 7.20 ± 0.66 4.86 ± 0.73 
80 12.00 ± 3.91 7.26 ± 2.40 4.82 ± 1.26 
 
11.78 ± 2.23 7.44 ± 1.29 4.90 ± 0.66 
 
11.72 ± 1.44 7.59 ± 0.81 4.89 ± 0.42 
135 12.28 ± 2.90 7.45 ± 3.18 5.00 ± 1.30 
 
12.30 ± 1.26 7.37 ± 1.56 5.02 ± 0.59 
 
12.29 ± 0.70 7.50 ± 0.95 5.04 ± 0.35 
 
           
  FWHM 7 Hz, SNR 5 
 
FWHM 7 Hz, SNR 15 
 
FWHM 7 Hz, SNR 25 
TE (ms) Glu mI Lac 
 
Glu mI Lac 
 
Glu mI Lac 
35 11.80 ± 3.78 6.85 ± 1.57 4.91 ± 1.82 
 
11.67 ± 1.76 6.87 ± 0.74 4.69 ± 0.91 
 
11.71 ± 1.05 6.87 ± 0.46 4.73 ± 0.57 
80 11.21 ± 3.49 7.27 ± 1.99 4.73 ± 1.10 
 
10.66 ± 2.02 7.35 ± 0.99 4.70 ± 0.59 
 
10.34 ± 1.22 7.41 ± 0.69 4.66 ± 0.34 
135 11.96 ± 1.85 7.12 ± 2.06 4.95 ± 0.87 
 
11.80 ± 0.96 6.79 ± 0.98 4.90 ± 0.45 
 
11.72 ± 0.64 6.67 ± 0.58 4.81 ± 0.32 
Table 4-2: Mean ± SD metabolite concentration for Glu (12.5 mM), mI (7.50 mM) and Lac (5 mM) in the brain model system. 
68 
 
 
 
Figure 4-4: Root mean square (RMS) percentage error from the simulated concentration for 
glutamate (Glu), myo-Inositol (mI) and lactate (Lac) in the brain model system with SNRs and FWHMs 
of a) SNR 5; FWHM 3 Hz; b) SNR 15, FWHM 3 Hz;  c) SNR 25, FWHM 3 Hz; d) SNR 5, FWHM 7 Hz; e) 
SNR 15, FWHM 7 Hz; f) SNR 25, FWHM 7 Hz  
 
Two additional spectral model systems were simulated to assess the effect of overlapping 
metabolite resonances on metabolite quantification. The NAA, Glu and Gln model and the 
GPC, PCh, mI and Gly model are shown in Figure 4-4 and Figure 4-5 respectively. The mean 
and standard deviations concentration estimates are presented in Table 4-3 and Table 4-4. 
The RMS percentage errors for the NAA, Glu and Gln are shown in Figure 4-6 and for tCho 
(GPC + PCh), mI and Gly in Figure 4-7. 
The RMS percentage errors for NAA and Glu in the brain and in the NAA, Glu, Gln model 
systems were compared. The increase of spectral overlap due to the presence of Gln did not 
lead to a change in RMS percentage errors for NAA (6.3% vs 6.4%; Student’s t-test, t = 0.62, P 
69 
 
= 0.62) or Glu (20.1% vs 20.1%; t = -0.04, P = 0.96) when the RMS percentage errors were 
averaged over all TEs and all experimental conditions. 
 
Figure 4-5: Simulated metabolite spectra and TARQUIN fits of the NAA, Glu, Gln model system at TEs 
a) 35 ms, b) 80 ms and c) 135 ms with SNR 25 and FWHM 3 Hz. 
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Figure 4-6: Simulated metabolite spectra and TARQUIN fits of the NAA, Glu, Gln model system at TEs 
a) 35 ms, b) 80 ms and c) 135 ms with SNR 5 and FWHM 7 Hz. 
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Figure 4-7: Simulated metabolite spectra and TARQUIN fits of the GPC, PCh, Gly and mI model system 
at TEs a) 35 ms, b) 80 ms and c) 135 ms with SNR 25 and FWHM 3 Hz.  
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Figure 4-8: Simulated metabolite spectra and TARQUIN fits of the GPC, PCh, Gly and mI model system 
at TEs a) 35 ms, b) 80 ms and c) 135 ms with SNR 5 and FWHM 7 Hz.  
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 FWHM 3 Hz, SNR 5  
 
FWHM 3 Hz, SNR 15 
 
FWHM 3 Hz, SNR 25 
TE (ms) 
NAA Glu Gln 
 
NAA Glu Gln 
 
NAA Glu Gln 
35 0.98±0.11 0.99±0.36 0.98±0.37 
 
0.99±0.06 0.99±0.20 0.98±0.23 
 
1.00±0.04 0.98±0.13 1.00±0.17 
80 0.98±0.10 0.94±0.33 0.96±0.25 
 
1.00±0.05 0.93±0.19 0.96±0.15 
 
1.00±0.03 0.96±0.13 0.98±0.09 
135 0.98±0.10 0.98±0.22 0.98±0.19 
 
0.98±0.05 0.98±0.11 1.01±0.09 
 
0.99±0.03 0.98±0.07 1.02±0.06 
 FWHM 7Hz,SNR5  
 
FWHM 7Hz,SNR15 
 
FWHM 7Hz,SNR25 
TE(ms) NAA Glu Gln 
 
NAA Glu Gln 
 
NAA Glu Gln 
35 1.00±0.09 0.98±0.31 0.98±0.36 
 
1.00±0.05 0.98±0.15 0.99±0.21 
 
1.00±0.03 0.98±0.10 1.00±0.13 
80 1.00±0.09 0.93±0.31 0.96±0.23 
 
0.99±0.05 0.92±0.18 0.92±0.14 
 
0.99±0.03 0.89±0.12 0.91±0.09 
135 0.98±0.08 0.99±0.18 0.99±0.15 
 
0.95±0.04 0.95±0.09 0.98±0.07 
 
0.93±0.03 0.93±0.05 0.98±0.04 
Table 4-3: Mean ± SD metabolite concentration for the Glu (1 mM), Gln (1 mM) and NAA (1 mM) model system.  
 FWHM 3 Hz, SNR 5  
 
FWHM 3 Hz, SNR 15 
 
FWHM 3 Hz, SNR 25 
TE(ms) tCho mI Gly 
 
tCho mI Gly 
 
tCho mI Gly 
35 0.94±0.10 1.98±0.67 0.92±0.43 
 
0.99±0.04 1.99±0.33 0.94±0.22 
 
0.99±0.03 2.00±0.20 0.97±0.14 
80 0.93±0.10 2.00±0.64 0.90±0.32 
 
0.97±0.05 2.03±0.35 0.93±0.18 
 
1.00±0.03 1.98±0.23 0.96±0.11 
135 0.93±0.10 2.09±0.93 0.84±0.43 
 
0.97±0.05 2.04±0.54 0.92±0.26 
 
0.99±0.03 2.10±0.39 0.93±0.18 
 FWHM 7Hz, SNR 5  
 
FWHM 7 Hz, SNR 15 
 
FWHM 7 Hz, SNR 25 
TE(ms) tCho mI Gly 
 
tCho mI Gly 
 
tCho mI Gly 
35 0.98±0.07 1.98±0.48 0.91±0.33 
 
0.98±0.04 1.96±0.26 0.95±0.19 
 
0.98±0.03 1.94±0.18 0.97±0.15 
80 0.97±0.07 1.88±0.54 0.87±0.29 
 
0.98±0.04 1.98±0.25 0.94±0.14 
 
0.99±0.03 1.97±0.16 0.95±0.09 
135 0.97±0.07 2.07±0.76 0.86±0.38 
 
0.99±0.04 2.13±0.47 0.90±0.22 
 
0.99±0.03 2.05±0.37 0.94±0.17 
Table 4-4: Mean ± SD metabolite concentration for the tCho (1 mM), mI (2 mM) and Gly (1 mM) model system, where tCho = GPC (0.5 mM) + PCh (0.5 mM). 
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Figure 4-9: Root mean square (RMS) percentage error from the simulated concentration for NAA, Glu, Gln 
and Glx, where Glx = Glu + Gln, with SNRs and FWHMs of a) SNR 5; FWHM 3 Hz; b) SNR 15, FWHM 3 Hz ; c) 
SNR 25, FWHM 3 Hz; d) SNR 5, FWHM 7 Hz; e) SNR 15, FWHM 7 Hz; f) SNR 25, FWHM 7 Hz 
 
Figure 4-10: Root mean square (RMS) percentage error from the simulated concentration for tCho, mI, Gly 
and mI + Gly, where tCho = GPC + PCh, with SNRs and FWHMs of a) SNR 5; FWHM 3 Hz; b) SNR 15, FWHM 
3 Hz; c) SNR 25, FWHM 3 Hz; d) SNR 5, FWHM 7 Hz; e) SNR 15, FWHM 7 Hz; f) SNR 25, FWHM 7 Hz 
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The RMS percentages for Cho and mI in the brain and in the tCho, mI and Gly model systems 
were also compared. There was a small, but not significant, increase in the RMS percentage 
error of mI in the presence of Gly (21.7% vs 22.7%; Student’s t-test, t = 0.71, P = 0.54), when 
the RMS percentage errors were averaged over all TEs and all experimental conditions.  
There was a significant increase in the RMS percentage error of tCho compared with Cho 
(8.2% vs 6.2%, Student’s t-test, t = 5.98, P = 10-5). At SNR 25 and FWHM 3 Hz, the RMS 
percentage errors of GPC were 21%, 27% and 28% at TEs 35, 80 and 135 ms respectively. For 
PCh, the RMS percentage errors were 21%, 27% and 30%. The RMS percentage error of Gly 
was larger than the RMS errors of both mI and tCho, but smaller than those of GPC and PCh.  
The accuracy of metabolite quantification was worse for multiplets compared to metabolites 
with singlet peaks without significant spectral overlap. The presence of additional, but not 
total, spectral overlap did not significantly affect quantification accuracy; however, the 
accuracy of quantification was poorest for the metabolites with near total overlap of 
resonances (Gly, GPC, PCh). 
4.2.2.3 Accuracy of Metabolite Quantification at Different Echo Times 
The spectral appearance of Glu, Gln, mI and Lac changes considerably with echo time due to 
J-modulation. The three model systems were simulated at echo times of 35 ms, 80 ms and 
135 ms to determine whether quantification accuracy depends on echo time choice. 
For NAA, Cho and Cr, the RMS percentage errors were similar at each of the three TEs. The 
RMS percentage errors were smallest for Glu and Gln at TE 135 ms with 80 ms having 
smaller RMS errors for Gln compared with 35 ms. The RMS percentage errors were smallest 
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for Gly using a TE of 80 ms and worst with a TE of 135 ms. For mI, the RMS percentage errors 
were smallest for 35 and 80 ms. 
When the RMS percentage errors were averaged over all metabolites and all model systems 
for SNR 25 and linewidth 3 Hz, the mean RMS percentage error was 9.7% at 35 ms, 8.3% at 
80 ms and 8.8% at 135 ms. 
4.2.3 Summary of Findings 
There was not a single optimal echo time for accurate metabolite quantification of all 
metabolites. Instead the accuracy of metabolite quantification depended largely on the SNR 
and linewidth of the data. Metabolites with prominent single peaks, without significant 
spectral overlap, could be quantified to within 10% of their simulated concentrations at SNRs 
of 15 and above. The quantification accuracy of coupled metabolites did not change when 
additional, but not total, spectral overlap was introduced. The quantification accuracy was 
worst for metabolites with near total overlap of resonance peaks.  
The three spectral model systems provided a means for investigating the effects of spectral 
overlap and J-modulation on metabolite quantification. However, experimental factors such 
as T2 relaxation, macromolecular baseline and differences between the basis set and 
experimentally acquired data were not modelled.
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4.3 Metabolite Quantification of Experimentally Acquired Spectra  
4.3.1 Methods 
4.3.1.1 Phantoms 
Phantom Preparation 
All experimental data were acquired on a clinical 3.0 T Phillips Achieva scanner (Phillips 
Medical Systems, Best, the Netherlands) equipped with a 32-channel 1H Phillips head coil.  
The braino phantom contained 12.5 mM NAA, 12.5 mM Glu, 10 mM Cr, 7.5 mM mI, 5 mM 
Lac, 3 mM Cho. 1 g of sodium azide was added as a biocide to prevent the growth of 
bacterial organisms. 1 mL/L of gadolinium was added to each phantom as a relaxation agent 
to shorten the T1 relaxation time. The pH of the phantom was adjusted to 7.2 in line with 
healthy tissue. 
Data Acquisition 
A cubic 25 x 25 x 25 mm voxel placed in the centre of the phantom (Figure 4-8). 
 
Figure 4-11: Typical placement of a 25x25x25 mm voxel in a phantom. 
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Spectroscopy was acquired using three sequences: 
 PRESS: TE 35 ms, TR 2s, NSA 128 
 3 TEs: TE 35, 80 and 135 ms, with a TR of 2s and NSA 128. The three echo times were 
linked as a parameter series to prevent changes in the receiver gain. 
 18 TEs: 18 equally spaced TEs from 35-290 ms with 15 ms spacing. The TR was 2s and 
the NSA per TE was 8. The 18 echo times were linked as a parameter series to 
prevent changes in the receiver gain. 
Data were acquired at room temperature.  
Data Processing 
Metabolite concentrations were initially quantified at each echo time with TARQUIN v4.3.8 
using a basis set containing only the metabolites present in the phantom. Metabolite 
concentrations were referenced to an unsuppressed water signal and a pure water 
concentration of 55556 mM was assumed. The water attenuation parameter was fixed to 
1.00 to neglect relaxation effects in the TARQUIN analysis. 
T2 Estimation 
Water and metabolite T2 relaxation times, T2w and T2m respectively, were estimated by 
fitting the signal amplitudes from each echo time to a monoexponential decay curve. The T2 
relaxation times were estimated from both the JPRESS and 3TE acquisitions. 
Concentration Correction for Relaxation Effects 
The metabolite concentration at each echo time was corrected by multiplying the 
concentration by an attenuation factor, Watt, that accounts for the relaxation of the water 
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and metabolite signals. Metabolite concentrations were only corrected for relaxation effects 
where non-negative T2 relaxation times were estimated. Metabolites where negative T2 
relaxation times were estimated were not assessed. 
The metabolite concentration reported for phantoms is the mean of the concentrations 
from all echo times collected in that sequence. 
Analysis and Statistics 
The estimated mean metabolite concentrations were compared to the known phantom 
concentration. The percentage error and rms percentage error from the known phantom 
concentration were calculated.  
Statistical comparisons were performed using a Student’s t-test and statistical significance 
was declared for P < 0.05. 
4.3.1.2 Volunteers  
Data Acquisition 
Informed consent was obtained from 5 healthy adults (4 males and 1 female) with a mean 
age of 26 ± 2 years. In four cases a voxel of size 25 x 25 x 25 mm was placed over parietal 
white matter. In the fifth case a cubic voxel of size 25 x 25 x 25 mm was placed in occipito-
parietal grey matter across the midline to investigate the influence of cerebrospinal f luid 
(CSF).  
Spectroscopy data were acquired using the same three sequences used for the phantoms. 
Data Processing 
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Segmentation was performed using FSL (Smith et al., 2004) to determine the amount of grey 
matter (GM), white matter (WM) and CSF present in the voxel. A full description of steps 
taken for segmentation is presented in Chapter 3.3.1. Metabolite concentrations were 
quantified with TARQUIN v4.3.8 using the 1H brain + Glth, Cit, Gly internal basis set. The 
water attenuation factor was set to 1 and the water concentration was set to that of pure 
water, 55,556 mM. 
T2 determination 
The metabolite signal amplitudes were fitted to a monoexponential decay curve.  
The water T2 relaxation time of the 3 TEs sequence was fitted to a monoexponential decay 
curve. To negate the influence of CSF components on T2 relaxation, only the water signal 
collected from the first five TEs of the 18 TEs sequence were fitted to a monoexponential 
decay. 
Concentration Correction for Relaxation Effects 
The reported metabolite concentrations were corrected for relaxation effects in accordance 
with the method detailed by Gasparovic et al (Gasparovic et al., 2006b) using literature 
values for T2 relaxation times. A comparison is also made to values corrected using the 
estimated Watt assuming monoexponential decay of the data acquired. 
The metabolite concentration reported for volunteers is the mean of the concentrations 
from all echo times collected in that sequence. 
4.3.2 Results 
Example spectra at TEs 35, 80 and 135 are given for the braino phantom (Fig  4-12), 
NAA/Glu/Gln phantom (Fig 4-13), tCho/mI/Gly phantom (Fig 4-14) and healthy volunteer (Fig 
4-15). 
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Figure 4-12: Example phantom data and TARQUIN fits of the braino model system at TEs a) 35 ms, b) 
80 ms and c) 135 ms.  
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Figure 4-13: Example phantom data and TARQUIN fits of the NAA, Glu, Gln model system at TEs a) 35 
ms, b) 80 ms and c) 135 ms.  
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 Figure 4-14: Example phantom data and TARQUIN fits of the GPC, PCh, Gly and mI model system at 
TEs a) 35 ms, b) 80 ms and c) 135 ms.  
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 Figure 4-15: Example phantom data and TARQUIN fits of healthy parietal white matter at TEs a) 35 
ms, b) 80 ms and c) 135 ms.   
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4.3.2.1 T2 Relaxation 
Knowledge of the T2 relaxation times of water and metabolites is required for accurate 
quantification of metabolite concentrations. The T2 relaxation times for tNAA, tCho and tCr 
are presented for the braino phantom in Table 4-5 and volunteer in Table 4-6. T2 relaxation 
times have been calculated using 2 TEs (35 and 135 ms) and using 18 TEs spaced between 35 
and 290 ms. Representative T2 relaxation fits for tNAA, tCho and tCr estimated from 18 TEs 
are presented for phantom and volunteer data in Figure 4-9. 
  T2 ± SD (ms) – Braino Phantom 
  NAA Cho Cr Water 
2 TEs 560 ± 50 194 ± 9 323 ± 10 278 ± 4 
18 TEs 524 ± 89 203 ± 6 318 ± 24 279 ± 2  
Table 4-5: T2 relaxation times for NAA, Cho, Cr and water in the braino phantom, estimated using 2 
TEs (35 and 135 ms) and 18 TEs. (n=4) 
  T2 ± SD (ms) – Volunteer   
  tNAA tCho tCr Wat 
2 TEs 288 ± 40 201 ± 10 141 ± 12 64 ± 1 
18 TEs 272 ± 23 208 ± 7 141 ± 12 69 ± 10 
Table 4-6: T2 relaxation times for tNAA, tCho, tCr and water in healthy volunteer, estimated using 2 
TEs (35 and 135 ms) and 18 TEs. (n=4) 
The mean T2 values for tNAA, tCho and tCr estimated using 2 TEs and using 18 TEs were not 
significantly different in either phantom or volunteer. A Pearson correlation coefficient of 
0.95 (P = 0.03) was found between the T2 values of tNAA, tCho and tCr estimated with 2 TEs 
and the relaxation times estimated with 18 TEs. There was not a significant difference in the 
mean T2 relaxation times estimated using the two methods in either phantoms (Student’s t-
test, t = 0.80, P = 0.42) or volunteers (t = 0.6, P = 0.53).  
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Figure 4-16: T2 relaxation decay for (t)NAA in a) phantom and b) volunteer; (t)Cho in c) phantom and 
d) volunteer; and (t)Cr in e) phantom and f) volunteer. 
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T2 relaxation times were estimated for Glu, mI and Lac in the braino phantom (Table 4-7) 
and volunteers (Table 4-8). Representative fits to 18 TEs are presented in Figure 4-10. There 
was a significant difference in the T2s estimated from 2 TEs and estimated from 18 TEs in the 
phantom (Student’s t-test, t = 5.4, P = 10-5) and in volunteers (t = -3.78, P = 0.001). 
T2 (ms) –Braino Phantom 
 Glu mI Lac Water 
2 TEs 118 ± 17 77 ± 11 86 ± 4 278 ± 4 
18 TEs 197 ± 20 142 ± 9 -3500 ± 2500 279 ± 2  
Table 4-7: T2 relaxation times for Glu, mI, Lac and water in the braino phantom, estimated using 2 
TEs (35 and 135 ms) and 18 TEs. (n=4) 
 
T2 (ms) –Volunteer 
 Glu mI Lac Water 
2 TEs 86 ± 7 138 ± 9 100 ± 4 64 ± 1 
18 TEs 184 ± 25 225 ± 52 50 ± 200 69 ± 10 
Table 4-8: T2 relaxation times for Glu, mI, Lac and water in healthy brain, estimated using 2 TEs (35 
and 135 ms) and 18 TEs. (n=4) 
The T2 relaxation times of tNAA, tCho and tCr estimated from two TEs were comparable 
with the T2 values estimated using 18 TEs in both phantom and volunteer. In contrast, the 
T2 values estimated varied considerably between the two methods. 
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Figure 4-17: T2 relaxation decay for Glu in a) phantom and b) volunteer; mI in c) phantom and d) 
volunteer; and Lac in e) phantom and f) volunteer. 
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The T2 relaxation time of water was estimated in the braino phantom (Table 4-7) and 
volunteers (Table 4-8). Monoexponential fits to the water signal are shown for phantom and 
volunteer data in Figure 4-11.  
 
Figure 4-18: Example semi-log T2 decays of water in a) phantom, b) parietal grey matter with CSF 
approximately 1% of the voxel and c) occipito-parietal lobe with CSF approximately 18% of the voxel. 
Dashed line represents a monoexponential fit to the data. 
The presence of CSF in acquisition voxels led to a multi-exponential decay of the water signal 
in vivo. A biexponential signal composed of varying amounts of CSF and WM was simulated 
to assess the influence that CSF could have on T2 estimates (Table 4-9). 
     Number of TEs Fitted To 
CSF F 8 TEs 5 TEs 3 TEs 2 TEs 
0.90 96.81 87.64 85.91 84.32 
0.95 83.06 78.43 77.58 76.80 
0.97 77.76 74.96 74.46 74.02 
0.99 72.57 71.63 71.48 71.33 
Table 4-9: Estimated T2 from a monoexponential fit to the first n TEs of a simulated signal (18 TEs, 
35-290 ms with 15 ms spacing between TEs). The signal was composed of two components, 
analogous to CSF and WM, with varying amounts of CSF (T2 = 1300 ms), given by CSF F, with the 
remaining fraction composed of WM (T2 = 70 ms), such that CSF F + WM F = 1.  
 
The T2 decay of the simulated signal arising from WM, as fitted to a monoexponential decay, 
was overestimated more as CSF F increased. Fitting the first 5 TEs or fewer of the multi -TE 
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water scan to a monoexponential decay can minimise the effect of CSF on the T2 
measurement. 
The T2 relaxation times estimated from 2 TEs (35 ms and 135 ms) and estimated from 18 TEs  
were comparable for metabolites with prominent singlets without significant spectral 
overlap and for water in both phantom and normal brain. The signal decay of water in vivo 
was not monoexponential and increasing the amount of CSF in the voxel increased the multi-
exponential behaviour of the decay curve. Estimating the T2 relaxation time of water with a 
maximum TE ≤ 135 ms reduced the influence of long T2 components on T2 estimation. The 
T2 relaxation times of coupled metabolites estimated from 2 TEs and 18 TEs were not 
comparable and there was a large variability in metabolite quantification at different echo 
times for couple metabolites. 
4.3.2.2 Metabolite Concentrations Corrected for T2 Relaxation in Phantoms 
Estimated T2 relaxation times were used to correct the metabolite concentration estimates 
of the braino phantom at TEs of 35, 80 and 135 ms. The corrected concentrations of NAA, 
Cho and Cr are shown in Figure 4-12. There was not a significant difference in the 
concentrations of NAA, Cho and Cr estimated at the three echo times.  
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Figure 4-19: Mean ± SEM concentrations corrected for T2 relaxation of a) NAA (12.5 mM), b) Cho 
(3mM) and c) Cr (10 mM) in the braino phantom. Dashed line represents the phantom concentration. 
 
Concentration estimates at TEs 35 ms, 80 ms and 135 ms are shown for Glu, mI and Lac in 
Figure 4-13. The mean concentration of Glu estimated at 135 ms was significantly smaller 
than that at 35 and 80 ms (Student’s t-test: t = 4.04, P = 0.001 and t = 5.84, P = 10-5 
respectively). The mean concentration of mI estimated at 135 ms was significantly smaller 
than that at 35 (t = 4.16, P = 0.001) and 80 ms (t = 3.99, P = 0.001). The mean concentration 
of Lac estimated at 80 ms and 135 ms were significantly smaller than that at 35 ms ( t = 4.91, 
P = 10-4 and t = 5.50, P = 10-4 respectively). 
 
Figure 4-20: Metabolite concentrations corrected for T2 relaxation for a) Glu (12.5 mM), b) mI (7.5 
mM) and c) Lac (5 mM) in the braino phantom. Dashed line represents the phantom concentration. 
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Figure 4-21: Mean ± SEM concentration estimated from one TE (35 ms), three TEs (35, 80 and 135 
ms) and 18 TEs (42 to 297 ms, 15 ms spacing between TEs) for a) NAA, b) Cho and c) Cr in the braino 
phantom. The dashed line represents the phantom concentration. Metaboli te concentrations have 
been corrected for T2 relaxation using T2 estimates from 18 TEs (n = 4). 
Figure 4-14 shows the estimates of NAA, Cho and Cr in the braino phantom from 35 ms 
PRESS, a mean estimate from 3 TEs (35 ms, 80 ms and 135 ms) and the mean estimated from 
18 TEs (42 ms – 297 ms). There was not a significant difference between the three values for 
any of the metabolites.  
Figure 4-15 shows the estimates of Glu and mI in the braino phantom from 35 ms PRESS, a 
mean estimate from 3 TEs (35 ms, 80 ms and 135 ms) and the mean estimated from 18 TEs 
(42 ms – 297 ms). The mean estimates of Glu and mI using 3 TEs were significantly different 
when T2s were estimated using 2 TEs instead of 18 TEs.  
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Figure 4-22: Mean ± SEM concentration estimated from one TE (35 ms), three TEs (35, 80 and 135 
ms) and 18 TEs (42 to 297 ms, 15 ms spacing between TEs) for a) Glu and b) mI in the braino 
phantom. The dashed line represents the phantom concentration. 1 TE and 18 TEs have been 
corrected for T2 relaxation using T2s estimated from 18 TEs. 3 TEs have been corrected for T2 
relaxation using concentrations corrected using 2 TEs (T2: 2 TEs) and 18 TEs (T2: 18 TEs) (n=4).  
 
Metabolite concentrations corrected for T2 relaxation were comparable at 35 ms, 80 ms and 
135 ms for NAA, Cho and Cr in the braino phantom. The mean estimates from 35 ms short-
TE MRS, from 3 TEs and from 18 TEs were similar for these three metabolites, with minimal 
difference between the concentrations estimated from 3 TEs and 18 TEs. The concentration 
estimates of coupled metabolites varied significantly with echo time with concentration 
estimates also affected by how the metabolite T2 relaxation was measured. 
4.3.2.3 The Effect of Intravoxel Heterogeneity and Metabolite Concentrations Corrected 
for T2 Relaxation in Volunteers 
Voxels placed in volunteers were segmented to determine the amount of grey matter, white 
matter and cerebrospinal fluid (CSF) in the voxel. Metabolite concentrations were corrected 
for both water content differences and T2 relaxation. Figure 4-16 shows the estimated NAA 
concentration at various TEs, corrected for T2 relaxation in various ways. Approximately 18% 
of the voxel was CSF. 
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Figure 4-23: Metabolite concentration of NAA quantified at various echo times. 18% of the voxel was 
CSF. Default concentrations had only the TARQUIN default T2 correction applied, T2 Wat Corrected 
were corrected assuming a monoexponential water decay whilst T2 Wat and T2 CSF corrected were 
corrected for GM, WM and CSF T2 and water content differences. 
 
Metabolite concentrations corrected using default TARQUIN settings steadily increased with 
echo time. Conversely, metabolite concentrations corrected for metabolite T2 relaxation and 
assuming a single T2 for water decreased with echo time. When metabolite concentrations 
were corrected for metabolite T2 relaxation times, as well as for GM, WM and CSF 
components, a stable metabolite concentration was observed when determined at different 
echo times. This was true for tNAA, tCho and tCr in all volunteers.  
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4.3.3 Summary of Findings 
The T2 relaxation time of metabolites with large singlets without significant spectral overlap 
estimated from 2 TEs were comparable with those estimated from 18 TEs in both phantom 
and volunteer. Similarly, the T2 estimates of water from 2 TEs and 18 TEs were also 
comparable; however, a non-monoexponential signal decay was observed for water in vivo 
and intravoxel heterogeneity should be accounted for when estimating metabolite 
concentrations at long TEs. The influence of long-T2 components in the water decay can be 
minimised by using a maximum TE of 135 ms. For coupled metabolites, the T2 estimates 
from 2 TEs were not consistent with those from 18 TEs. Furthermore, the relaxation-
corrected concentrations of coupled metabolites were significantly different at the three TEs 
examined.  
4.4 Discussion 
In this chapter, a combination of simulations, phantom and volunteer data have been used 
to assess the accuracy of metabolite quantification. Simulations were used to assess how 
changes in experimental conditions affect quantification accuracy while investigating the 
effects of spectral overlap and echo time choice have on quantification.  
4.4.1 Simulations 
Three spectral model systems were investigated using simulations. A brain model system, 
based on the braino phantom, containing some of the major brain metabolites; a model 
system containing Glu, Gln and NAA; and a model of GPC, PCh, mI and Gly. The second and 
third model systems were chosen as changes in Glu and Gln, and in mI and Gly, can lea d to 
contrasting clinical outcomes and the pairs of metabolites have spectra which overlap.  
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Simulated spectra were constructed for the three model systems at three echo times to 
investigate how the J-evolution of coupled metabolites affects metabolite quantification. 
Echo times of 35 and 135 ms were chosen because of their common use in clinical practice, 
whilst an echo time of 80 ms – which has been proposed for measurement of Glu (Schubert 
et al., 2004a) – would allow for the decay of short-T2 macromolecule and lipid components 
in vivo.  
Results of the simulations showed that the main determinant of quantification accuracy was 
data quality rather than echo time choice. The mean concentration estimates became more 
accurate as SNR increased and were more accurate in spectra simulated with narrow line 
widths.  
The RMS percentage errors of multiplets were consistently larger than those of metabolites 
with large singlets, which is likely due to inherent differences in SNR for multiplets, while the 
SD and RMS percentage error of Gly was greater than that of other metabolites. The RMS 
percentage error of Gly was smallest at TE 80 ms and this is likely due to the reduction of the 
overlapping mI resonance at this TE. Of the three echo times investigated, the mean 
concentration of Glu was most accurate at 35 ms but with a considerably smaller SD and 
RMS percentage errors at 135 ms. For Gln the RMS percentage errors were smallest at 135 
ms and largest at 35 ms. An echo time of 80 ms was least accurate for both Glu and Gln 
estimation.  This is in contrast to previous simulation studies which have suggested 80 ms for 
improved quantification of Glu (Hancu, 2009) and Gln (Hancu and Port, 2011).  
Whilst the current study had a 1:1 ratio of Glu:Gln, Hancu investigated a 10:4.5 ratio with a 
higher amount of NAA. While a 10:4.5 ratio may be typical of normal brain, the ratio can 
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vary considerably in pathology (Davies et al., 2008a; Panigrahy et al., 2006). A 1:1 ratio was 
therefore chosen to investigate overlap with comparable resonance intensities. The Glu 
signal intensity differences between these studies is the most likely cause of the 
discrepancies between these studies. Another key difference was the inclusion of a 
macromolecular baseline in the Hancu studies which is likely to affect Glu measurement at 
35 ms. 
Interestingly, the standard deviations of metabolite concentrations were consistently 
smaller at FWHM 7 Hz compared with 3 Hz. Whilst the standard deviations were smaller at 7 
Hz, the mean concentrations were typically less accurate than those with smaller linewidths. 
While the reason for this is unclear, this has also been observed in a similar study at 4 T, and 
could be attributed to an increase in signal area following line broadening (Bartha, 2007).  
Previous investigations into the influence of experimental conditions have shown the 
importance of high SNR and narrow linewidths for quantification precision at 1.5 T (Bartha et 
al., 2000; Kanowski et al., 2004) and 4 T (Bartha, 2007), while estimates of the precision of 
GABA measurements at 3 T have been previously been presented (Near et al., 2013). This 
chapter presents values for the precision of NAA, Cho and Cr which indicate that individual 
concentration estimates of these metabolites are reliable to within 10% at SNRs of 15 and 
above. For metabolites which present as multiplets or single peak resonances with 
considerable overlap, such as Gly, GPC and PCh, an SNR greater than 25 would be required 
for quantification at this level of accuracy on a case-by-case basis. Accuracy of within 10% for 
coupled metabolites would likely require a spectrum SNR in the region of 40 and above at 
typical in vivo concentrations, given reports at 4 T (Bartha, 2007). However, this prediction is 
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predicated on the presence of a large single peak in the spectrum and metabolite-specific 
SNRs for accurate quantification of coupled metabolites have not been investigated.  
The results presented in this chapter could be used to help power future sample sizes.  For 
cohort studies, the mean metabolite concentrations are likely to be accurate regardless of 
echo time choice, providing the sample size is large enough. However, while the SNRs and 
linewidths chosen for the simulations are comparable to those seen in clinical data, they do 
not represent the full range observed clinically. Future work should therefore establish at 
what SNRs and linewidths the accuracy of quantification completely breaks down.  
The use of idealised conditions has inevitably meant there are limitations to this work. As the 
purpose of this work was to assess the effect of J-coupling evolution with echo time on 
quantification, T2 relaxation and baseline effects which would be present in vivo were not 
included in the simulations. Though the presence of macromolecules and lipids has been 
ignored, the models selected may provide a surrogate indication of their effects as the equal 
ratio of Glu:Gln and Gly:mI intensities allow for inferences of the effect of spectral overlap to 
be made. This is likely reflected in the increased errors associated with multiplets, Gly, GPC 
and PCh when compared with those of NAA, tCho and Cr. The presence of a baseline may 
therefore affect coupled resonance or metabolites at low concentrations more than 
prominent singlets. Fitting routines such as TARQUIN can model the baseline either using 
experimentally acquired data or as individual measurements; both of these methods provide 
reproducible concentrations and resonances with a high SNR are likely to be determined 
accurately even with overlap with the presence of a baseline. 
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Asymmetric non-Gaussian lineshapes and lineshapes distorted by eddy currents were not 
modelled in this data. While these effects can affect quantification methods which do not 
allow freedom in the fitting routines (Wilson et al., 2011), lineshapes can be improved when 
processing the data by applying either eddy current correction or by performing lineshape 
correction (De Graaf et al., 1990). Heavily distorted lineshapes are rare and can be excluded 
through visual inspection of the data, the influence of linewidth and SNR is therefore more 
pertinent for the majority of acquired spectra.  
Signals from outside the intended region of interest can be excited due to slice selection and 
chemical shift errors. These errors will lead to small errors in the overall metabolic profile of 
the region of interest and knowledge of the voxel profile can help identify the influence of 
any such contamination. The use of small voxels and pulse sequences such as LASER which 
minimise chemical shift errors can render the influence of these effects small in comparison 
to that of SNR and linewidth.  
A further limitation is that the simulated spectra were constructed using the same process 
that TARQUIN simulates its basis sets with. The simulations therefore do not account for 
incomplete or inaccurate prior knowledge that can arise in experimentally acquired data.  
Chemical shift displacement errors are likely to be the most significant unmodelled effect. 
Chemical shift displacement errors will lead to the simulation of inaccurate basis models for 
coupled metabolites which will lead to inaccurate quantification, however they can be 
corrected for by using experimentally acquired basis sets. Phantom and volunteer data were 
therefore acquired to investigate what effect unmodelled experimental factors can have on 
quantification. 
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4.4.2 Phantom and Volunteer Studies 
One such factor is T2 relaxation which should be accounted for in metabolite quantification. 
The T2 relaxation time was estimated in phantoms using 2 TEs and using 18 TEs. The mean 
T2 relaxation times were estimated from a monoexponential fit and the two values were 
comparable. A multi-exponential decay was observed in the water signal of volunteers in 
vivo. This effect was attributed to the presence of CSF and an increase in the amount of CSF 
was associated with greater multi-exponential behaviour.  
The influence of CSF on a biexponential signal decay was investigated using a mathematically 
constructed water decay signal. CSF has a much longer T2 than tissue water and the disparity 
in signal decays becomes more pronounced as TE increases. The effect of CSF can therefore 
be minimised by estimating the T2 relaxation with a final TE of 135 ms and shorter.  
The T2 relaxation times of metabolites were estimated using 2 TEs (35 ms and 135 ms) and 
using 18 TEs for NAA, Cho and Cr. The estimated mean T2 relaxation times were similar. 
Following the earlier simulation study, this is likely due to the high signal of the NAA, Cho 
and Cr peaks. This suggests that estimating the T2 relaxation time of these metabolites from 
data collected at the short and long TEs commonly used in clinical practice is a valid 
approach. 
The concentration of tNAA, tCho and tCr were estimated at echo times of 35 ms, 80 ms and 
135 ms in the braino phantom and volunteer. The mean metabolite concentrations 
corrected for T2 relaxation times were similar at each TE, indicating that concentrations can 
likely be estimated accurately at each of the echo times providing a reasonable T2 estimate 
is available. 
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The T2 relaxation times of the coupled metabolites Glu, mI and Lac were also estimated 
using the 2 TE and 18 TE approaches. In each case, the mean T2 relaxation times were 
significantly different between the two methods. Whilst simulations have shown the J-
evolution of metabolites with echo time does not appear to affect metabolite quantification 
as much as data quality, it does appear to influence T2 estimation. This is likely due to a 
combination of the inherently lower SNR of multiplets compared with singlets and small 
errors in the signal fitting at multiple echo times compounding when estimating T2 values. 
The true metabolite signal will not exactly match the simulated one in the basis set for a 
number of experimental reasons. Careful selection of appropriate echo times and acquisition 
protocol is required for accurate evaluation of the T2 relaxation time of coupled metabolites 
(Ganji et al., 2012b; Madan et al., 2015b; Xin et al., 2008a).  
Consistent with the simulated analysis, a greater variation in metabolite concentrations was 
observed for multiplets compared to singlets between the three echo times of 35, 80 and 
135 ms. The errors associated with the concentrations measured in phantoms were larger 
than those seen in the simulations. In volunteers the estimated concentrations varied 
significantly for mI and Glu depending on the echo time that data was acquired at. These 
errors could be due to inaccurate T2 relaxation times. This could also be attributed to small 
differences in the basis set compared with the expe rimental spectrum leading to significant 
errors. Differences in the temperature and pH can lead to changes in spectral appearance, 
while the chemical shift displacement artefact can also affect the acquired spectrum. The 
chemical shift displacement artefact is a likely cause of the signal and T2 variation of lactate 
in the braino phantom. 
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The use of multiple echo times to estimate metabolite concentrations was investigated. 
There was not a significant difference in the measurement of NAA, Cho or Cr using mean 
estimates from one, three and 18 TE acquisitions. There was a significant difference in the 
mean concentration estimates of Glu and mI from 3 TEs when different T2 relaxation time 
values were used, illustrating the importance of accurate T2 relaxation times for metabolite 
quantification. The use of two TEs has previously been shown to improve the classification 
accuracy in paediatric brain tumours (Vicente et al., 2013), however it did not improve the 
accuracy of metabolite quantification in phantoms in our experiments. A logical extension to 
this study would be to use an experimentally acquired basis set to quantify phantom data. 
However, this would not remove all of the problems associated with obtaining an accurate 
basis set for in vivo studies as tissue conditions will vary. 
4.5 Conclusions 
This study has used a combination of simulations, phantoms and volunteer data to 
investigate the accuracy of metabolite quantification at different echo times. Simulated 
spectra demonstrated that while the mean concentration estimate of a cohort is generally 
accurate to within 10% within the parameters of current quality control criteria. 
Quantification accuracy is improved with high SNR and narrow line widths. The precision of 
any single measurement is highly dependent on SNR. Concentration estimates for 
metabolites with large single peak resonances, such as NAA, Cho and Cr, are likely reliable to 
within 10% of the true value with SNR levels of 15 and above. However, for metabolites with 
spectroscopy dominated by multiplets, an overall spectrum SNR greater than 25 with further 
investigation needed to determine metabolite-specific SNRs required for accurate 
quantification of multiplets. Additional spectral overlap did not significantly affect the 
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accuracy of metabolite quantification of multiplets; however, measurement of Gly, GPC and 
PCh – metabolites which completely overlap with other metabolites and are predominantly 
large single peaks – was less accurate. 
The simulations did not identify a single optimal echo time for metabolite quantification of 
all metabolites. There was a significant difference in the metabolite concentration estimates 
in phantoms and in vivo depending on TE choice. Correction for T2 relaxation effects was 
demonstrated to be important for accurate metabolite quantification. The T2 relaxation time 
of water and metabolites with large single peak resonances can be estimated from two echo 
times; however, T2 estimates for multiplets will require careful protocol design. 
The use of short-TEs is recommended for future studies as they will reduce the influence of 
T2 relaxation on quantification and have inherently higher SNR. The use of reasonable T2 
estimates is required to correct for relaxation effects. In cases where these are not available, 
these can be measured from two echo times to keep the acquisition time to within a 
clinically acceptable timeframe. In particular, the measurement of water T2 is rapid due to 
its very high natural abundance and could be added to all in vivo studies. 
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5. VARIATION OF T2 RELAXATION TIMES IN PAEDIATRIC BRAIN 
TUMOURS AND THEIR EFFECT ON METABOLITE 
QUANTIFICATION AT 1.5 TESLA  
5.1 Introduction 
Brain tumours are the most common solid tumours in children and a significant cause of 
morbidity and mortality. 1H magnetic resonance spectroscopy (MRS) provides a non-
invasive means of profiling the chemical composition of brain tumours, providing prognostic 
and diagnostic biomarkers which can be used for tumour classification (Davies et al., 2008; 
Vicente et al., 2013) and for monitoring treatment response (Quon et al., 2011). As 
quantitative metabolite biomarkers start to be proposed for clinical decision making in 
individual patients (Wilson et al., 2014, 2013), accurate measurement becomes of increasing 
importance.  
MRS is typically implemented clinically by adhering to an agreed protocol and comparing the 
results to those obtained using the same protocol. Whilst metabolite levels can be reported 
as ratios, quantification is typically performed by fitting to a set of metabolite basis functions 
and concentrations are calculated with reference to an unsuppressed water signal (R. Kreis 
et al., 1993).   
Popular analysis packages, LCModel (Provencher, 1993) and TARQUIN (Wilson et al., 2011), 
are often used for metabolite quantification, assuming T2 relaxation times typical of normal 
brain in their calculations. However, relaxation times are sensitive to microenvironment and 
have been shown to change with pathology (Isobe et al., 2002; Li et al., 2008; Madan et al., 
2015; Sijens and Oudkerk, 2002). In the previous major studies of brain tumours using MRS, 
further correction for the differences in T2 relaxation between brain tumours and healthy 
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brain has not been performed and the effects of T2 relaxation variation have been assumed 
to be small at short-TE (Davies et al., 2008; Panigrahy et al., 2006; Vicente et al., 2013).  
The use of longer TEs for metabolite quantification has been proposed recently (Choi et al., 
2013; Napolitano et al., 2013; Schubert et al., 2004), however, T2 relaxation times are known 
to have a significant effect on concentration determination at long-TEs (Yamamoto et al., 
2015, Chapter 4) and correction for T2 relaxation has been shown to have a significant effect 
on metabolite ratios at 3T (Li et al., 2008).  Accurate water and metabolite T2 relaxation 
times are therefore likely to be required for reliable metabolite quantification. With the 
emergence of various acquisition protocols, it is becoming increasingly important to explore 
the effects of relaxation on quantification at various echo times. 
In a recent multi-center study of paediatric brain tumours (Vicente et al., 2013), reporting 
concentrations measured at both short and long-TE, there was a large difference between 
the concentrations measured at the two echo times. Though a recent study has examined 
the effect of using long-TEs for quantification using LCModel (Yamamoto et al., 2015), the 
influence of varying T2 relaxation times on brain tumour quantification at short-TE has not 
been formally assessed. 
Whilst previous studies of adult brain tumours have shown significant differences in both 
water and metabolite T2 relaxation times (Isobe et al., 2002; Li et al., 2008; Madan et al., 
2015; Sijens and Oudkerk, 2002), T2 relaxation in childhood brain tumours has  not been 
extensively studied to date. Investigation of relaxation times in the paediatric population is 
of particular importance as metabolite T2 relaxation times in normal brain have been shown 
to change with age (Kirov et al., 2008). In addition, for brain tumours, specific studies in 
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children are required since the tumours are histologically and biologically different from 
their adult counterparts (Gilheeney and Kieran, 2012; Merchant et al., 2010). Further 
differences arise in the incidence of brain tumours, with low grade gliomas and 
medulloblastoma occurring more frequently in children than in adults. 
Measuring T2 formally is challenging since acquisition protocols require multiple echo times 
and this leads to long acquisition times. This issue is particularly pertinent to the study of 
children where long scans are poorly tolerated. However, protocols using two echo times 
have been implemented clinically (Sijens and Oudkerk, 2002; Vicente et al., 2013). 
Furthermore, the T2 relaxation times of NAA, Cho, Cr and water, estimated from two TEs (35 
and 135 ms), were shown to be comparable with those estimated using more TEs at longer 
echo times in Chapter 4. A protocol using two echo times therefore has the potential to 
estimate the T2 values of metabolites and water whilst keeping acquisition times within 
reasonable limits.   
In this chapter, metabolite and water T2 relaxation times in apparently normal brain and 
childhood brain tumours have been retrospectively calculated from data collected at both 
short and long-TE with the aim of establishing how the relaxation properties of major 
metabolites vary and the effect this has on metabolite quantification.  
5.2 Methods 
5.2.1 Patients 
Two cohorts were retrospectively selected from patients where single-voxel MRS had been 
performed prior to treatment between September 2006 and July 2011. The first cohort 
consisted of 31 children with brain tumours. This tumour group was comprised of four 
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diffuse intrinsic pontine gliomas (4 male, mean age 11.4 years), 10 medulloblastomas (6 
male and 4 female, mean age 6.1 years) and 17 pilocytic astrocytomas (9 male and 8 female, 
mean age 7.4 years). 
Comparison was made with a second cohort consisting of 24 children (18 male and 6 female, 
mean age 6.4 years) with normal-appearing MRI and MRS. These children had undergone 
investigation for a suspected metabolic disorder which was subsequently ruled out. All 
patients were under 16 years of age and informed parental consent and research ethics 
approval was obtained. 
5.2.2 MRS Acquisition 
MRS was acquired using a Siemens Symphony Magnetom NUM4 1.5 T scanner following 
conventional imaging. The standard imaging set of T1-weighted, T2-weighted and T1-
weighted images post contrast administration was used to delineate the tumour margins. 
Cubic voxels of side length 1.5 cm or 2 cm were placed entirely within the solid component 
of the tumour avoiding any cyst or necrosis and point-resolved spectroscopy (PRESS) was 
performed. Cubic voxels of side length 2 cm were placed in the basal ganglia and parietal 
white matter in the cohort with normal-appearing MRI and MRS. Water suppressed data 
were acquired with 128 repetitions from the larger voxels and 256 repetitions from the 
smaller ones. For all scans, a TR time of 1500 ms was used and data were acquired at both 
short (30 ms) and long (135 ms) TE. Water unsuppressed MRS data were also acquired with 
4 repetitions as a concentration reference at both TEs. 
5.2.3 Processing and Analysis 
Raw spectroscopy data were automatically processed using TARQUIN v 4.3.8 (Wilson et al., 
2011b). TARQUIN models experimental data as a linear combination of simulated basis 
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signals. To extract metabolite concentrations, the fitted signal amplitudes â are scaled by 
two factors: Watt and Wconc.   
The Watt parameter accounts for the reduction of the water signal relative to metabolite 
signals due to differences in T2 relaxation at a given TE and is defined as  Watt = [exp(-
TE/T2water) / exp(-TE/T2metabolite)]. This parameter is used to adjust the metabolite 
concentrations to be independent of TE and will give the correct value if T2water and 
T2metabolite are known accurately. Wconc denotes the assumed water concentration for a given 
tissue type and is used to scale â to the amplitude of the unsuppressed water signal. Wconc 
and Watt are assumed as 35880 mM and 0.7 respectively by TARQUIN as default. 
Tumour spectra were referenced to the total choline signal to account for frequency drift, 
while normal brain spectra were referenced to a combination of total choline-creatine-NAA-
lipids. MRS was quantified using the internal basis set 1H brain + Gly, Cit, Glth. Due to 
significant spectral overlap at 1.5 T, the following metabolites were combined in the 
subsequent analysis: Gln + Glu = Glx; NAA + NAAG = tNAA; Cr + PCr = tCr and GPC + PCh = 
tCho.  
T2 Measurement 
T2 relaxation times were estimated by fitting TARQUIN estimates of signal amplitude â 
(Wilson et al., 2011b) for each metabolite from the two echo times to a monoexponential 
function.  
Concentration Calculation 
To assess the importance of accurate T2 relaxation times for metabolite quantification, 
metabolite concentrations corrected using various combinations of measured and literature 
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T2 values were compared. The following terms are used for the various methods of 
obtaining the T2 values.  Tissue type refers to pilocytic astrocytoma, medulloblastoma or 
normal brain. 
Individual water (IW) correction uses the T2 relaxation time of water measured as part of the 
MRS acquisition for that case. 
Individual metabolite (IM) correction uses the case’s estimated metabolite T2 values where 
the metabolite could be quantified accurately at both echo times. Where a metabolite T2 
could not be estimated for a case, the tissue’s mean average T2 value from the rest of the 
cases in the study was used for tNAA, tCho and tCr and a metabolite T2 of 300 ms was 
assumed for all other metabolites.  
Average water (AW) correction uses the average T2 relaxation time of water obtained from 
the cases in the study with the same tissue type.  
Average metabolite (AM) correction uses the average T2 relaxation time for the metabolites 
obtained from the cases in the study with the same tissue type for NAA, tCho, Cr and Tau 
and a metabolite T2 of 300 ms for all other metabolites. 
Literature water (LW) T2 relaxation times were taken to be 174.5 ms in both brain tumour 
types and 88.6 ms in normal brain (Isobe et al., 2002).  
Literature metabolite (LM) T2 values of 368.8, 205.3 and 265.4 ms were used for tNAA, tCr 
and tCho respectively in healthy brain (Isobe et al., 2002). In both brain tumour types, the T2 
values used for tNAA, tCr and tCho were 227.5, 196.3 and 275.3 ms. A T2 of 300 ms was 
assumed for all other metabolites. 
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The term default is used for concentrations estimated using TARQUIN’s default Watt value of 
0.7. This value is based on TE = 30 ms data collected in adults at 1.5 T and assumes T2 
relaxation times typical of white matter.  
Metabolite concentrations quantified at short-TE were corrected for relaxation effects by 
calculating case-specific Watt values using IM and IW T2 values. These values are assumed to 
be the best estimates of the metabolite values and all other methods are compared against 
these with the root mean square (rms) differences being reported.  
Quality Control  
MRS data were required to have a water linewidth (full-width-at-half maximum, FWHM) < 
15 Hz and signal-to-noise ratio ≥ 4. Spectra were reviewed for quality by two expert 
spectroscopists. Short- and long-TE spectra were assessed to identify metabolites present at 
both echo times for inclusion in the T2 analysis. 
Statistics 
One-way ANOVA tests were used to analyze the mean T2 relaxation times and metabolite 
concentrations for the four tissue groups and paired Mann-Whitney U tests were performed. 
Statistical significance was declared for P < 0.05. A Mann-Whitney U test was chosen ahead 
of a Student’s t-test as it is more conservative for small sample sizes (Fay and Proschan, 
2010). 
5.3 Results 
Following quality control, a total of 26 tNAA (10 pilocytic astrocytomas, 5 medulloblastoma, 
16 normal), 36 tCr (8 pilocytic astrocytomas, 9 medulloblastoma, 16 normal), 38 tCho (11 
pilocytic astrocytomas, 9 medulloblastoma, 16 normal) could be reliably measured across all 
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tissue types. Figure 5-1 shows example pilocytic astrocytoma and medulloblastoma spectra. 
Figure 5-2 shows example basal ganglia and white matter spectra. 
 
Figure 5-1: Example spectra from a) pilocytic astrocytoma and b) medulloblastoma at short and long-
TE with TARQUIN fits (red) and fit residuals shown beneath the spectra 
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Figure 5-2:  Example spectra from a) basal ganglia and b) white matter at short and long-TE with 
TARQUIN fits (red) and fit residuals shown beneath the spectra 
5.3.1 T2 Results 
  T2 Relaxation Time (ms) 
 
PA 
 
MB 
 
WM  
 
BG 
 
Mean ± SD n 
 
Mean ± SD n 
 
Mean ± SD n 
 
Mean ± SD n 
tNAA 191 ± 56 10 
 
333 ± 124 5 
 
423 ± 113 14 
 
436 ± 140 16 
tCho 372 ± 176 11 
 
587 ± 143 9 
 
313 ± 154 15 
 
344 ± 122 14 
tCr 217 ± 65 8 
 
305 ± 51 9 
 
237 ± 72 10 
 
225 ± 78 16 
Water 181 ± 35 11   123 ± 45 10   90 ± 9 15   86 ± 8 16 
Table 5-1:  Estimated T2 relaxation times (ms) in pilocytic astrocytoma (PA), medulloblastoma (MB), 
basal ganglia (BG) and white matter (WM). 
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Figure 5-3: Mean (standard error) T2s of tNAA, tCho, tCr, Tau, Glx and water for pilocytic 
astrocytomas, medulloblastomas, basal ganglia and normal white matter. *P < 0.05, ** P < 0.001  
T2 values for metabolites and water are represented in Figure 5-3 with the values given in 
Table 5-1. tCho was significantly longer in medulloblastomas compared to pilocytic 
astrocytoma (Mann-Witney U-test, P = 0.04) and compared to white matter (Mann-Witney 
U-test, P < 0.001) and basal ganglia (Mann-Witney U-test, P < 0.001). The T2 relaxation time 
of tNAA was significantly shorter in pilocytic astrocytomas compared to white matter (Mann-
Witney U-test, P < 0.001) and basal ganglia (Mann-Witney U-test, P < 0.001).  
The T2 relaxation times of tissue water in pilocytic astrocytomas 181 ± 35 ms, diffuse 
intrinsic pontine glioma 133 ± 25 ms and medulloblastomas 123± 45 ms were found to be 
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significantly longer than in white matter 90 ± 9 ms and basal ganglia 86 ± 8 ms (Mann-
Witney U-test, P = 10-6) in all cases). The T2 relaxation time of water was significantly longer 
in pilocytic astrocytomas than in medulloblastoma and diffuse intrinsic pontine gliomas 
(Mann-Witney U-test, P = 0.001).  
The mean Watt values, calculated using the mean tissue water and metabolite T2 relaxations 
times, were 0.95, 0.85 and 0.80 for pilocytic astrocytomas, medulloblastomas and normal 
brain respectively at TE= 30ms. There was no correlation between T2 relaxation times and 
age in normal brain for water or any of the metabolites. 
5.3.2 Metabolite Concentrations Corrected for T2 Relaxation Times 
Table 5-2 shows the mean metabolite concentrations in the different tissue types, corrected 
for water (IW) and metabolite T2 (IM) relaxation. The concentration of tNAA (Mann-Witney 
U-test, P = 10-23), tCr (P = 10-6), GABA (P = 10-5), Glu (P = 10-7) and Glx (P = 10-6) were 
significantly lower in tumours compared to normal brain, whilst Lac (P = 10-4) was 
significantly higher in tumours. The concentration of tCho (P = 10-5), Tau (P = 10-4), Glth (P = 
10-4), Gly (P = 0.02) and tCr (P = 0.03) were significantly higher in medulloblastomas 
compared to pilocytic astrocytomas whilst Glc (P = 0.01) was higher in pilocytic astrocytomas 
compared to medulloblastomas. All significant differences in concentration levels that were 
observed in the fully corrected data were also present when concentrations were estimated 
using default TARQUIN settings. Classification accuracy of paediatric brain tumours was not 
improved when using fully-corrected metabolite concentrations. 
5.3.3 Concentration Correction Comparisons 
Metabolite concentrations were measured and adjusted using various combinations of T2 
values as detailed in the methods section. Mean metabolite concentrations corrected using 
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default T2 values and short-TE MRS and long-TE MRS corrected for the prolonged echo time 
of 135 ms using default T2 values are given in Table 5-3 and Table 5-4 respectively.  
116 
 
Concentration (mmol/kg) 
 
 
ANOVA 
all groups 
(P value) 
 
Pilocytic Astrocytomas 
 
Medulloblastomas 
 
Pilocytic astrocytoma  
vs  
medulloblastoma 
(P value) 
 
Normal 
 
Normal vs 
all tumours  
(P value)  
Mean 
 
SD Mean 
 
SD Mean 
 
SD 
tNAA 
 
10-22 
 1.63 
± 0.66  1.28 
± 1.35  
0.52 
 7.44 
± 4.45  
10-23 
tCho 
 
10-10 
 
1.18 ± 0.39 
 
5.53 ± 2.24 
 
< 0.001 
 
1.62 ± 0.64 
 
< 0.01 
tCr 
 
10-6 
 
0.85 ± 0.61 
 
3.73 ± 2.28 
 
< 0.05 
 
5.69 ± 2.10 
 
10-6 
Lac  10-4  1.35 ± 0.59  4.03 ± 2.47  0.06  0.32 ± 0.97  10-4 
Ala  0.09  0.29 ± 0.36  0.30 ± 0.46  0.63  0.12 ± 0.17  < 0.05 
Glu 
 
10-6 
 
2.58 ± 1.01 
 
3.15 ± 0.95 
 
0.81 
 
6.05 ± 2.47 
 
10-7 
Gln 
 
0.43 
 
2.64 ± 1.59 
 
2.04 ± 1.80 
 
0.69 
 
1.71 ± 1.48 
 
0.22 
mI 
 
0.16 
 
1.12 ± 1.14 
 
3.08 ± 3.13 
 
0.32 
 
3.48 ± 3.72 
 
0.17 
Tau 
 
10-5 
 
0.65 ± 0.47 
 
4.39 ± 2.19 
 
< 0.01 
 
0.98 ± 1.23 
 
< 0.05 
Glc 
 
0.08 
 
3.04 ± 1.37 
 
1.13 ± 1.08 
 
< 0.01 
 
2.40 ± 1.23 
 
0.32 
GABA 
 
10-4 
 
0.47 ± 0.32 
 
1.46 ± 1.52 
 
< 0.05 
 
2.93 ± 0.81 
 
10-5 
Glth 
 
< 0.05 
 
0.27 ± 0.42 
 
1.36 ± 0.84 
 
< 0.01 
 
0.68 ± 0.60 
 
0.78 
Gly 
 
10-5 
 
0.33 ± 0.54 
 
4.15 ± 1.87 
 
< 0.01 
 
0.42 ± 0.62 
 
0.06 
Scy 
 
< 0.01 
 
0.00 ± 0.00 
 
0.65 ± 0.51 
 
< 0.05 
 
0.19 ± 0.14 
 
0.34 
Glx 
 
10-5 
 
5.22 ± 2.59 
 
5.20 ± 2.75 
 
0.42 
 
7.75 ± 3.95 
 
10-6 
Table 5-2: Estimated metabolite concentrations (mmol/kg) of pilocytic astrocytomas, medulloblastomas and normal brain, corrected for individually 
estimated water and metabolite T2 relaxation times.
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When averaged over all metabolites and all tissue types, the mean metabolite 
concentrations calculated using the default T2 relaxation times and short echo time MRS 
were underestimated by 26% compared to the mean concentrations determined using the 
IW and IM relaxation times (Mann-Whitney U-test, P = 10-5). 
When averaged over all metabolites, the mean metabolite concentrations using the default 
T2 relaxation times and short echo time MRS were underestimated by 37% in pilocytic 
astrocytomas, by 16% in medulloblastomas and by 16% in normal brain, compared to the 
mean concentrations determined using the IW and IM relaxation times.  
 The mean concentrations measured using LW, LM T2 relaxation times were not significantly 
different from concentrations corrected using IW, IM T2 values. 
   Concentration (mmol/kg)  
   Pilocytic Astrocytomas 
 
Medulloblastomas 
  
Normal 
 
 
Mean 
 
SD Mean 
 
SD Mean 
 
SD 
tNAA   1.09 ± 0.47  0.96 ± 0.85   6.53 ± 2.68  
tCho   0.85 ± 0.22  4.90 ± 2.01   1.40 ± 0.37  
tCr   0.58 ± 0.34  3.14 ± 1.87   4.74 ± 1.30  
Lac   1.01 ± 0.43  3.36 ± 2.02   0.28 ± 0.85  
Ala   0.22 ± 0.28  0.25 ± 0.37   0.11 ± 0.15  
Glu   1.95 ± 0.79  2.64 ± 0.78   5.25 ± 1.92  
Gln   1.99 ± 1.18  1.71 ± 1.50   1.52 ± 1.35  
mI   0.85 ± 0.89  2.58 ± 2.63   2.95 ± 2.55  
Tau   0.49 ± 0.35  3.68 ± 1.85   0.81 ± 1.05  
Glc   2.29 ± 1.01  0.95 ± 0.91   2.06 ± 1.07  
GABA   0.35 ± 0.24  1.22 ± 1.29   2.59 ± 0.75  
Glth   0.20 ± 0.32  1.14 ± 0.70   0.60 ± 0.53  
Gly   0.25 ± 0.40  3.47 ± 1.56   0.39 ± 0.56  
Scy   0.00 ± 0.00  0.54 ± 0.43   0.17 ± 0.13  
Glx   3.94 ± 1.97  4.35 ± 2.28   6.78 ± 3.27  
Table 5-3: Metabolite concentrations (mmol/kg) of pilocytic astrocytomas, medulloblastomas and 
normal brain, estimated using TARQUIN’s default settings at short TE. 
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   Concentration (mmol/kg) 
   Pilocytic Astrocytomas 
 
Medulloblastomas 
  
Normal 
 
Mean 
 
SD Mean 
 
SD Mean 
 
SD 
tNAA   0.39 ± 0.21  0.62 ± 0.23   5.81 ± 0.96  
tCho   0.41 ± 0.13  4.15 ± 1.82   1.13 ± 0.17  
tCr   0.26 ± 0.09  2.29 ± 1.18   3.43 ± 0.88  
Lac   0.46 ± 0.24  1.38 ± 0.74   0.39 ± 0.28  
Ala   0.06 ± 0.08  0.61 ± 0.77   0.03 ± 0.08  
Glu   0.32 ± 0.24  0.50 ± 0.56   2.68 ± 1.07  
Gln   0.31 ± 0.23  0.83 ± 0.38   0.69 ± 0.80  
mI   0.52 ± 0.56  8.47 ± 4.01   3.64 ± 1.65  
Tau   0.63 ± 0.79  2.65 ± 1.61   0.78 ± 0.48  
Glc   1.78 ± 3.87  0.00 ± 0.00   0.95 ± 1.18  
GABA   0.21 ± 0.09  1.40 ± 1.37   1.86 ± 0.52  
Glth   0.17 ± 0.06  0.39 ± 0.31   0.42 ± 0.24  
Gly   0.35 ± 0.57  1.89 ± 1.31   0.33 ± 0.35  
Scy   0.13 ± 0.21  0.44 ± 0.33   0.14 ± 0.12  
Glx   0.64 ± 0.47  1.34 ± 0.94   3.37 ± 1.86  
Table 5-4: Metabolite concentrations (mmol/kg) of pilocytic astrocytomas, medulloblastomas and 
normal brain, estimated using TARQUIN’s default Watt having allowed for a TE of 135 ms.  
 
5.3.4 Estimated Errors in Metabolite Concentrations Calculated using Various T2 
values 
The percentage rms difference of the metabolite concentrations from the values determined 
using the individually measured water (IW) and metabolite (IM) T2 relaxation times are 
presented in Table 5-5. 
At short-TE, average rms differences of 6.3% from the individually-corrected concentrations 
were found when the IW T2 values (with LM or AM) were used. At long-TE differences of 
27% were found.  
The percentage rms difference observed at short-TE was significantly smaller than at long-TE 
(22% vs. 53%; Mann-Witney U-test,  P = 10-26) across all tissue types and for all T2 correction 
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methods. The percentage rms differences were significantly smaller when the IW T2 were 
used compared with the other methods of T2 water correction (16% vs. 24%; Mann-Witney 
U-test,  P = 10-16) across all tissue types.  
 
Medulloblastomas 
 
Default LM, LW AM, AW LM, IW AM, IW 
Short TE Singlets 18.8 14.8 5.9 5.1 4.5 
Long TE Singlets 50.6 63.7 25.9 22.9 19.7 
 
 Pilocytic Astrocytomas 
 
Default LM, LW AM, AW LM, IW AM, IW 
Short TE Singlets 34.5 27.9 26.9 9.8 10.1 
Long TE Singlets 78.0 79.5 78.7 41.4 41.8 
 
 Normal Brain 
 
Default LM, LW AM, AW LM, IW AM, IW 
Short TE Singlets 13.1 5.5 5.1 4.4 4.2 
Long TE Singlets 70.5 24.3 22.7 19.8 18.6 
Table 5-5: The root mean square percentage difference between metabolite concentrations 
corrected using different combinations of T2 relaxation times (see Methods and Materials) compared 
to the corrected concentration using the patient’s measured T2 values (IM, IW): Key: L – literature; A 
– average; I – individual; M – metabolite; W – water.  
 
5.4 Discussion 
In this study, T2 relaxation times of metabolites and water have been estimated in childhood 
brain tumours and metabolite concentrations corrected for relaxation effects are reported. 
The importance of T2 relaxation times for quantification has also been assessed.  
In previous major studies of metabolite concentrations in brain tumours (Davies et al., 2008; 
Howe et al., 2003; Panigrahy et al., 2006; Vicente et al., 2013), no correction for the 
differences in T2 relaxation times of brain tumours and healthy brain was performed. A 
water attenuation factor of 0.7 is applied to the data by default in LCModel and TARQUIN. 
This value is calculated using data collected at 1.5 T in healthy adult brain assuming an echo 
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time of 30 ms and is not suitable for quantification of long-TE data.  In this study, 
concentrations measured without further correction for the differences in relaxation were 
typically underestimated by approximately 25% at short-TE.   
This is the first study that has reported metabolite concentrations corrected for T2 
relaxation effects in paediatric brain tumours. Whilst there are differences between the 
concentrations corrected for water and metabolite T2 and the default T2 values, the main 
features in the metabolite profiles reported for medulloblastomas and pilocytic 
astrocytomas in children have been substantiated (Davies et al., 2008; Panigrahy et al., 2006; 
Vicente et al., 2013).  tNAA, tCr, Glu, and Glx were all significantly reduced in tumours 
compared to healthy controls, while Lac was significantly increased in tumours compared 
with normal brain. Concentrations of tCho, tCr, Glth, Tau and Gly were all signi ficantly higher 
in medulloblastomas compared to pilocytic astrocytomas; however Glc was significantly 
higher in pilocytic astrocytomas when compared to medulloblastomas. While previous 
studies have assessed the influence of T2 relaxation on metabolite ratios (Li et al., 2008) and 
quantification at long-TE (Yamamoto et al., 2015), this study has assessed the variation in 
relaxation time in paediatric brain tumours and normal brain and the effect on metabolite 
quantification. The relative importance of water and metabolite T2 relaxation times has also 
been assessed. 
The T2 relaxation time of tissue water was found to have a greater effect on concentration 
measurements than the T2 relaxation time of metabolites. Due to the high SNR of the water 
signal, an additional multi-TE acquisition to measure the T2 of water can be implemented 
with a scan time of less than a minute and is recommended to improve the accuracy of 
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metabolite quantification. However, if water T2 values for individual cases are not available, 
then the mean values for the relevant tissue type should be used. 
At long-TE, the rms percentage differences from concentrations corrected for both IW and 
IM T2 relaxation were larger than at short-TE, suggesting that accurate metabolite T2 values 
are of more importance at long echo times than at short. This is as expected since signal 
losses due to T2 relaxation effects increase with echo time and hence inaccurate T2 
estimation will lead to greater errors in concentration determination at longer echo times.  
Use of short echo times, reduces the errors due to poor T2 estimates and this should be 
taken into consideration where concentration determination is important. Since no 
significant differences in the T2 measurements  were detected between tissue types for the 
majority of metabolites, T2 values determined from normal brain could reasonably be used 
in determining concentrations for tumours. More accurate values are likely to be obtained if 
metabolite specific T2s are used, although this is somewhat more challenging to implement. 
It should be recognized that even with this correction, errors will increase with echo time 
and that errors can be large for individual cases. 
A number of studies have reported T2 relaxation times of adult brain tumours at 1.5 (Isobe 
et al., 2002; Sijens and Oudkerk, 2002) and 3 T (Li et al., 2008; Madan et al., 2015), however 
relaxation times in paediatric brain tumours have been relatively unexplored.  Consistent 
with observations of prolonged water T2 in adult brain tumours, the T2 relaxation time of 
water was found to be significantly longer in tumours than normal brain and in pilocytic 
astrocytomas compared to medulloblastomas and diffuse intrinsic pontine gliomas. The long 
T2 in brain tumours is consistent with the high signal seen on T2 weighted imaging 
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compared with grey matter and corresponds to the high water content, especially in 
pilocytic astrocytomas. No correction has been made for variations of water tissue content 
in keeping with previous studies of brain tumours and it is not known what error this will 
introduce on concentration measurements. However voxels were placed entirely within the 
solid component of the tumour to exclude all cystic components. 
The T2 of tCho was found to be significantly longer in medulloblastomas  compared to 
pilocytic astrocytomas. Previous reports of tCho T2 in brain tumours have been variable, 
with tCho T2 observed to be longer in brain tumours compared to normal brain at 3T (Li et 
al., 2008; Madan et al., 2015) but shorter in a prior 1.5T study (Sijens and Oudkerk, 2002). 
Previous studies have observed differences in the T2 relaxation times of tNAA (Isobe et al., 
2002) and tCr (Isobe et al., 2002; Madan et al., 2015) in tumours compared to healthy 
controls, but no significant differences were observed in our study. The reason for the long 
T2 of tCho in medulloblastoma is uncertain. However, the resonance at 3.20 ppm is 
composed mainly of PCh in medulloblastomas and GPC in gliomas (Albers et al., 2005; 
Wilson et al., 2009a), while free choline can also contribute significantly to the tCho peak in 
medulloblastomas. The prolonged T2 of tCho in medulloblastomas may therefore be due to 
the difference in T2 values between these metabolites , with a longer PCh T2 being 
consistent with its lower molecular weight relative to GPC, and could reflect different 
environments for choline metabolites in the two tumour types  
Previous studies of the T2 relaxation time of tCr have indicated there may be differences in 
the T2 relaxation of the methyl and methylene groups (Deelchand et al., 2012; Ganji et al., 
2012). Whilst the whole tCr spectrum is fitted in the analysis, a correction term is included 
123 
 
which corresponds to a resonance at 3.91 ppm to allow for attenuation of this signal 
following water suppression and the tCr T2 may therefore be biased towards the 3.02 ppm 
methyl group resonance.  
NAA is typically only present at low concentrations in pilocytic astrocytomas and very low 
concentrations in medulloblastomas. However, it is unlikely that the signal is from 
surrounding brain since voxels were placed entirely within the tumor margins and NAA has 
been observed previously in ex vivo analysis of these tumours with HRMAS (Wilson et al., 
2009a).  The significantly lower T2 in pilocytic astrocytomas compared with normal brain 
would be consistent with some of the signal around 2ppm being from a macromolecular 
component, although it is not sufficiently low for this to explain the entire signal (Tamrazi et 
al., 2016). 
A bias towards overestimated metabolite T2 relaxation times may have been introduced due 
to exclusion of cases where the signal could not be accurately fitted at the longer echo time. 
The relatively short range of TE values used may also have led to an overestimation of 
metabolite T2 values (Brief et al., 2005). Brief et al recommended T2 estimation with a 
maximum TE of 800 ms; however, acquiring MRS at TE 800 ms would add considerable time 
to the protocol as the NSA would need to be increased to obtain data of a suitable SNR.  
A limitation of this retrospective study is that only two TEs have been used to evaluate T2 
relaxation times. The use of multiple TEs will improve the accuracy of T2 estimation by 
reducing the influence of poorly determined metabolite concentrations. However, in 
Chapter 4, metabolite and water T2 relaxation times estimated from two TEs and estimated 
from 18 TEs (maximum TE 290 ms) were comparable in phantom and volunteer data for 
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NAA, Cho, Cr and water and justifies the dual TE protocol approach. This was not true for 
coupled metabolites, however, and the T2 relaxation times of coupled metabolites were 
therefore not estimated in this study. For optimal evaluation of the relaxation times of 
coupled metabolites appropriate TE values should be determined following evaluation of the 
J-evolution of metabolite signals as overlap of chemically inequivalent species will have an 
effect on the apparent T2 of MRS peaks (Xin et al., 2008). However, the optimal TE values 
vary between metabolites and using additional TEs is prohibitively time consuming for 
routine tumour evaluation in a clinical environment.  If a dual echo time acquisition is to be 
used, the optimum pair of values is not currently known. A shorter TE than 30 ms was not 
possible using PRESS due to the RF power requirements of this pulse sequence (Zhu and 
Barker, 2011). While the increased SNR associated with using a shorter final TE than 135 ms 
could allow more cases to be assessed, the use of a shorter TE could increase the influence 
of the baseline on T2 estimation and this would require assessment. Estimation of water T2 
values requires a much shorter acquisition due to its high signal intensity and could readily 
be included as part of the routine protocol.  
Whilst the effects of T2 on metabolite determination have been investigated, no attempt 
has been made to correct for T1 saturation effects. In clinical studies, a TR of 1500-2000 ms 
is typically used to maximize the signal acquired in an acceptable timeframe, with 1500 ms 
being commonly used in paediatric single voxel spectroscopy studies at 1.5T (Davies et al., 
2008; Panigrahy et al., 2006; Vicente et al., 2013). This relative consistency of acquisition 
should provide comparability of data between studies.  Furthermore, a previous study of 
relaxation effects in adult brain tumours found no significant differences in the T1 between 
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metabolites or between tissue types (Sijens and Oudkerk, 2002), implying that metabolite 
values may be comparable even if a different TR is used.   
5.5 Conclusions 
T2 relaxation times of water and metabolites vary between tissue types in children. Using a 
short echo time and correcting for T2 effects with the best values available reduce 
inaccuracies due to T2 variability. The T2 relaxation time of water had a greater influence on 
metabolite quantification than the T2 relaxation time of metabolites. Estimation of tissue 
water T2 is quick due to its high natural abundance and the use of case-specific water T2 
values is preferable for correction of relaxation effects. 
Further evaluation of the T2 relaxation times is needed using an appropriate set of TEs for 
coupled metabolites. The T2 relaxation time of tissue water should also be assessed in 
paediatric brain tumours at other field strengths. T2 values themselves are a measure of 
molecular environment and provide an additional means of investigating and characterizing 
tissue. 
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6. METABOLITE QUANTIFICATION AT 3 T OF PAEDIATRIC BRAIN TUMOURS 
AND CONGENITAL ADRENAL HYPERPLASIA 
6.1 Introduction 
Chapter 5 established that the use of appropriate estimates of the T2 relaxation time of 
water was the most important factor for accurate metabolite quantification at 1.5 T. The 
mean metabolite concentrations for the cohort were not significantly different when 
literature, rather than case-specific, relaxation times were used to correct for relaxation 
effects. On a case by case basis, however, the root mean square percentage difference from 
the concentration corrected using case-specific water and metabolite T2 relaxation times 
were significantly smaller when case-specific water relaxation times were used rather than 
values obtained from the literature.  
With magnetic field strengths of 3 T and greater becoming more common in clinical practice 
there is now an interest in establishing how changes in field strength affect quantification. 
Previous comparisons of T2 relaxation times in normal brain have shown that the T2 
relaxation times of water (Gelman et al., 1999; Wansapura et al., 1999) and metabolites 
(Barker et al., 2001; Mlynárik et al., 2001) are significantly reduced at 3 T compared with 1.5 
T. The correction factor used to correct for relaxation effects is based on the ratio of two 
exponentials, representing water and metabolite, and shorter relaxation times could have a 
significant effect. 
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Variation of T2 relaxation times with field strength and its effect on metabolite 
quantification in paediatric brain tumours has not been formally assessed. The additional 
time required to formally estimate metabolite relaxation times can be prohibitive in a clinical 
setting. The T2 relaxation time of water, however, can be measured in less than a minute by 
collecting unsuppressed water spectra at multiple echo times. This chapter uses this 
approach to estimate the T2 relaxation time of water in paediatric brain tumours and in 
patients with congenital adrenal hyperplasia (CAH).  
CAH is an inherited recessive disease which is typically treated with steroids. Treatment with 
steroids is known to increase water absorption (McKay and Cidlowski, 2003) and this could 
be reflected by changes in the T2 relaxation time of water. Furthermore, it is not currently 
known if CAH is associated with changes in T2 relaxation times.  
The purpose of this chapter is to introduce a clinical protocol which is designed to quickly 
obtain the T2 relaxation times of water. This protocol is used to estimate the T2 relaxation 
time of water at 3 T in normal brain, paediatric brain tumours and in CAH. The effect on 
metabolite quantification due to variation of metabolite and water T2 relaxation times at 3 T 
is also assessed. 
6.2 Methods and Materials 
6.2.1 Paediatric Brain Tumours 
Data Acquisition 
MRS was acquired using a Phillips Achieva 3 T scanner following conventional imaging. The 
standard imaging set of T1-weighted, T2-weighted and T1-weighted images post contrast 
administration was used to delineate the tumour margins. Cubic voxels of side length 1.5 cm 
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or 2 cm were placed inside the tumour and point-resolved spectroscopy (PRESS) was 
performed. MRS was acquired at a short echo time using a TR of 2000 ms was used and a TE 
38-41 ms.  Water suppressed data were acquired with 128 repetitions from the larger voxels 
and 192 repetitions from the smaller ones. Water unsuppressed MRS data were also 
acquired with 4 repetitions as a concentration reference. 
Age Sex Diagnosis VOI Treatment 
9.36 F PA 15mm Pre-Treatment 
9.74 M PA 20mm Chemotherapy 
1.66 M PA 20mm Chemotherapy 
8.03 F PA 15mm Resected 
5.82 F PA 15mm Resection 
1.40 F OPG 15mm Chemotherapy 
1.40 F OPG 15mm Chemotherapy 
5.17 F OPG (NF1) 15mm Pre-Treatment 
4.91 M OPG 20mm Resected, Chemotherapy 
7.31 F OPG (NF1) 20mm Chemotherapy 
6.48 M OPG 15mm Resected, Chemotherapy, Radiotherapy 
12.67 M DIPG 20mm Radiotherapy 
8.00 M DIPG 15mm Radiotherapy 
8.14 M DIPG 15mm Radiotherapy 
0.50 M DIPG 15mm Radiotherapy 
8.51 M Medulloblastoma 15mm Pre-Treatment 
     Table 6-1: Age, sex, tumour type, voxel size and treatment details of the paediatric brain tumour 
cohort. 
 
The patient details are presented in Table 6-1. In addition to the short-TE MRS, a multi-TE 
water sequence was collected. The multi-TE water sequence collected water unsuppressed 
MRS data from 18 echo times spaced every 15 ms from an initial TE of 42 ms to a final TE of  
297 ms. Data were collected using a TR of 2000 ms and one repetition was collected per TE.  
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Data Processing 
Metabolite concentrations were initially quantified with TARQUIN v4.3.8 using the internal 
basis set 1H brain + Cit, Glth, Gly. The water attenuation parameter, Watt, was set to 1 and 
the water concentration was assumed to be 43300 mM, the same as grey matter.  
T2 Estimation 
Following the results of Chapter 4, the first five points of the multi -TE water were fitted to a 
monoexponential decay to minimise the influence of long-T2 components when estimating 
the T2 relaxation time of water. The T2 relaxation time of water was also estimated by fitting 
the first (TE = 42 ms) and seventh (TE = 132 ms) points to a monoexponential to compare the 
effect of fitting using multiple echo times with T2s estimated from short and long-TE  
Quantification 
The metabolite concentrations were multiplied by the calculated Watt to obtain metabolite 
concentrations corrected for T2 relaxation.  
The effect of the T2 relaxation time of water on metabolite quantification at 3 T was 
estimated by using different values for the T2 relaxation time of water. The T2 relaxation 
times used were as follows: case-specific T2 relaxation times, estimated from the first 5 
points of the multi-TE water; adult glioma values of 145 ms for low grade gliomas and 155 
ms for high grade gliomas taken from the literature (Madan et al., 2015a). Due to the similar 
appearance of paediatric brain tumours and grey matter on T2-weighted imaging, 
comparison was also made using the T2 of grey matter, 100 ms (Stanisz et al., 2005). 
Pilocytic astrocytomas (PAs) and optic pathway gliomas (OPGs) were assumed to be low 
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grade gliomas while anaplastic astrocytomas and diffuse intrinsic pontine gliomas (DIPGs) 
were assumed to be high grade gliomas.  
Metabolite T2 relaxation times were assumed to be similar to adult brain tumours and were 
set as 256 ms, 285 ms and 168 ms for tNAA, tCho and tCr respectively (Madan et al., 2015a). 
A T2 of 250 ms was assumed for all other metabolites, with the exception of lipids and 
macromolecules which were assumed to have a T2 of 60 ms. 
The metabolite concentrations estimated using GM and adult glioma T2 relaxation times 
were compared to the metabolite concentrations estimated using case-specific T2 relaxation 
times for water. The mean and rms percentage difference of GM and adult glioma-corrected 
concentrations from concentrations corrected using case-specific values were estimated. 
Statistics 
The T2 relaxation time of water as estimated using the first 5 points of the multi-TE water 
and using the first and seventh points, and the mean percentage difference between T2 
relaxation correction methods were compared using a Student’s t-test. An ANOVA was used 
to compare the mean values of the T2 relaxation times of each tumour type, and the mean 
metabolite concentrations for each tumour type. A Student’s t-test was used to compare 
mean values where ANOVA P < 0.05. 
6.2.2 Congenital Adrenal Hyperplasia 
Patients 
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The CAH study consisted of two cohorts. The first cohort contained 17 females with CAH due 
to 21-hydroxylase deficiency (mean age 32.7 years). Comparison was made with a second 
cohort consisting of 17 healthy female controls (mean age 28.6 years). 
Data Acquisition 
MRS was acquired in both cohorts using a Phillips Achieva 3 T scanner following 
conventional imaging. The standard imaging set of T1-weighted, T2-weighted and T1-
weighted images post contrast administration was used to delineate the tumour margins. 
Cubic voxels of side length 2 cm were placed in parietal white matter and the temporal lobe. 
In all cases MRS was acquired using PRESS with TR 2000 ms and collected at short (37-41 ms) 
and long (135 ms) TE. Water suppressed data were acquired with 128 repetitions from the 
larger voxels and 192 repetitions from the smaller ones. Water unsuppressed MRS data were 
also acquired with 4 repetitions as a concentration reference. A multi -TE water scan was also 
acquired as before. 
Data Processing 
A T1-weighted image was segmented using FSL to determine the GM, WM and CSF 
composition of the voxel. Metabolite concentrations were initially quantified with TARQUIN 
v4.3.8 using the internal basis set 1H brain + Glth, Cit, Gly. The water attenuation parameter, 
Watt, was set to 1 and the water concentration was assumed to be that of pure water, 55556 
mM, in accordance with (Gasparovic et al., 2006a) 
T2 Estimation 
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The metabolite signal amplitudes were fitted to a monoexponential decay curve to estimate 
the T2 relaxation times of metabolites. The T2 relaxation time of water was estimated by 
fitting the first five TEs of the multi-TE water to a monoexponential. To avoid bias from 
voxels containing large amounts of CSF, the T2 relaxation time of water was only measured 
in voxels containing less than 5% CSF as determined by segmentation. The results and 
discussion that justify this choice are presented in Chapter 4. 
Quantification 
The reported metabolite concentrations were corrected for relaxation effects following the 
method detailed by Gasparovic et al (Gasparovic et al., 2006b). 
Three combinations of metabolite and water T2 relaxation times were used to assess the 
influence of relaxation on quantification. The combinations were as follows: 
LM, LW: This combination assumed literature values for metabolites (LM) (Träber et al., 
2004b) and for GM, WM and a CSF T2 of 1300 ms (LW) (Stanisz et al., 2005). 
 
LM, IW: This combination assumed literature values for metabolites (LM) a value of 1300 ms 
for CSF. The T2 relaxation times of GM and WM were assumed to be equal and a case-
specific water T2 relaxation time, as measured from the multi-TE water, was used (IW). 
IM, IW: This combination used the estimated case-specific T2 relaxation times for tNAA, tCho 
and tCr (IM). A T2 relaxation time of 1300 ms was used for CSF. The T2 relaxation times of 
GM and WM were assumed to be equal and a case-specific water T2 relaxation time, as 
measured from the multi-TE water, was used (IW). 
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Statistics 
Student’s t-tests were used to compare T2 relaxation times between tissue types. Statistical 
significance was declared for P < 0.05. 
6.3 Results 
6.3.1 T2 Relaxation Times and Metabolite Concentration Correction in Paediatric 
Brain Tumours 
The T2 relaxation time of water was estimated from the multi-TE water in PAs, OPGs, DIPGs 
and medulloblastoma (Figure 6-1). An ANOVA determined that the mean T2 relaxation times 
were significantly different (P = 0.02). 
 
Figure 6-1: Mean water T2 relaxation times ± SEM in pilocytic astrocytomas (PA), optic 
pathway gliomas (OPG), diffuse intrinsic pontine gliomas (DIPG) and medulloblastoma (MB). 
* P < 0.05 
The mean T2 relaxation time of PAs was significantly longer than the mean T2 relaxation 
times of OPG and DIPG (Student’s t-test, P = 0.04 and 0.02 respectively).The mean T2 
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relaxation time of water in pilocytic astrocytomas was significantly shorter at 3T compared 
with 1.5T (Student’s t-test, P < 0.01). 
The T2 relaxation times of water as estimated using the first 5 points and as estimated using 
only the first and seventh points (TEs 42 and 132 ms) were compared. Over the whole 
patient cohort, there was not a significant difference between the two values (Student’s t-
test, P = 0.98). No significant differences were found for PAs (Student’s t-test, P = 0.88), 
OPGs (Student’s t-test, P = 0.95) or DIPGs (Student’s t-test, P = 0.96). Though some cases 
exhibited multi-exponential behaviour, there was not a significant difference between the T2 
relaxation times estimated using the first 5 points and estimated using only the first and 
seventh points for these cases. 
The metabolite concentrations of the gliomas in the cohort were corrected using case-
specific water T2 relaxation times. These concentrations were compared to concentrations 
which had been corrected using the T2 relaxation time of water in grey matter and corrected 
using the T2 relaxation time of low and high grade adult gliomas. The mean percentage 
difference and the root mean square (rms) percentage differences are given in Table 6-2. 
 GM Adult Glioma T2s 
Mean Percentage Difference -0.9% 10.7% 
Rms Percentage Difference 8.6% 13.7% 
Table 6-2: Mean percentage difference and rms percentage difference of concentrations corrected 
using grey matter water and adult glioma T2 relaxation times when compared to concentrations 
corrected using case-specific T2 relaxation times. 
The percentage difference from the concentrations corrected using case-specific T2 
relaxation times was significantly smaller when the water T2 relaxation time was assumed to 
be that of GM rather than that of adult gliomas (Student’s t-test, P = 10-13). There was not, 
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however, a difference in the mean concentrations when case-specific water T2 relaxation 
times were used compared with concentrations corrected assuming GM T2 relaxation times 
for the water T2 (Student’s t-test, P = 0.93) or adult glioma T2 relaxation times for the water 
T2 (Student’s t-test, P = 0.24).  
The mean percentage difference and rms percentage differences of metabolite 
concentrations corrected for T2 relaxation effects using adult glioma water T2 relaxation 
times compared with metabolite concentrations corrected using case-specific water 
relaxation times are show in Table 6-3 for 1.5 and 3 T.   
 1.5 T 3 T 
Mean Percentage Difference 0.0% 10.7% 
Rms Percentage Difference 2.9% 13.7% 
Table 6-3: Mean percentage difference and rms percentage difference at 1.5 (from Chapter 5) and 3T 
of concentrations corrected using adult glioma T2 relaxation times from  concentrations corrected 
using case-specific T2 relaxation times for water and literature values for metabolites. 
The percentage difference was significantly smaller at 1.5 T than at 3 T (Student’s t-test, P = 
10-15). 
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Mean metabolite concentrations for PAs, OPGs and DIPGs corrected using case-specific T2 
relaxation times are presented in Table 6-4.  
  
PA 
   
OPG 
   
DIPG 
  
MB 
 
Mean 
 
SD 
 
Mean 
 
SD 
 
Mean 
 
SD 
 
Conc. 
NAA 2.47 ± 1.81 
 
2.61 ± 1.63 
 
2.33 ± 1.54 
 
1.94 
Cho 2.79 ± 0.86 
 
2.95 ± 0.94 
 
2.63 ± 0.25 
 
3.84 
Cr 4.73 ± 2.39 
 
5.06 ± 2.08 
 
4.74 ± 1.82 
 
5.03 
Glu 4.06 ± 2.88 
 
4.16 ± 1.88 
 
5.16 ± 2.58 
 
2.09 
Gln 2.01 ± 1.88 
 
1.64 ± 1.63 
 
4.55 ± 1.86 
 
4.73 
mI 5.63 ± 6.29 
 
3.77 ± 2.59 
 
4.90 ± 4.55 
 
3.21 
Lac* 0.55 ± 0.74 
 
0.48 ± 0.34 
 
2.60 ± 0.79 
 
0.91 
Tau 1.19 ± 2.37 
 
0.14 ± 0.28 
 
0.79 ± 0.96 
 
1.85 
Ala 0.17 ± 0.10 
 
0.18 ± 0.21 
 
0.77 ± 0.82 
 
1.17 
Asp** 1.11 ± 2.16 
 
4.98 ± 1.58 
 
8.83 ± 1.96 
 
14.49 
Cit 0.53 ± 0.29 
 
0.75 ± 0.50 
 
0.93 ± 0.64 
 
0.92 
GABA 0.24 ± 0.33 
 
1.51 ± 2.43 
 
2.49 ± 1.73 
 
0.00 
Glc 1.75 ± 1.49 
 
2.46 ± 2.36 
 
1.48 ± 1.41 
 
3.82 
Glth 0.80 ± 0.72 
 
0.91 ± 0.41 
 
0.51 ± 0.51 
 
0.91 
Gly 1.84 ± 2.24 
 
1.92 ± 1.04 
 
1.88 ± 0.68 
 
10.08 
Scy 0.29 ± 0.53 
 
0.07 ± 0.09 
 
0.02 ± 0.04 
 
0.00 
TLM09 6.01 ± 3.56 
 
5.08 ± 3.89 
 
4.45 ± 1.88 
 
7.10 
TLM13 13.42 ± 6.83 
 
12.76 ± 5.14 
 
19.62 ± 8.35 
 
21.17 
TLM20 13.20 ± 3.31 
 
10.06 ± 5.36 
 
11.09 ± 3.33 
 
8.54 
Table 6-4: Mean ± standard deviation (SD) metabolite concentrations for pilocytic astrocytomas (PAs, 
n=5), optic pathway gliomas (OPGs, n=5) and diffuse intrinsic pontine gliomas (DIPGs, n=4) and 
medulloblastoma (MB, n=1). Metabolite concentrations have been corrected using case-specific T2 
relaxation times for water and adult glioma T2 relaxation times for tNAA, tCho and tCr. Lipids and 
macromolecules were assumed to have a metabolite T2 of 60 ms whilst 250 ms was assumed for all 
other metabolites. * ANOVA P < 0.01, ** P <0.001. 
Lac was significantly higher in DIPGs compared with OPGs (Student’s t-test, P < 0.01) and PAs 
(Student’s t-test, P < 0.01). Similarly, Asp was significantly higher in DIPGs compared with 
OPGs (Student’s t-test, P = 0.02) and PAs (Student’s t-test, P < 0.01), whilst Asp was also 
higher in OPGs compared with PAs (Student’s t-test, P = 0.02).  
6.3.2 T2 Relaxation Times and Metabolite Concentration Correction in CAH 
T2 Relaxation Times 
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T2 relaxation times were estimated for the temporal lobe and parietal white matter in 
patients with CAH and healthy controls. The T2 relaxation times are shown in Figure 6-2.  
 
Figure 6-2: Mean T2 relaxation times ± SEM for NAA, Cho, Cr and tissue water from voxels 
placed in parietal white matter and the temporal lobe in healthy controls and patients with 
CAH. * P < 0.05, ** P < 0.01. 
The T2 of NAA was significantly longer in CAH parietal white matter compared with CAH 
temporal lobe (Student’s t-test, t = 2.65, P = 0.02). The T2 of tissue water in the parietal 
white matter of controls was significantly shorter compared with the T2 in the temporal lobe 
of controls (t = 4.91, P = 0.0001) and CAH patients (t = 3.79, P = 0.002). The T2 of tissue 
water was significantly longer in the temporal region than in parietal white matter of CAH 
patients (t = 3.64, P = 0.005). 
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Metabolite Concentrations Corrected for Relaxation Effects 
The metabolite and water T2 relaxation times were used to correct for relaxation effects and 
are shown in Figure 6-3. 
 
Figure 6-3: Mean metabolite concentrations ±SEM for a) healthy parietal, b) CAH parietal, c) healthy 
temporal, d) CAH temporal. Metabolite concentrations were corrected for relaxation effects using 
various combinations of T2 relaxation times: literature T2 values for metabolites and CSF and a case -
specific measured T2 for grey and white matter which were assumed to be equal (LM, IW); and case-
specific measured T2 relaxation times for metabolites and water with grey matter and white matter 
assumed to have equal T2 relaxation times (IM, IW). 
There were no significant changes in metabolite concentration when case-specific T2 
relaxation times were used to correct for relaxation effects.  Table 6-5 shows the percentage 
difference from metabolite concentrations corrected for using literature values, assumed to 
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be the gold standard, for metabolite concentrations corrected for using case-specific T2 
relaxation times. Table 6-6 shows the rms percentage difference. 
PD Default LM, LW LM, IW AM, AW AM, IW 
Controls -9.46 2.41 -0.19 -0.81 -0.87 
Patients -9.78 1.41 0.48 -0.20 -0.67 
Table 6-5: Percentage Difference from IM, IW in congenital adrenal hyperplasia and healthy controls. 
Key: IM: Individual Metabolite T2, IW: Individual Water T2, LM: Literature MetaboliteT2, LW: 
Literature Water T2, AM: cohort Average Metabolite T2, AW: cohort Average Water T2. 
 
RMS Default LM, LW LM, IW AM, AW AM, IW 
Controls 11.77 5.09 4.51 3.72 3.72 
Patients 12.09 5.77 4.57 4.66 3.34 
Table 6-6: RMS Percentage Difference from IM, IW in congenital adrenal hyperplasia and healthy 
controls. Key: IM: Individual Metabolite T2, IW: Individual Water T2, LM: Literature MetaboliteT2, 
LW: Literature Water T2, AM: cohort Average Metabolite T2, AW: cohort Average Water T2.  
6.4 Discussion 
In this study, multi-TE water data has been used to estimate the T2 relaxation times of water 
in pathology and the effect of changes in the T2 relaxation on quantification has been 
assessed at 3 T. 
The T2 relaxation time of PA, none of which were found in the optic pathway, was 
significantly longer than those of both OPG and DIPG. The T2 relaxation times of optic 
pathway glioma, diffuse intrinsic pontine glioma and medulloblastoma were similar to that 
of grey matter at 3T. These findings are consistent with T2-weighted imaging, where OPGs, 
DIPGs and medulloblastoma tend to have a similar appearance to grey matter. Conversely, 
PAs, which are often cystic, are typically associated with areas of high intensities on T2-
weighted images. 
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Consistent with reports in normal brain (Gelman et al., 1999; Wansapura et al., 1999), the T2 
relaxation time of water was significantly shorter in paediatric gliomas at 3 T compared with 
1.5 T. There is little published data about the T2 relaxation time of water in paediatric brain 
tumours and a formal comparison of T2 relaxation time changes with field strength has not 
been performed in adult tumour populations. However, published relaxation times at 1.5 
(Isobe et al., 2002) and 3 T (Madan et al., 2015a) in adults indicate that this may be true in 
adults too. The T2 relaxation times for OPGs and DIPGs estimated in this study are not 
consistent with the higher T2 values seen in adult cohorts.  
T2 relaxation times were estimated from the first five points of the multi -TE water to 
minimise the potential influence of long-T2 components, for example from CSF or cystic 
components, on the water signal (consult Chapter 4 for further details). T2 relaxation times 
were also estimated from the first and seventh points, TEs 42 and 132 ms respectively. 
Whilst a slight difference in T2 relaxation times estimated by the two methods was noted for 
cases where the water signal decay was not monoexponential, the difference was small and 
the difference between the two methods was not significant.  This finding adds further 
weight to the use of two TEs for estimating T2 relaxation times, as was used in the paediatric 
brain tumour study at 1.5 T detailed in chapter 5. Whilst it is not necessary to collect more 
than two echo times to estimate the T2 relaxation time of water, the additional echo times 
allow an assessment of whether the relaxation of water is mono- or multi-exponential. In the 
cases in this study where the decay was not mono-exponential, the T2-weighted imaging 
indicated that multiple components were present in the voxel. Collecting multiple echo 
times could therefore provide information about the voxel composition, in particular the 
amount of CSF present (Kreis et al., 1993), without a significant additional time penalty. 
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The effect of T2 relaxation time differences on metabolite quantification in paediatric brain 
tumours was investigated by correcting for relaxation effects using different T2 relaxation 
times. The rms percentage difference, from concentrations corrected using case-specific T2 
values, was largest when adult glioma T2 values were used compared with the use of GM 
T2s. This is consistent with most paediatric brain tumours appearing similar to GM on T2-
weighted imaging. Though differences were observed on a case-by-case basis, there was not 
a significant difference in the mean concentrations estimated for either the whole patient 
cohort or for individual tumour types. This effect could be due to the small sample sizes 
available for individual tumour types. The mean and rms percentage differences were larger 
at 3 T compared with 1.5 T. This is likely due to the shorter relaxation times at 3 T and 
suggests that if quantified MRS is to be used for clinical decision making, then case-specific 
T2 relaxation times should be used.  
T2 relaxation times of water and metabolites were also estimated in congenital adrenal 
hyperplasia. It was hypothesised that the treatment patients with CAH with steroids could 
lead to changes in the T2 relaxation time of water, however there was only a trend towards 
changes in water T2 relaxation times in this study. The only T2 relaxation time differences 
observed were between the T2 relaxation times of water in the parietal and mesial temporal 
lobe. These differences reflect the differing amounts of grey and white matter found in these 
locations. 
Quantification of MRS data was using various combinations of T2 relaxation times was 
assessed. There was not a significant difference in the mean metabolite concentrations 
estimated when case-specific relaxation times were used compared with the use of 
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literature values. Furthermore, the mean and rms percentage differences were small. This 
indicates that it is not necessary to correct for relaxation effects using case-specific values 
unless there is compelling evidence that there are significant changes in T2 relaxation times.  
There are a number of limitations to this study. The water contents and relaxation times of 
normal brain are well studied, meaning accurate quantification of normal brain MRS 
presents a straightforward task if the amounts of GM, WM and CSF are known. Accurate 
quantification of brain tumours, however, presents a more difficult problem. MRS 
investigations of paediatric brain tumours often use the concentration of water in GM as a 
concentration reference, however the water concentration of paediatric brain tumours is 
not well known. Furthermore, while segmentation of normal brain is a relatively simple task, 
segmentation of paediatric brain tumours is complicated by the microcystic nature of some 
tumour types and varying appearance of tumours on T2 imaging. Whilst accurate 
quantification of tumour MRS would account for changes in water content, as well as T2 
relaxation, an investigation of water content is beyond the scope of this work. Similarly, an 
analysis of the metabolite T2 relaxation times and of T1 relaxation in brain tumours would 
add significant time to the scanning session which is not feasible in a paediatric clinical 
setting. 
The paediatric brain tumour cohort investigated is also not ideal. The heterogeneous cohort 
used consists of patients undergoing various treatments and it is not known what effect 
treatment will have on T2 relaxation times. The statistical power of this study is also limited 
by the small numbers of each tumour type available. 
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6.5 Conclusions 
A quick, one-minute sequence has been introduced which can measure the T2 relaxation 
time of water with a scan time of less than a minute. The tissue water T2 relaxation times of 
paediatric brain tumours are shorter at 3 T than at 1.5 T. The RMS percentage differences 
were larger at 3 T when compared with 1.5 T. Case-specific water T2 relaxation times are 
therefore recommended if metabolite concentrations are to be used for clinical decision 
making. However, for analysis of cohorts, appropriate literature T2 relaxation times can be 
used. The water and metabolite T2 relaxation times were not significantly changed in 
congenital adrenal hyperplasia when compared with healthy controls. The use of case-
specific water or metabolite T2 relaxation times did not significantly change metabolite 
quantifications in CAH or normal brain. In normal brain and CAH there was a RMS 
percentage difference of approximately 5% when concentrations corrected using case-
specific values were compared with concentrations corrected using literature values. Future 
work should investigate potential changes in the metabolite T2 relaxation times of paediatric 
brain tumours at 3 T and what affect this might have on the accuracy of metabolite 
quantification.  
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7. JPRESS  
7.1 Introduction 
Short and long echo time spectroscopy, as conventionally used in MRS investigations, 
provides a convenient vehicle for visually identifying changes in the metabolites NAA, Cho, 
Cr and Lac compared with normal brain. With prominent singlets without substantial 
spectral overlap, tNAA, tCho and tCr can be readily identified at all echo times whilst the 
inverted Lac doublet at long TE allows unambiguous identification. However, unambiguous 
assignment of a number of coupled metabolites presents a challenging task due to crowded 
spectra. 
MRS is often analysed by fitting the whole spectrum to a range of metabolites using prior 
knowledge. In large cohorts of paediatric tumours, a number of other metabolites, such as 
Glu (Davies et al., 2008a), Gln (Wilson et al., 2013), Gly (Davies et al., 2010a, 2008a), mI 
(Harris et al., 2008a; Panigrahy et al., 2006; Peet et al., 2007), Tau (Davies et al., 2008a; 
Kovanlikaya et al., 2005; Panigrahy et al., 2006), have emerged as being important in 
paediatric brain tumours, a finding confirmed by ex vivo analysis (Wilson et al., 2009b). 
However whilst visual inspection alone can identify changes in tNAA, tCho and tCr, visual 
identification of Glu, Gln, Gly, mI, Tau is more difficult. These metabolites are typically 
present in smaller concentrations or are coupled metabolites that are difficult to identify 
due to the crowded regions they occupy in the spectrum (Govindaraju et al., 2000). 
Various methods have been proposed for identification of these metabolites; however there 
are limited options available that have the potential to identify all metabolites. optimised 
PRESS sequences for Gly (Choi et al., 2011a) and Glu (Schubert et al., 2004b), spectral editing 
for Gly (Choi et al., 2008) and mI (Choi et al., 2005; Kim et al., 2004), TE-averaging for Gly 
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(Prescot et al., 2006) and Glu (Hurd et al., 2004), CT-PRESS for Glu (Mayer and Spielman, 
2005) and difference spectroscopy for Glu, Gln and mI (Snyder et al., 2010). These methods 
have limitations, however, with spectral editing providing limited information about other 
metabolites, optimised sequences resulting in significant signal loss and TE-averaging 
sacrificing the information available from J-evolution. 
Another option, commonly used in vitro, is J-resolved spectroscopy, a two dimensional 
spectroscopy technique which is called JPRESS when used in vivo (Ryner et al., 1995; Thomas 
et al., 2003, 1996). JPRESS is acquired by collecting PRESS spectra at multiple echo times, 
retaining the chemical shift information typical of conventional one dimensional 
spectroscopy in F1, the x-dimension, and indirectly encoding the scalar coupling information 
for each metabolite in F2, the y-dimension. This spreads coupled metabolites into two 
dimensions, allowing identification of metabolites using the known chemical shift and scalar 
coupling constants for each metabolite based on their position in the spectrum (Govindaraju 
et al., 2000). 
A number of limitations have hindered the adoption of JPRESS in a clinical setting. JPRESS is 
associated with long acquisition times, with literature studies often over 20 minutes long 
(Nagarajan et al., 2010; Soeiro-de-Souza et al., 2015; Thomas et al., 2003). A long scan 
duration is not typically feasible in routine clinical practice where advanced MR techniques 
typically follow the standard clinical MRI investigation. Of the reported literature studies 
with an acquisition time less than 20 minutes (Furuyama et al., 2012; Lin et al., 2014; Sarma 
et al., 2014; Weaver et al., 2015), two studies utilise compressed sensing (Furuyama et al., 
2012; Sarma et al., 2014) to collect data in 12 minutes, while another requires a large voxel 
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size of size 4 x 4 x 4 cm which is impractical in a paediatric brain tumour cohort to collect 
data in 9.6 minutes (Weaver et al., 2015). The shortest reported acquisition time is 8 
minutes and 32 seconds which was reported by Lin et al, however children with paediatric 
brain tumours do not tolerate long scan times well and a further reduction in acquisition 
time would be welcome in this cohort. 
Visualisation of the data requires postprocessing techniques which are not commercially 
available on clinical scanners, limiting its utility to radiologists. Quantification of the data also 
presents a problem. Whilst robust fitting routines are available for 1D spectroscopy, the 
options available for JPRESS are limited and are tailored to specific acquisition protocols 
(Fuchs et al., 2014; Schulte and Boesiger, 2006). Peak area integration presents an imprecise 
method for determining metabolite concentrations. A final option available for 
quantification of JPRESS data is to extract the spectroscopy data from each echo time and 
analyse using conventional 1D fitting packages.  
In this chapter, an acquisition protocol and processing pipeline is developed and optimised 
for use in paediatric brain tumours on a clinical 3T scanner. As children do not tolerate long 
imaging sessions well, the acquisition protocol was optimised to collect clinically useful data 
within 6 minutes. Use of the protocol is then demonstrated in four paediatric brain tumours.  
7.2 Methods 
7.2.1 Protocol Development and Optimisation 
7.2.1.1 Protocol Development 
A braino phantom containing 12.5 mM N-acetylaspartate, 12.5 mM glutamate, 10 mM 
creatine, 7.5 mM myo-Inositol, 5 mM lactate, 3 mM choline was scanned. 1 g of sodium 
azide was added to each phantom as a biocide to prevent the growth of bacterial organisms.  
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1 mL/L of gadolinium was added to each phantom as a relaxation agent to shorten the T1 
relaxation time. The pH of all phantoms was adjusted to 7.2 in line with healthy tissue.  
Details of the protocol are presented in Table 7-1. 
 TR (ms) Starting TE NSA/TE TE spacing #TEs 
Volunteer 1 2000 36 16 10 16 
Volunteer 2 2000 36 8 10 32 
Volunteer 3 2000 36 16 10 64 
Volunteer 4 2000 36 8 15 30 
Braino Phantom 2000 36 8 5 128 
Table 7-1: Acquisition protocols in phantom and volunteer for JPRESS protocol and processing 
development. 
 
Informed consent was obtained from 3 healthy adults (2 males and 1 female) with a mean 
age of 25 ± 2 years. A 30x30x30mm voxel was placed in occipitoparietal grey matter and 
scans were performed. All scans were performed with TR = 2000 ms and starting echo time 
TE1 = 36ms with NSA = 8 or 16 whilst equal-spacing of either 10 or 15 ms was used to collect 
16, 30, 32 or 64 free induction decays. Full details of the protocols used on volunteers are 
listed in Table 7-1. 
7.2.1.2 Postprocessing Development 
The raw data for each experiment was transferred to a personal computer and processed 
using code written in-house in Python. The water component of the free induction decays 
was removed using Hankel singular value decomposition and the baseline was corrected for 
any displacement to reduce interference. Baseline displacement correction is performed by 
taking the average value of a region of the spectrum containing only noise and no signal and 
subsequently subtracting this value from the spectrum.  
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Estimates of the water peak position in the water suppressed spectra, ref, were collected 
from the TARQUIN analysis and were used to correct for frequency drift effects by 
multiplying each point, k, of the FID by exp⁡(−2𝜋𝑖 × 𝑟𝑒𝑓 × 𝑘 × (128 2000)) . 
 
To optimise the visualised spectrum, the combined TARQUIN fits for the tNAA, tCho and tCr 
singlets at the final echo time were duplicated and converted into FIDs to simulate additional 
echo times up to a final TE of 500 ms. A penalty of 0.9 was applied to each successive echo 
time to simulate T2 relaxation effects. The data was then apodised in both dimensions using 
a squared sine bell filter and Fourier transformed in two dimensions.  
7.2.2 JPRESS of Paediatric Brain Tumours 
7.2.2.1 MRS Acquisition 
Four patients with paediatric brain tumours were investigated Table 7-2. Informed parental 
consent was acquired and JPRESS investigation followed conventional imaging. 
Age (years) Sex Tumour Type 
9.8 Male Medulloblastoma 
10.6 Male Diffuse Intrinsic Pontine Glioma (DIPG) 
8.2 Male Pilocytic Astrocytoma 
6.5 Female Optic Pathway Glioma 
Table 7-2: Patient details of paediatric brain tumour patients studied with JPRESS. 
 
JPRESS was collected from cubic voxels of size 30 x 30 x 30 mm for all cases using the final 
optimised protocol and processing steps. A repetition time of 2000 ms was used with a 
starting TE of 42 ms and 15 ms spacing between echo times. 8 averages were acquired per 
echo time for a total acquisition time of 6 minutes. The starting TE of 42 ms was chosen as 
149 
 
this was the minimum echo time that that could be achieved with all possible voxel 
orientations. 
PRESS with an echo time of 35 ms, TR of 2000 ms and 128 averages was also collected from 
the medulloblastoma and DIPG cases.   
7.2.2.2 Metabolite Quantification 
Metabolite concentrations were calculated by extracting the 1D FIDs associated with each 
echo time and writing them into a DICOM file using Python code developed in house. The 
DICOM files were processed with TARQUIN using the brain + Glth basis set for healthy 
volunteers and the brain + Glth, Gly, Cit basis set for brain tumour patients. 
T2 relaxation times were estimated for water and metabolites and metabolite 
concentrations were corrected for relaxation effects. The reported concentration is the 
mean of all estimated corrected concentrations from TEs 35-140 ms for that metabolite. A 
full description of metabolite quantification and correction for relaxation effects is provided 
in Chapter 2. 
7.2.2.3 JPRESS Visualisation 
To visualise the data the 2D Fourier transformed matrix was displayed as a contour plot in 
magnitude mode. Lower and upper bounds were used to ensure that the spectra remained 
free of noise. Spectral quality was determined through visual inspection of the display for 
artifacts. The thresholds of the display were further optimised to ensure that all desired 
peaks were present and fully resolved.  
A. 
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The protocol and processing pipeline is shown in Figure 7-1.
  
Figure 7-1: Optimised acquisition protocol and processing pipeline for JPRESS. 
7.3 Results 
7.3.1 Protocol Optimisation 
Acquisition parameters were varied to optimise the protocol. The effect of changing the 
spacing between successive echo times is shown in Figure 7-1.  How changing the number of 
echo times collected is shown in Figure 7-2. Figure 7-3 shows how the choice of final echo 
time affects the resolution of the spectrum.   
Changing the increments between successive echo times had no effect on the quality of the 
spectrum (Figure 7-1). Changing the echo time spacing only has the effect of changing the 
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spectral width of F1. The relationship between echo time spacing and spectral width is given 
by spectral width = 1 /(TE spacing). All metabolites present in the braino phantom and visible 
in volunteer spectra were within a range of ± 30 Hz, which corresponds to an echo time 
spacing of 15 ms.  
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.  
Figure 7-2:JPRESS spectrum of braino phantom with a) Echo time spacing of 5 ms. b) Echo time 
spacing of 10 ms. c) Echo time spacing of 15 ms. 
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The effect of collecting a larger number of echo times was assessed in Figure 7-2. Visual 
inspection shows that the two spectra are comparable. The final echo time sampled, rather 
than the number of echo times collected, appears to have a greater effect on visualisa tion of 
the 2D data (Figure 7-3). When the final echo time is not long enough, the coupled 
metabolites have not completely modulated or completely decayed and the spatial 
resolution is poor. 
 
Figure 7-3: JPRESS spectrum of braino phantom with a) 55 TEs collected with a spacing of 5 ms between 
echo times and b) 19 TEs collected with a spacing of 5 ms between echo times. Both spectra had a final TE 
of 315 ms. a) Has been magnified to show the same spectral range as b).  
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Figure 7-4: JPRESS spectra with a) 43 TEs collected with a spacing of 5 ms between echo times, final 
TE = 246 ms; b) 43 TEs collected with a spacing of 10 ms between echo times, final TE = 456 ms and c) 
43 TEs collected with a spacing of 15 ms between echo times, final TE =666 ms. a) and b) have been 
magnified to show the same spectral range as c). 
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7.3.2 Processing Optimisation 
 
 
Figure 7-5: An example braino phantom JPRESS spectrum with the residual water signal still present. 
 
The intensity of the residual water signal greatly outweighed the intensity of coupled 
metabolite peaks (Figure 7-5). The relative intensity differences meant that a number of the 
resonance peaks of Glu and mI were effectively reduced into the noise of the 2D contour 
plots and could not be identified.   Removal of the residual water using the HSVD algorithm 
enabled detection of lower intensity resonances from coupled metabolites to be identified.  
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Figure 7-6: Stack plot of NAA peak position at various echo times in a healthy volunteer. 
 
Figure 7-6 shows the position of the NAA at various echo times. The position of the peak 
altered due to frequency drift. This led to truncation artifacts above the tNAA, tCho and tCr 
singlets and wider peak intensities on the 2D plot.  
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Figure 7-7: a) MRS data without residual water (green) and with the residual water (blue). Removal of 
the residual displaced the baseline of each TE’S spectrum. This created a large band across 0 Hz in b) 
the JPRESS spectrum. Aligning the baseline of each TE reduced the effect of the 0 Hz baseline in c) 
the JPRESS spectrum   
Removal of the residual water peaks displaced the baseline of the 1D MRS (Figure 7-6). The 
band created at 0 Hz in the JPRESS spectrum complicated determination of low intensity 
peaks in the region of 0 Hz.  
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Figure 7-8: a) MRS collected at TE = 35 ms and b) MRS collected at TE = 295 ms in healthy volunteer. 
 
All coupled metabolites had decayed into the noise by an echo time of 295 ms, with only 
tNAA, tCho and tCr observable in volunteers (Figure 7-7).  
The optimised protocol is demonstrated on phantom data in Figure 7-8. 
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Figure 7-9: Magnified JPRESS and peak assignments for braino phantom.  
7.3.4 JPRESS in Healthy Volunteers 
 
JPRESS was collected from a healthy volunteer using ideal acquisition parameters for NSA 
and maximum TE with an acquisition time of 35 minutes (Figure 7-8). The JPRESS spectrum 
was compared with phantom JPRESS data and with simulated JPRESS spectra to assign 
metabolite peaks. 
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Figure 7-8: Magnified JPRESS of normal brain in healthy volunteer and peak assignments. JPRESS was 
collected with 16 NSA/TE and 64 TEs with 10 ms spacing from TE 35 ms to TE 655 ms. The acquisition 
time was 35 minutes.  
 
Figure 7-9: Final JPRESS protocol following protocol and processing optimisation. The acquisition time 
was 6 minutes. 
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Figure 8 shows the optimised final protocol following optimisation of the protocol and 
following all postprocessing steps. This reduced the acquisition time to 6 minutes with all 
metabolites were well resolved.  
7.3.5 JPRESS in Paediatric Brain Tumours 
Figure 7-10 shows the JPRESS spectrum and a short-TE 35 ms PRESS spectrum collected in 
the same scanning session of a medulloblastoma. The position of JPRESS resonance peaks 
can be described by their J-coupling (Hz) values and chemical shift (ppm) positions on the F1 
and F2 axes respectively. The JPRESS spectrum contained a resonance at 3.54 ppm, 0 Hz, this 
resonance is most consistent with glycine and no myo-Inositol cross peaks were observed.  
The JPRESS spectrum also contained resonances at 3.40 ppm, 0 Hz and at 3.34 ppm, -7 Hz. 
The resonance at 3.40 ppm, 0 Hz was twice as large as the resonance at 3.34 ppm, - 7 Hz. 
The JPRESS spectrum of Tau was simulated and the corresponding resonances at 3.40 ppm, 0 
Hz and 3.34 ppm, - 7 Hz had equal intensities. TARQUIN fits to the 35 ms PRESS did not 
assign any peaks to mI The apparent doublet at 3.4 ppm was not well fitted by TARQUIN. 
The lactate doublet and lipid peak at 1.3 ppm were well separated in JPRESS.  
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Figure 7-10: a) JPRESS spectrum of medulloblastoma, b) 35 ms PRESS of medulloblastoma collected 
in the same session. TARQUIN residual and fits for Gly and Tau included. 
 
163 
 
 
Figure 7-11: a) JPRESS spectrum of pilocytic astrocytoma, b) 1D MRS extracted from the pilocytic 
astrocytoma JPRESS dataset with a TE of 42 ms. TARQUIN fits for mI, Gly and Scy included. 
164 
 
Figure 7-11 shows the JPRESS spectrum and the extracted short-TE (42 ms) MRS of a 
pilocytic astrocytoma. The TARQUIN fit of the TE 42 ms estimated resonances from Gly and 
mI of approximately equal intensity at a chemical shift of 3.54 ppm. The intensities of the 
peaks at 3.54 ppm, 0 Hz and 3.54 ppm, -11 Hz are approximately equal. The SNR of the 
extracted 42ms PRESS spectrum was 12.8. 
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Figure 7-12: JPRESS spectrum of diffuse intrinsic pontine gliomas (DIPG), b) 35 ms PRESS of DIPG 
collected in the same session. TARQUIN residual and fits for mI and Gly included. 
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The JPRESS and short-TE PRESS spectra of a DIPG are shown in Figure 7-12. The resonances 
between -20 Hz and 10 Hz at approximately 3.54 ppm are most consistent with mI 
Concentration (mM) 
  Medulloblastoma   DIPG 
  PRESS JPRESS   PRESS JPRESS 
tNAA 0.86 1.70 
 
1.66 1.86 
tCho 3.97 3.72 
 
1.67 2.09 
tCr 6.29 6.54 
 
5.88 5.74 
Glu 3.54 0.75 
 
1.27 0.72 
Gln 4.80 1.94 
 
0.80 2.99 
mI 0.00 1.49 
 
13.05 7.34 
Gly 5.19 3.38 
 
0.51 0.45 
Tau 9.02 5.45 
 
0.00 2.42 
Glx 8.34 2.68   2.07 3.71 
Table 7-3: Metabolite concentrations (mM) of medulloblastoma and diffuse intrinsic pontine glioma 
(DIPG) estimated by 35 ms PRESS and JPRESS. 
Table 7-3 shows the estimated concentrations for a range of metabolites as determined by 
35 ms PRESS and JPRESS.  
7.4 Discussion 
This study presents a clinical protocol for JPRESS which can acquire clinical data in a 6 minute 
timeframe. The protocol was optimised for visual detection of metabol ites with a boundary 
condition of a 6 minute acquisition time, rather than for explicit metabolite quantification.  
The protocol parameters were optimised to produce a suitable protocol with a 6 minute 
scan time. A substantial time reduction was achieved by collecting data with 8 NSA/TE rather 
than 16, after visual inspection of phantom and volunteer spectra indicated that Glu, Gln and 
mI could still be identified when collecting fewer averages . The spacing between echo times 
was optimised to ensure the spectral width of the y-dimension, related to the J-coupling 
values of metabolites, was large enough to allow detection of all metabolite peaks. The 
protocol was optimised using a braino phantom and volunteer data. All metabolites in the 
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braino phantom and volunteer data fell within a range of ± 30 Hz. Spectral width is inversely 
proportional to echo time spacing and consequently an of 15 ms was used in the protocol. 
While it is possible that metabolites of small concentrations may fall out of this spectral 
range, it is not expected due to the published chemical shifts and coupling constants for 
brain metabolites (Govindaraju et al., 2000). Furthermore, it is also not likely that these 
metabolites would be observable in the 2D spectrum, given the low quantities  they would be 
present in compared to more prominent metabolites like tNAA, tCho and tCr. 
The number of echo times and the final echo time collected were also assessed. These two 
concepts are inextricably linked after determining the optimal final echo time and will be 
discussed in tandem.  The final echo time collected had a greater bearing on the visualisation 
of the spectrum and the final echo time and had a considerable effect on resolution of 
coupled metabolites. By keeping the number of echo times constant, but varying the echo 
time spacing, it was determined that the final echo time should be long enough for coupled 
metabolites to have both undergone complete J-evolution, to improve the resolution of the 
spectrum (Edden and Barker, 2011), and to have completely decayed into the noise to avoid 
unwanted artefacts in the spectrum. Coupled metabolites have a reported in vivo T2 
relaxation time of the order of approximately 180-200 ms (Ganji et al., 2012c) and a final 
echo time of 290 ms was sufficient for good resolution of coupled metabolites in phantom 
and in vivo data. 
A number of postprocessing steps were utilised to improve visualisation of the data. Though 
coupled metabolites had typically decayed into the noise by an echo time of 290 ms, the 
tNAA, tCho and tCr singlets were typically still present. As such, spectra at longer echo times 
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were simulated by duplicating the combined fit to the tNAA, tCho and tCr singlets at 290 ms 
and applying a relaxation penalty to effectively simulate the collection of longer echo times. 
This had an effect analogous to the zero filling of a 1D spectrum to artificially improve 
resolution. There was no benefit conferred by simulating past the point where singlets 
would also have effectively decayed into the noise. 
The intensity of the residual water peak in the spectrum dominated the JPRESS spectrum. 
With the residual peak still present in the FID, typically only the tNAA, tCho and tCr singlets 
had sufficient intensity to be detected using JPRESS. The residual water peak was removed 
using the HSVD algorithm (Barkhuijsen et al., 1987) and enabled visualisation of the lower 
intensity resonances of coupled metabolites. Removal of the residual water peak altered the 
‘height’ of the extracted 1D MRS baseline. Variation in the baseline  height among echo times 
reduced the resolution of the spectrum and reduced the ability to identify smaller 
resonances at J = 0 Hz. Frequency drift of the spectrum due to magnetic field 
inhomogeneities also reduced the resolution of the spectrum and created truncation 
artifacts above high intensity resonances.  
At typical clinical field strengths ≤ 3 T, unambiguous detection of coupled resonances can be 
hampered by severe spectral overlap with neighbouring metabolites. While this problem is 
reduced at higher field strengths, which have improved spectral resolution and higher SNR 
(Bartha, 2007; Snyder and Wilman, 2010), MRS methods which can improve detection of key 
metabolites such as Tau, Glu, Gln and mI would be welcome. Various methods have been 
proposed for optimised identification of coupled metabolites such as optimised-TE (Choi et 
al., 2012; Snyder and Wilman, 2010) and spectral editing (Choi et al., 2008, 2005; Snyder et 
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al., 2010), however these methods are typically metabolite-specific which null surrounding 
resonances and reduce the information that can be extracted from an acquisition. A two-
dimensional method that retains all metabolite information by spreading coupled 
metabolite resonances into a second dimension was therefore chosen. Of the most common 
2D MRS techniques, JPRESS was chosen ahead of L-COSY (Thomas et al., 2003) as it was 
available on our clinical 3 T MR system without modification and is CE-marked. JPRESS also 
offers the facility to extract the short and long-TE 1D MRS spectra that the radiologists at 
Birmingham Children’s Hospital were already familiar with interpreting which aided its 
translation into a clinical setting. 
The JPRESS protocol presented in this study acquires data in approximately 6 minutes. When 
compared to the shortest reported JPRESS study time of 8 minutes 32 seconds (Lin et al., 
2014), the protocol duration presented in this chapter was primarily reduced by collecting 
data at fewer TEs (18 vs 32). This reduction in TEs was achieved by increasing the step size 
between TEs from 10 ms to 15 ms, which still enabled all metabolites to be observed in the 
spectrum, and by choosing a final TE which ensured coupled metabolites had both 
undergone full J-modulation and T2 decay.  
The main Glu and mI resonances that were observed in the braino phantom were also 
observed in healthy volunteers in the optimised protocol. However, a number of the NAA 
cross-peaks associated with the aspartate moiety were not observed in the in vivo spectrum. 
This is likely due to the limits of SNR in vivo with this protocol; however, the missing cross -
peaks could also be a result of motion and the effects of motion on the spectrum warrants 
further investigation. 
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While a 6 minute acquisition time appears suitable for detection of novel metabolite 
biomarkers, it may not be best suited for metabolite quantification, particularly in the case 
of the coupled metabolites. In this study, metabolites were quantified as a series of 1D 
experiments and corrected for T2 relaxation effects. A more sophisticated analysis method, 
ProFit, is available which fits the full 2D spectrum using prior knowledge (Schulte and 
Boesiger, 2006). ProFit was designed for analysis data with smaller increments between 
echo times, however, and was therefore not used in this study.  
A JPRESS spectrum was acquired in four paediatric brain tumour cases. The signal to noise of 
the DIPG was low and no meaningful conclusions could be made from the OPG. The diffuse 
resonances at approximately 3.50 ppm between -25 Hz and 15 Hz have been assigned to mI. 
While the resolution of this feature is poor, its appearance is consistent with mI peaks 
present in the phantom; though the reason for the relatively poor signal in comparison to 
the phantom is unclear, one possible explanation for this is motion during the acquisition.  
 In medulloblastoma, the35 ms PRESS analysed with TARQUIN assigned the peak at 3.54 ppm 
to Gly and determined that no mI was present in the spectrum. The acquired JPRESS 
spectrum was compared with a simulated mI JPRESS spectrum and the characteristic peaks 
off 0 Hz in the F1 dimension were not present in the acquired spectrum. This confirms 
TARQUIN’s assignment. The JPRESS spectrum contained resonances at 3.40 ppm, 0 Hz and a 
resonance at 3.34 ppm, -7 Hz. The corresponding resonances in the 35 ms PRESS spectrum 
were assigned to Tau by TARQUIN, however this region of the spectrum was not completely 
fitted. The corresponding Tau JPRESS spectrum had equal intensities for these two 
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resonances and this suggests that one of the peaks was not included in the basis set. It is not 
known what this peak might be. 
In pilocytic astrocytoma, comparison of the JPRESS spectrum with the extracted 1D MRS at 
42 ms verified the identification of scyllo-Inositol in the TARQUIN fit to the 1D data. The 
TARQUIN fit also suggested a considerable amount of Gly was present in the voxel. The 
intensities of the resonances at 3.54 ppm, 0 Hz and 3.54 ppm, -11 Hz in the JPRESS spectrum 
were approximately equal, however simulations of Gly and mI indicated that, if Gly was 
present in the spectrum, the resonance at 3.54 ppm, 0 Hz would be higher. The number of 
averages, 8, collected for the 42 ms spectrum was small. It is possible that a TARQUIN fit of a 
standard short-TE PRESS sequence with 128 averages would have led to a different TARQUIN 
fit. However, the SNR of the extracted spectrum was 12.8 and this would typically pass 
quality control. This suggests that JPRESS could be a potential method for discriminating 
between Gly and mI.  
While the JPRESS protocol has the potential to collect clinically useful data, there are a 
number of significant limitations to it. A voxel size of 30 x 30 x 30 mm was required to collect 
data with sufficient SNR. This voxel size is large by spectroscopic standards, with voxel sizes 
ranging from 13 x 13 x 13 mm to 20 x 20 x 20 mm more common in a clinical setting, 
however this JPRESS protocol could be suitable for brain tumours which have not been 
resected.  
Even with a 30 x 30 x 30 mm, SNR still presented a slight issue for the less cellular tumours 
assessed with JPRESS. SNR could be improved by increasing the number of averages 
collected per echo time, however this would have a considerable impact on the scan 
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duration which would render it unsuitable for clinical use where scanning time for functional 
imaging is limited. 
Despite reducing the scan duration to 6 minutes, limited scanning time will still affect its 
clinical uptake. While JPRESS has the potential to identify or confirm the presence of novel 
metabolite biomarkers, as evidenced by the medulloblastoma example, confirmation of 
metabolite assignment is difficult. JPRESS spectra are complex and can be difficult to 
interpret by the untrained eye and processing packages which confirm metabolite 
assignment are not available to radiologists. With scanning time limited and little confirmed 
benefit for either metabolite identification or quantification, conventional short and long-TE 
MRS is likely to remain the popular choice for clinical use.  
7.5 Conclusions 
A clinical JPRESS protocol has been developed which has the potential to help identify novel 
metabolite biomarkers by utilising the MRS J-evolution of coupled metabolites with TE. For 
JPRESS to enter routine clinical use, robust and improved quantification over conventional 
one dimensional MRS would need to be demonstrated and postprocessing packages will 
need development for use by radiologists
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8. CONCLUSIONS AND FUTURE WORK 
 
Metabolite concentration estimates have been established as fundamental biomarkers of 
disease and prognosis in a research setting. There is increasing interest in validating the use 
of metabolite concentrations for clinical decision making. A number of acquisition protocols 
and quantification techniques exist and the choice of these will affect the estimated 
concentration values. The aim of this thesis was to address how echo time choice and T2 
relaxation affect the accuracy of metabolite quantification. 
With increasing interest in using metabolite concentrations for patient management, t he 
influence of echo time choice on metabolite quantification was assessed in chapter 4. 
Conventional short and long-TEs of 35 and 135 ms and an intermediate echo time of 80ms 
were assessed using a combination of simulations, phantoms and volunteer data. Though 
exploiting the J-evolution of metabolites can improve the accuracy of metabolite 
quantification, no single TE consistently estimates all metabolite concentrations most 
accurately in either simulations or phantom data. Echo time choice should therefore be 
guided by the clinical question being addressed by MRS. 
Instead the accuracy of any one individual measurement is predominantly determined by 
the quality of the data given appropriate postprocessing techniques. tNAA, tCho and tCr can 
be measured to within <10% of their actual value for SNRs of 15 and above. Accurate 
measurement of the less prominent Glu, Gln, mI, Gly only approaches an accuracy of within 
10 % when the spectrum’s SNR is 25 and above for concentrations commonly found in vivo.  
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The macromolecular baseline which would be present in vivo was not modelled in this work. 
While this would not typically affect measurements at echo times of 80 and 135 ms, where 
baseline interference is reduced due to T2 relaxation, inclusion of macromolecular baselines 
typical of both normal brain and pathology would be an interesting extension to this work. 
Future work should also investigate quantification of more complex spectra with 
concentrations typical of brain tumours. An assessment of the limits of MRS quantification 
and how very poor SNRs and linewidths affect quantification accuracy should also be 
performed. 
T2 relaxation times were estimated from two protocols in Chapter 4. The T2 estimates of 
NAA, Cho, Cr and water are comparable when estimated from two TEs (35 and 135 ms) and 
from 18 TEs, however T2 estimation of coupled metabolites is challenging even with multiple 
TEs. While the long-T2 components in the water signal influence the T2 estimation of water, 
this is minimised by using a maximum TE of 135 ms. 
Chapter 5 presented a retrospective study of paediatric brain tumour MRS collected from 
two echo times at 1.5 T. The T2 relaxation times of water and metabolites are significantly 
different between normal brain and tumour and between different tumour types. The 
difference in the T2 relaxation times of tumour and normal brain significantly affects 
metabolite concentrations and the T2 relaxation time of water has a greater effect on 
metabolite quantification than that of metabolites. Correction for T2 relaxation is 
particularly important for MRS collected at long-TE. The use of case-specific T2 relaxation 
times may therefore be necessary for accurate metabolite quantification at long-TE.  
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A multi-TE water scan is introduced in chapter 6 which was used to estimate the T2 
relaxation time of water with an acquisition time of one minute. The T2 relaxation time of 
water in paediatric brain tumours is significantly shorter at 3 T compared with 1.5 T. 
Correction using case-specific values may be of more importance as field strength increases 
in paediatric brain tumours. The T2 relaxation times of tNAA, tCho and tCr were estimated in 
congenital adrenal hyperplasia (CAH). The root mean square percentage difference between 
concentrations corrected using case-specific metabolite T2 values and those corrected using 
literature values is less than 5%, implying that case-specific T2 correction is not required in 
CAH. 
Metabolite T2 relaxation times were not assessed in paediatric brain tumours at 3 T and this 
should form the basis of future work. Variation in the T2 relaxation times of coupled 
metabolites should also be assessed at both 1.5 and 3 T.  
Spectral overlap of metabolites makes unambiguous identification of coupled metabolites 
difficult at 3 T. In chapter 7 a clinical protocol for JPRESS was presented which can acquire 
clinically useful data with an acquisition time of 6 minutes  which represents a substantial 
reduction in scan time and makes acquisition feasible for clinical use. JPRESS was acquired in 
four paediatric brain tumour cases and can aid discrimination between myo-Inositol and 
glycine. Acquisition of JPRESS could therefore provide early metabolite biomarkers of 
prognosis and this warrants further investigation.  Future work should focus on assessing the 
accuracy of metabolite quantification of JPRESS.  
To summarise, the data quality of MRS was found to affect the accuracy of metabolite 
quantification more than spectral overlap and echo time choice. T2 relaxation times were 
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found to vary significantly between field strengths and between normal brain and pathology. 
The use of case-specific water T2 relaxation times significantly affected metabolite 
quantification at both 1.5 and 3 T. Further work is required to investigate potential variation 
of metabolite T2 relaxation times in paediatric brain tumours at 3 T and how variation might 
affect metabolite quantification. The use of short echo times will improve spectral  SNR and 
reduce the influence of T2 relaxation; however, the effect of baseline interference on 
metabolite quantification accuracy requires further investigation. The T2 relaxation time of 
water is quick to measure and is recommended for accurate metabolite quantification. 
The 2D spectroscopy technique JPRESS was developed for clinical investigation of paediatric 
brain tumours. While JPRESS can aid the detection and assignment of novel metabolite 
biomarkers of diagnosis and prognosis, there is currently no evidence to suggest it currently 
should replace conventional short or long-TE PRESS for metabolite quantification.  
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